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General introduction and outline of this thesis 
introduction
In 1978, a clinical research program on the use of adjuvant local hyperthermia in re­
current breast cancer was started in the Erasmus MC Cancer Institute. At that time, no 
eff ective treatment for locoregional failures in previously irradiated regions existed. In 
general, eff ectiveness of reirradiation at low dose was anticipated to be very poor and 
tolerance limits for reirradiation were not known [1,2,3].
Over time, multiple trials reporting strongly improved clinical results have generated 
a growing interest in and enthusiasm for applying hyperthermia in combination with 
other cancer treatment modalities [4]. Importantly, toxicity of adjuvant hyperthermia is 
acceptable.
Three and a half decades later, extensive progress has been made and hyperthermia 
is considered regular treatment for recurrent breast cancer in previously irradiated areas 
in the Netherlands.
This thesis summarizes the Rotterdam clinical research on superfi cial hyperthermia 
and shows the results of reirradiation and hyperthermia in patients with microscopic 
and macroscopic breast cancer recurrences, the tolerance of reirradiation and hyper­
thermia in breast cancer patients with reconstructions and the results of patients with 
radiation­induced angiosarcoma treated with reirradiation and hyperthermia. Further, 
it describes the innovations and adaptations in hyperthermia application procedure, 
technology, registration and treatment schedule that have been realized and it indicates 
future ways to improve treatment quality and clinical outcome.
HyPertHermia
Hyperthermia is the use of elevated temperature for the treatment of cancer, i.e. tis­
sue temperatures between 40 to 45°C. In general, treatment duration is 30­60 minutes 
and treatments are applied 2­6 times once or twice weekly. Hyperthermia results in cell 
death, by direct cytotoxicity. The direct cytotoxic eff ects are augmented in a nutrition­
ally deprived chronically hypoxic and acidic environment in tumor tissue [5]. Hence 
heat alone applied at a temperature of 43°C can selectively destroy tumor cells without 
damaging normal tissue cells.
The quality of the hyperthermia treatment, i.e. the temporal behavior of the tempera­
ture in the tumor is usually expressed as the cumulative equivalent time at 43°C (CEM43) 
[6], using the formula:
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In 1978, a clinical research program on the use of adjuvant local hyperthermia in recurrent 
breast cancer was started in the Erasmus MC Cancer Institute. At that time, no ffective 
treatment for locoregional failures in previously irradiated regions existed. In general, 
effectiveness of reirradiation at low dose was anticipated to be very poor and tolerance 
limits for reirradiation were not known [1,2,3].
Over time, multiple trials reporting strongly improved clinical results have generated 
a growing interest in and enthusiasm for applying hyperthermia in combination with other 
cancer treatment modalities [4]. Importantly, toxicity of adjuvant hyperthermia is 
acceptable.
Three and a half decades later, extensive progress has been made and 
hyperthermia is considered regular treatment for recurrent breast cancer in previously 
irradiated areas in the Netherlands.
This thesis summarizes the Rotterdam clinical research on superficial hyperthermia 
and shows the results of reirradiation and hyperthermia in patients with microscopic and 
macroscopic breast cancer recurrences, the tolerance of reirradiation and hyperthermia in 
breast cancer patients with reconstructions and the results of patients with radiation-
induced angiosarcoma treated with reirradiation and hyperthermia. Further, it describes 
the innovations and adaptations in hyperthermia application procedure, technology, 
registration and treatment schedule that have been realized and it indicates future ways to 
improve treatment quality and clinical outcome. 
Hyperthermia 
Hyperthermia is the use of elevated temperature for the treatment of cancer, i.e. tissue 
temperatures between 40 to 45°C. In general, treatment duration is 30-60 minutes and 
treatments are applied 2-6 times once or twice weekly. Hyperthermia results in cell death, 
by direct cytotoxicity. The direct cytotoxic effects are augmented in a nutritionally deprived 
chronically hypoxic and acidic environment in tumor tissue [5]. Hence heat alone applied 
at a temperature of 43°C can selectively destroy tumor cells without damaging normal 
tissue cells. 
The quality of the hyperthermia treat ent, i.e. the temporal behavior of the 
temperature in the tumor is usually expressed as the cumulative equivalent time at 43°C 
(CEM43) [6], using the formula:
[min]
In this formula T represents the actual applied temperature of the target tissue and 
R the factor to compensate for a 1°C temperature change. R is experimental determined 
and has been set at a value of 0.5 for T>43°C, i.e. the equivalent time doubles per degree 
temperature increase, and 0.25 for T43°C, i.e. the equivalent time decreases by a factor 
of four per degree temperature decrease. In clinical practice the temperature distribution 
is heterogeneous. The quality of a hyperthermia treatment can be summarized by 
CEM43T90 or CEM43T50. T90 or T50 indicates the level where 90% or 50% of the 
temperature readings is above. 
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In this formula T represents the actual applied temperature of the target tissue and R 
the factor to compensate for a 1°C temperature change. R is experimental determined 
and has been set at a value of 0.5 for T>43°C, i.e. the equivalent time doubles per degree 
temperature increase, and 0.25 for T£43°C, i.e. the equivalent time decreases by a factor 
of four per degree temperature decrease. In clinical practice the temperature distribu­
tion is heterogeneous. The quality of a hyperthermia treatment can be summarized by 
CEM43T90 or CEM43T50. T90 or T50 indicates the level where 90% or 50% of the temperature 
readings is above.
HyPertHermia in combination witH radiotHeraPy
Hyperthermia has both complementary and sensitizing effects to radiotherapy.
Hyperthermia is especially effective in the hypoxic areas of the tumor, where radio­
therapy is less effective. The sensitization effects of hyperthermia take place through 
multiple biological principles such as improving tumor blood flow and oxygenation, 
and inhibition of DNA repair [7­11]. Radiation induces DNA double strand breaks (DSBs) 
and elevated temperature interacts with various DNA repair processes [12]. For example, 
Krawczyk et al. [11] demonstrated that raising temperature results in degradation of 
BRCA2 and subsequently inhibits homologous repair of DNA damage. Further hyper­
thermia may cause an increase in tumor blood flow and an improvement in tumor 
oxygenation, which then results in a temporarily increased radiosensitivity [13­16].
The thermal enhancement ratio (TER) of normal cells as well as tumor cells depends 
on the height of the temperature and the duration of treatment at elevated temperature 
[4]. The maximum TER is realized when radiotherapy and hyperthermia are combined 
simultaneously, but then there is no difference between TER for tumor and normal 
tissue. In this case, a therapeutic gain is obtained only when the tumor is heated to a 
higher temperature than the normal tissue. On the other hand, when radiotherapy and 
hyperthermia are applied consecutively, the radiotherapy effect will remain enhanced 
in tumor much longer than in normal tissue. So, in order to obtain a satisfactory TER in 
tumor tissue with minimum or no enhancement in normal tissue, it is common practice 
to apply hyperthermia with a time interval between radiotherapy and hyperthermia.
Several studies have examined the effect of sequence and interval between radio­
therapy and hyperthermia on mouse tumors and normal skin [17,18]. For the sequence 
of radiotherapy followed by hyperthermia, they showed that the TER of radiotherapy 
damage in skin returns to 1 within 2 hours after the radiotherapy treatment; whereas 
even after 8 hours the TER for tumor cells is still at 1.5. Therefore, therapeutic gain is 
achieved, when radiation and hyperthermia are combined with a time interval. With a 
2­4 hours interval the TER in normal tissue may have completely disappeared (Figure 
13
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1). Only when selective tumor heating can be achieved, simultaneous heating can be 
considered, resulting in maximum therapeutic gain.
Figure 1. A­selective heating: Top panel; Thermal enhancement ratio (ratio of the radiation doses for radia­
tion alone and radiation plus heat to produce the same tumor effect) as a function of the time interval and 
sequence between heating and irradiation. First part, heat before irradiation and second part, heat after 
irradiation. Lower panel; Clinical impact of TER (= 1.5) for simultaneous or sequential heat and radiation 
treatments in tumors assuming equal temperature of normal and tumor tissue (courtesy of M.M. Paulides).
The effectiveness of hyperthermia added to radiotherapy for multiple cancer types has 
been shown in several randomized trials [4,19­37].
Superficially hyperthermia combined with radiotherapy is mainly applied in the 
treatment of locally advanced breast cancer, malignant melanoma, and advanced neck 
nodes. Improved treatment outcome was found in all these tumor types with a TER of 
approximately 1.5.
Ten randomized trials investigated the value of superficial hyperthermia in combina­
tion with radiotherapy. Five of these trials on breast cancer were combined into one 
study and are published by Vernon et al. [19]. The study of Jones et al. compared addi­
tion of low vs. high dose hyperthermia to radiotherapy [20]. Six trials show significant 
improvement of complete response and/or local control. All studies are summarized in 
Table 1.
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table 1. Results of randomized clinical trials in superficial hyperthermia
Study N Tumor type RT+HT (%) RT (%) Significant 
difference
Perez et al. 
[38,39]
236 patients Superficial tumors (primarily chest 
wall and neck nodes)
32 30 No
DHG [19] 38 patients Chest wall and some intact breast 74 74 No
MRC­BrI [19] 30 patients Intact breast 56 67 No
MRC­BrR [19] 149 patients Chest wall and some intact breast 57 29 Yes
ESHO [19] 56 patients Chest wall and some intact breast 78 38 Yes
PMH [19] 33 patients Chest wall 29 31 No
Overgaard et 
al. [29]
128 lesions Melanoma 62 35 Yes
Egawa et al. [37] 92 patients Various 82 63 Yes
Valdagni et al. 
[22,27]
41 lesions Lymphnodes of head and neck 
tumors
83 41 Yes
Jones et al. [20] 122 patients Superficial tumors (primarily chest 
wall and neck nodes; melanoma)
66 (no prior RT ) 42 Yes
Legend to Table 1:
RT = Radiotherapy; HT = Hyperthermia
The greatest benefit of adding hyperthermia to radiotherapy has been seen in patients 
previously irradiated. In the study by Jones et al. [20] previously irradiated patients had a 
complete response rate of 24% after radiotherapy plus low dose hyperthermia and 68% 
after radiotherapy plus high dose hyperthermia. In the ESHO trial (published in [19]) the 
complete response rates were 38% after reirradiation alone, and 78% after combined 
treatment. The Jones et al. trial [20] confirmed the results of the ESHO and the MRC­BrR 
trials. In four trials there was no apparent difference between the treatments. The lack of 
therapeutic gain can be explained by the small number of patients and/or poor quality 
of the hyperthermia treatment [38]. All trials show comparable acute and late toxicity in 
both treatment arms: radiotherapy alone versus radiotherapy and hyperthermia, except 
for a higher incidence of thermal blisters in the hyperthermia group.
HyPertHermia in combination witH cHemotHeraPy
In combination with chemotherapy hyperthermia has similar complementary and 
sensitizing effects. The concentration and the effect of chemotherapy will be less in the 
insufficiently perfused regions [40]. The most important mechanisms for interactive 
effect of hyperthermia and chemotherapy are an increased intracellular drug uptake, 
enhanced DNA damage and higher intratumor drug concentrations, resulting from 
thermally induced increased blood flow. The elevated temperature initiated inhibition 
15
General introduction and outline of this thesis 
of DNA damage repair interferes with multiple pathways, through unclear mechanisms 
[7­13]. Several clinical studies on the addition of hyperthermia to chemotherapy has 
shown improved treatment outcome. The latest study of Issels et al. [35,36] showed in a 
large randomized trial that hyperthermia added to chemotherapy improves the overall 
5 years survival in patients with soft tissue sarcoma by 12%.
breast cancer recurrence
background
A locoregional breast cancer recurrence can occur at the chest wall region or in the 
axillary, infraclavicular, parasternal or supraclavicular lymph nodes after primary treat­
ment [41]. In a comprehensive literature review of Clemons et al. [42] the overall 10­year 
incidence of relapse is 13% after mastectomy and 12% after breast conserving therapy 
(BCT). The chance of developing a local recurrence is mainly depending on the tumor 
stage and age. In ductal carcinoma in situ the 10­year local recurrence chance is 10­15% 
after BCT and 0­4% after mastectomy. Half of these recurrences is invasive [43,44].
In trials that randomized between mastectomy and BCT the local recurrence rate after 
mastectomy is usually lower than after BCT without affecting survival, including in the 
long term [45,46]. Young age is specifically for BCT an unfavorable prognostic factor for 
the probability of local recurrence [45­47].
treatment of breast cancer recurrence
For patients with a recurrent breast cancer the treatment of choice is surgery. If surgery 
results in an irradical resection additional treatment is required. For radiotherapy naïve 
patients, full dose radiotherapy provides a good probability of local control.
The treatment of locoregional failures (microscopic or macroscopic) in previously 
irradiated regions presents a difficult problem as the radiation dose that can be given 
without a high risk of unacceptable toxicity is lower than considered adequate [1­
3,35,36]. For these patients the recommended treatment is reirradiation combined with 
hyperthermia.
In the Netherlands patients are selected for reirradiation and hyperthermia on the 
following criteria: recurrent tumor, inoperable or after microscopically incomplete exci­
sion; and systemic therapy is either inadequate to control regional tumor, or is deemed 
inappropriate, in the absence of (symptomatic) systemic disease [48].
Many patients [49] who experience a recurrence have disease that has metastasized 
or spread throughout the body. These patients require systemic treatment; this includes 
chemotherapy, hormonal therapy, and targeted therapies, such as Herceptin (chemical 
name: trastuzumab) [50,51].
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aPPlication oF radiotHeraPy Plus HyPertHermia For breast 
cancer recurrence: clinical Practice
current treatment schedules for superficial hyperthermia treatment
When we started combining reirradiation with hyperthermia, the tolerance limits for 
reirradiation were not known. Initially the radiation dose was low, with total doses of 
12–25 Gy, in fraction sizes of 2 to 4 Gy. After a period of cautiously increasing the dose 
we arrived at the current reirradiation schedule of 8 times 4 Gy, twice weekly [48,52]. 
This appeared to be a safe, effective and well tolerated schedule and was therefore 
selected as the standard. In this schedule hyperthermia was given twice weekly after 
radiotherapy with at least 3­day intervals to avoid thermotolerance [53].
In 1996 we had a capacity problem for superficial hyperthermia. In view of the results 
of several published randomized studies comparing a low with a high number of hy­
perthermia treatments, usually one versus two treatments per week, which showed no 
difference in results [54], we decreased the number of hyperthermia sessions to four.
technique/ procedure
Hyperthermia is prescribed for 60 minutes, including a heating­up period of 10 minutes, 
and is applied after radiotherapy. Before the first treatment catheters for thermometry 
are inserted subcutaneously in the treatment volume, with preferably at least one inter­
stitial temperature measuring point below each antenna.
Multisensory probes are always placed in the catheters and multi­ or single­sensor 
probes are placed superficially, prior to each hyperthermia treatment [55]. The tem­
perature of the tissue surface is controlled by a temperature controlled, perfused water 
bolus. The temperature of the circulating water in the bolus is selected in accordance to 
the desired heating depth as published in a previous paper [56].
superficial hyperthermia strategy
Superficial hyperthermia has been used for more than 3 decades in the Netherlands. The 
Erasmus MC protocol “superficial hyperthermia” prescribes how to start a treatment and 
how to adjust treatment settings such as power and water bolus temperature during 
treatment to obtain maximum achievable temperatures in the target volume.
The adjustments in treatment settings are based on 2 sources of information: interpre­
tation of the measured temperatures during treatment and feedback of the patient. The 
aim is to have all interstitial temperatures above 40°C throughout the target volume. 
The allowed interstitial normal tissue temperature is maximum 43°C during the first 30 
minutes, thereafter maximum 44°C. In tumor tissue at a distance of more than 10 mm 
from normal tissue higher temperatures are allowed. A power­related unpleasant feel­
17
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ing reported by the patient is considered as a too high temperature and reason to adjust 
treatment settings [45,57].
the rotterdam superficial hyperthermia system
In most centers applying hyperthermia, microwaves are used for tissue heating. The 
custom­built Rotterdam superficial hyperthermia system consist of six solid­state ampli­
fiers, operating at 433 MHz and each capable of delivering an RF­output of 200W for the 
Lucite Cone applicators (LCAs) [58].
The LCA has a square aperture of 10 x 10 cm2; the effective field size is up to 80% of 
the aperture. With six applicators combined an area of 20 x 30 cm2 can be effectively 
heated to a depth of up to 4 cm [45,55]. In comparison to the effective field size of a 
conventional waveguide the heating area of the LCA is ± 2.5 times larger [58]. The ap­
plicator array is chosen such that the radiation field is widely covered with an overlap of 
the applicator aperture by 10 mm all around [54].
For thermometry, a 24­channel fiber­optic system (in this study: FT1210 and FT1310, 
Takaoka, Japan) is used with five multisensor probes (with up to four sensors per probe) 
and four single­sensor probes for continuous measurements during treatment [54].
The system provides automatic data registration. The software provides remote con­
tinuously control of the RF­output (0­200W) per LCA and visualization of forward and 
reflected power (Figure 2). Temperatures are measured interstitially, within catheters, and 
on the surface. The monitor shows time­temperature plots of each measurement point 
under its corresponding LCA footprint and the actual temperature distribution is shown 
onto a representation of the patient anatomy for ease of interpretation (see Figure 3).
Figure 2. Monitor for superficial hyperthermia treatments for power steering. In large font the measured 
forward power is indicated and in small font the power setpoint. The reflected powers are represented 
graphically in a color code (green <5%, yellow 5­10%, orange 10­15%, red >15% reflected power). (Figure 
adapted from van der Zee [54]).
Chapter 1
18
Figure 3. Screenshot of the temperature monitoring. On screen (a), temperature­time graphs for the sen­
sors below each applicator are shown. On screen (b), the measured temperatures are mapped onto a sketch 
that includes anatomical features, the location of the tumor and scar tissue, apertures of the applicators, 
catheter tracks and margins of the radiation field. For each measurement point the tissue type, depth, tem­
perature and temperature difference over 20 seconds is also shown. (Figures adapted from van der Zee 
[54]).
During treatment, the hyperthermia technician uses the presented interstitial and skin 
temperatures and the feedback of the patient to optimize treatment.
For each treatment the Tmax, Tave, T90 and CEM43 is calculated from measurements 
taken after the 10 minutes heating­up phase and stored in the treatment report together 
with the complaints of the patient.
HyPertHermia treatment quality
From experimental studies it is clear that the effect of hyperthermia depends of tem­
perature elevation and duration of treatment. Defining the thermal dose for a clinical 
treatment, however, is difficult due to the temporal and spatial inhomogeneity of tem­
perature distribution. Currently there is no objective indicator for hyperthermia treat­
ment quality. Several thermal dose parameters derived from measured temperatures, 
and SAR coverage of the target volume have been suggested and investigated as quality 
indicators.
thermal dose-effect studies
For thermal dosimetry analysis the minimum, mean, maximum or other values repre­
senting the temperature distribution over time or CEM43 have been studied. For all kind 
of thermal dose parameters, a dose­effect relationship has been demonstrated in one or 
several retrospective studies but not consistently. [19,39,60]. A major point of concern 
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for those studies is that the parameter found retrospectively, might well be just a sur­
rogate for another important prognostic parameter.
For instance, de Bruijne et al. [59] demonstrated that the CEM43T90 dose effect rela­
tionship with complete response disappeared after correction for the relation between 
CEM43T90 and tumor volume.
The clinical study of Jones et al. [20] and the animal study of Thrall et al. [64] have 
prospectively shown the existence of a thermal dose effect. Thrall et al. [64] treated 
canine sarcomas with radiotherapy and hyperthermia. They randomized the dogs for 
hyperthermia treatments with a low (2­5 CEM43T90) or high (20­50 CEM43T90) thermal 
dose. Jones et al. [20] treated superficial tumors with thermoradiotherapy. All patients 
received hyperthermia for 60 minutes for a test treatment and, when deemed heatable, 
these patients were randomized between further treatment with or without hyperther­
mia. The patients in the hyperthermia group were given up to a maximum of 10 hyper­
thermia treatments in order to apply a CEM43T90 of at least 10 minutes. A critical remark 
should, however, be made for both studies. The high dose was obtained by increasing 
the duration and number of the hyperthermia sessions. Control of the temperature 
distribution was not easy even though Thrall et al. used extensive thermometry and 
the animals were anesthetized during treatment [64]. In Jones et al. [20] thermometry 
was limited to one catheter, so that it can be questioned how reliable the derived T90 
represented the actual temperature distribution.
Following the study of Jones et al. [20] we evaluated the prognostic value of CEM43T90 
for complete response rates in our patients. Similar complete response rates were found 
for patients who were deemed heatable or unheatable according to the Jones et al. 
[20] criterion and for patients who received less or more than 10 CEM43T90 during the 
whole treatment series. We also did not find a dose­effect relationship for CEM43T90 in 
multivariate analysis.
sar dose-effect studies
In other studies, the prognostic value of energy distribution was investigated. Myerson 
et al. [65] and Lee et al. [66] demonstrated that coverage of the tumor by the applicator’s 
25% iso­SAR (2D) contour correlated positively with both complete response rate and 
local tumor control. A retrospective study by our group demonstrated the impact of 
heating technology: large tumors (diameter > 3 cm) heated with 433 MHz (penetration 
depth (PD) 3.5 cm) responded much better than those heated with 2450 MHz (PD 1.7 
cm), i.e. a complete response rate of 65% versus 31%, respectively [45]. In the same 
publication we reported that it is important to heat the whole volume at risk, in practice 
the whole radiotherapy field.
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Potential of hyperthermia treatment planning
An objective approach to define treatment quality would be to use the 3­dimensional 
(3D) energy distribution predicted by hyperthermia treatment modeling. In recent 
years, hyperthermia treatment planning has been developed to a useful tool. With hy­
perthermia treatment planning, a complete 3D SAR and temperature distribution in the 
treatment volume can be calculated. Different dose parameters derived from the energy 
distribution can be used to study relationships with clinical outcome retrospectively, us­
ing the actual applicator set­up. If such a SAR dose­effect relation can be demonstrated, 
SAR steering can be used to optimize hyperthermia treatments in a prospective manner 
and interstitial thermometry can be abandoned.
Kumuradas and Sherar [67] were the first to demonstrate the ability of hyperthermia 
treatment planning to predict the 3D SAR and temperature distribution obtained during 
heating of a patient with a superficial chest wall tumor. The superficial hyperthermia 
treatment planning system available at the Erasmus MC, SEMCAD X (= 4imulation 
platform for &lectroMagnetism Compatible, Antenna Design and %osimetry), has been 
shown to predict energy distribution reliably [68]. The performance of the 433 MHz ap­
plicators in phantoms is predicted well by the system [69]. The use of SEMCAD X in five 
patients with various unusual problems was very helpful in either acceptance of these 
patients for hyperthermia treatment, or for selection of an effective treatment technique 
[70].
tHis tHesis
In this thesis, the development in the use of hyperthermia in patients with breast cancer 
recurrence in the Erasmus MC Cancer Institute is presented and the research in this 
patient group is presented.
In chapter 1 a brief introduction to the rationale behind hyperthermia and my re­
search is presented. Part 1 of this thesis includes studies on clinical results in subgroups 
of these patients. chapter 2 describes the development of superficial hyperthermia for 
breast cancer recurrences at the Erasmus MC, presenting the treatment procedure and 
clinical results over the years and the lessons learned. This chapter further contains a 
summary of published clinical results with complete response rates varying widely from 
20% to 95%, whereas the Erasmus MC group achieves complete response rates of 65% 
to 87%. In chapter 3 the effect of a combined treatment of surgery, reirradiation and 
hyperthermia therapy in radio­induced angiosarcoma of the chest wall is presented. 
chapter 4 presents toxicity and local control following reirradiation and hyperthermia 
in breast cancer patients with reconstructions. In chapter 5 the results in 248 patients 
with macroscopic disease treated with 4 hyperthermia treatments and the impact of 
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prognostic factors are described. Treatment outcome is compared to the results of 
randomized trials to investigate whether the high complete response rate achieved 
in randomized trials is maintained in a large unselected group of patients. chapter 6 
presents the results of reirradiation and hyperthermia after surgery for recurrent breast 
cancer showing that treatment with reirradiation plus hyperthermia results in long last­
ing local control.
Part 2 of this thesis focus on the current role and future perspectives of the clinical use 
of hyperthermia treatment planning. In chapter 7 the procedure for creating a 3D model 
for superficial hyperthermia treatment planning is described. The objective of this work 
was to apply treatment modeling for superficial hyperthermia in a well­defined group of 
patients to investigate the potential of predicted 3D energy as source for a dose param­
eter that is prognostic for treatment outcome. In chapter 8, the development and first 
results of a 3D model for superficial hyperthermia in breast cancer patients to enable 
optimization before the start of the hyperthermia treatment is described.
Chapter 1
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abstract
For superficial hyperthermia a custom­built multi­applicator multi­amplifier superficial 
hyperthermia system operating at 433 MHz is utilised. Up to 6 Lucite Cone applicators 
(LCA) can be used simultaneously to treat an area of 600 cm.
Temperatures are measured continuously with fibre optic multi­sensor probes. For 
patients with non­standard clinical problems, hyperthermia treatment planning is used 
to support decision making with regard to treatment strategy.
In 74% of our patients with recurrent breast cancer treated with a reirradiation scheme 
of 8 fractions of 4 Gy in 4 weeks, combined with 4 or 8 hyperthermia treatments, a com­
plete response (CR) is achieved, approximately twice as high as the CR rate following 
the same reirradiation alone. The CR rate in tumours smaller than 30 mm is 80–90%, for 
larger tumours it is 65%. Hyperthermia appears beneficial for patients with microscopic 
residual tumour as well.
To achieve high CR rates, it is important to heat the whole radiotherapy field, and to 
use an adequate heating technique.
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introduction
Reirradiation combined with hyperthermia is an effective treatment for recurrent breast 
cancer. Results from five randomised trials have shown that the complete response 
(CR) rate in breast cancer recurrences increases from 41% to 59% when hyperthermia 
is added to radiotherapy [1]. For the subgroup of patients treated within the ESHO 5­88 
trial with a reirradiation schedule of 8 fractions of 4 Gy, applied twice weekly, the CR rate 
even increased from 38% after radiation alone to 78% after combined treatment.
In Rotterdam, the first patient with recurrent breast cancer was treated with hyper­
thermia in 1978. Over the years, many alterations were made in hyperthermia and ther­
mometry equipment, in treatment procedure, registration and treatment scheme. In 
this review we take you through some of the history of hyperthermia in our department, 
and present the resulting treatment procedure and a summary of our clinical results.
History oF equiPment used
Heating equipment
In 1978 we started our clinical research on hyperthermia with the Pomp­Siemens whole 
body hyperthermia cabin which included several applicators for local hyperthermia [2]. 
These were condenser plates operating at 27 MHz and dipole antennas operating at 
433 MHz or 2450 MHz. With these applicators, originally designed for physiotherapy, 
we treated patients who were reirradiated for palliative reasons, among whom patients 
with recurrent breast cancer.
The first applicators developed in our department were air­filled waveguides operat­
ing at 2450 MHz with aperture sizes of 8 × 4 cm2 and 8 × 6 cm2. The rectangular shapes 
allowed us to use combinations of up to eight applicators at the same time. The number 
of amplifiers was still limited so that up to four applicators were coupled to one power 
supply, without the possibility to control power supply to the individual applicators. 
Surface cooling, when necessary, was performed by directing air currents under the 
applicators.
In 1985 we started using custom built water­filled waveguides operating at 433 MHz 
with a radiating opening of 10 × 10 cm2. Until 1987 we could use maximally two applica­
tors simultaneously, thereafter five and some time later six. Each applicator was supplied 
with independent power control [3]. These standard waveguides were replaced in 1996 
by Lucite cone applicators (LCA), with a larger effective field size (EFS). The EFS of the LCA 
is approximately 100 cm2, which is considerably larger than the 33 cm2 of the standard 
waveguide [4]. The performance of both waveguide types was tested in the clinical 
setting by treating patients alternately by standard waveguides and LCA arrays. The 
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average invasive temperature was 0.28°C higher with the LCA’s than with the standard 
waveguides, which was primarily the result of higher temperatures in the periphery of 
the treatment field. A perfused waterbolus was used with the 433 MHz waveguide ap­
plicators to control surface temperatures.
waterbolus dimensions and selection of waterbolus temperature
The waterbolus placed between water­filled waveguides and skin (Figure 1) has two 
functions: improvement of coupling between the applicators and tissue and control of 
superficial temperature.
Figure 1. Close­up of the applicators placed above the thoracic wall, on top of the perfused waterbolus.
We investigated the effects of waterbolus configuration on the EFS of the LCA [5]. 
Placement of the LCA near the waterbolus edge reduced the EFS considerably. With 
waterbolus heights of more than 2 cm the EFS became more sensitive to distance to the 
waterbolus edge.
Based on the results, the guideline now is that the height of the waterbolus should 
not exceed 2 cm and the waterbolus should extend the LCA aperture at least 2.5 cm, 
especially at the Lucite windows. The two main parameters used for optimizing the tem­
perature distribution are the electromagnetic power and the waterbolus temperature. A 
3D model was set up to simulate an abstraction of the treatment. In the model a convec­
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tion coefficient for the waterbolus to skin surface was employed, which was measured 
for waterboluses of different sizes. The effect of perfusion and fat layer thickness were 
investigated in a layered model.
The performance of the general model was verified against clinical data. The model 
was found to predict the temperature distribution well on a global view, and was used to 
set up guidelines, specific for our equipment, for the waterbolus temperature selection 
for various target depths and applicator arrays [6].
thermometry
We started with thermocouples, either single sensor probes within a needle, or multi­
sensor probes within a catheter. These probes had to be placed perpendicular to the 
direction of the electric field (E­field) and temperatures were measured every 5 minutes 
with the power shut off. Since 1987 temperatures are measured continuously during 
treatments by a 24­channel fiber­optic system, with which five multi­sensor probes (up 
to four sensors) and four single sensor probes are available (Takaoka FT1210).
Closed­tip catheters are placed interstitially immediately before the first treatment 
and left in place till after the last treatment. The aim is to have both interstitial and su­
perficial thermometry under each applicator. Usually, these catheters cause no clinical 
problems [7].
use of hyperthermia treatment planning
Hyperthermia treatment planning tools have a significant potential to further improve 
the quality of hyperthermia treatments, by providing insight into the 3D absorbed 
power distributions. In some patients with non­standard clinical problems, SEMCAD X 
[8] hyperthermia treatment planning was successfully used to support decision making 
with regard to the treatment strategy [9]. Two cases are shortly described here.
A patient with recurrent breast cancer had undergone open heart surgery in the past, 
and sternal cerclage wires were within the target volume for hyperthermia. Treatment 
planning showed that the distortion of the electromagnetic field by the cerclage wires 
was neglectable with the E­field direction perpendicular to the cerclage wires. This 
patient was treated without problems with the applicator configuration advised by the 
planning. The tumour of a patient with a recurrent breast cancer in the infraclavicular 
region was located at a depth of 37 to 54 mm below the skin, which is beyond the super­
ficial system’s standard maximum target depth of 40 mm. However, the subcutaneous 
fat layer in this patient was above average: 29 mm. Because the effective conductivity of 
fatty tissue is relatively low, it could be anticipated that power absorption in the fat layer 
would be limited, and that the remaining power at depth would be sufficient within the 
tumour.
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This was confirmed by hyperthermia treatment planning, and during hyperthermia 
treatment the intratumor temperature reached therapeutic levels.
treatment scheme
When we started combining reirradiation with hyperthermia, the tolerance limits for 
reirradiation were not known. We started cautiously, with total doses of 12­25 Gy, in frac­
tion sizes of 2 to 4 Gy. To avoid thermotolerance, we chose a treatment scheme of hyper­
thermia twice weekly with at least 3­day intervals. In order to sensitize every radiation 
fraction, radiation was also given twice weekly, in fractions of 4 Gy. Hyperthermia was 
given after radiotherapy on the basis of experimental studies showing that maximum 
therapeutic benefit can be obtained with that sequence [10­14].
When we did the first evaluation of the results of reirradiation and hyperthermia in 
97 patients with recurrent breast cancer, we found a large influence of the applied reir­
radiation dose on CR rate. With a total dose of less than 29 Gy the CR rate was 24%, while 
it was 58% after a dose of 30 to 32 Gy. Time till progression was median 4 months after 
a partial response (PR) and 26 months for CR [15]. The reirradiation schedule of eight 
fractions of 4 Gy appeared safe, effective and well tolerated and was therefore selected 
as the standard scheme.
In 1996 we had a capacity problem for superficial hyperthermia. Taking in mind the 
results of several published randomised studies comparing a low with a high number of 
hyperthermia treatments, usually one versus two treatments per week, which showed 
no difference in results [16­21], we decreased the number of hyperthermia sessions to 
four.
The number of patients was insufficient to do a randomised trial ourselves and we 
planned to evaluate the results after treating a sufficient number of patients with the 
new schedule. We did a first analysis of results in patients treated with four hyperther­
mia sessions in 2004 [22] and compared these to those in patients who received eight 
hyperthermia sessions: 40 patients received four and 132 patients eight hyperthermia 
treatments. For patients with a maximum tumour diameter ≤ 30 mm CR rate was 86% 
after eight treatments and 82% after four treatments (not significant).
For patients with larger tumours, CR rate was 59% after eight treatments and 65% 
after four treatments (not significant). The preliminary conclusion is that a decrease in 
number of hyperthermia treatments does not lead to inferior results. On the other hand, 
the hoped­for decrease in hyperthermia toxicity was not observed as well.
A problem with this comparison is that, at around the same time that we changed the 
number of hyperthermia treatments, we also replaced the standard waveguide with the 
LCA, with which we achieved average 0.28°C higher temperatures. Although it is unlikely 
that a 0.28°C higher temperature compensates for 240 minutes treatment duration, we 
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will perform a detailed analysis of prognostic factors including thermal dose parameters 
in these patients.
Footnote;
A retrospective evaluation was performed to compare the outcome in patients with 
breast cancer recurrence treated with reirradiation and either 8 or 4 hyperthermia treat­
ments. One hundred forty­four patients were treated with 8 hyperthermia treatments 
and from 1996 to 2010, 394 patients were treated with 4.
Hyperthermia was given in addition to reirradiation with 8 fractions of 4 Gy in 4 weeks. 
The median follow­up for all patients was 52 months. Overall, CR was achieved in 73% 
of all patients, 79% with 8 hyperthermia treatments and 70% with 4 hyperthermia treat­
ments (p = 0.083). One, 3 and 5 years LC rates with 8 hyperthermia treatments were 79%, 
57%, and 57%, and with 4 hyperthermia treatments 73%, 58%, and 58%, respectively, 
not significantly different (p = 0.679).
Thermal parameters were similar. The cumulative incidence of late toxicity was 2.6%, 
5.0% and 6.2% at 1, 3 and 5 years, respectively. Late grade 3 and 4 toxicity was seen in 
25 patients, four in the 8 hyperthermia group and 21 in the 4 hyperthermia group (p = 
0.172). A detailed analysis of prognostic factors including thermal dose parameters in 
these patients is currently studied and will be published in the near future.
A problem with this comparison is that; Around the same time, we also replaced 
the standard waveguide with the LCA, with which we achieved average 0.28°C higher 
temperature compensates for 240 min treatment duration, the population changed 
from only macroscopic tumors to a group with more microscopic and less macroscopic 
tumors, the quality of the treatment of patients with breast cancer recurrences has 
undergone evolutionary changes over the last 30 years. The use of chemotherapy and 
hormonal therapy has been changed over the time.
lessons learned
no electromagnetically induced hyperthermia in anesthetized patient
We started our clinical hyperthermia research with the idea to apply local hyperthermia 
during whole body hyperthermia, in order to achieve a more homogeneous tempera­
ture distribution.
In the first patient in whom we tried whole body hyperthermia, it appeared that a 
core temperature > 40°C was not tolerated by the conscious patient. We therefore gave 
subsequent treatments under general anesthesia. During the third treatment, core 
temperature was increased to a temperature of 41.6°C and the recurrent tumour at the 
chest wall was simultaneously heated with 433 MHz. One of the thermometry probes 
suddenly showed a steep temperature increase to maximum 47°C.
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After the treatment, the patient developed a severe third degree burn of the thoracic 
wall with a diameter of 100 mm and including ribs [23].
We have seen similar toxicity in two other patients who were treated under general 
anesthesia. During normothermic regional isolation perfusion of the leg for multiple 
skin metastases of malignant melanoma, local hyperthermia was given to one of the 
metastases.
Hyperthermia was given with a 2450 MHz dipole antenna with a diameter of 80 mm 
and interstitial temperatures were average between 39.2°C and 40.9°C.
In two of three patients treated this way, in whom the measured maximum tempera­
ture had been 41.4°C and 40.3°C, a third­degree burn developed.
Unnoticed hot spots resulting in toxicity can occur in conscious patients as well, at 
sites of decreased sensitivity due to previous surgery, but usually some sensation of pain 
limits the extent of the damage.
no stray irradiation near linear accelerator
For a short period of time, we treated our patients in an orthovoltage room which was 
located next to a linear accelerator. The microwave equipment at that time consisted 
of a circular field dipole antenna connected to a generator operating at 433 MHz. In 
the Netherlands, 433 MHz can be used without shielding. The linear accelerator was a 
CGR­MeV Sagittaire. We found that the stray microwave radiation, at intensities of about 
0.4 mW/cm2 in the control room of the accelerator interfered with the beam energy 
settings. The microwave interference caused an increase in beam energy. At maximum 
power output this was a change from 25.5 to 29.1 MeV [24]. The most practical solution 
to this problem was to transfer the hyperthermia treatment to another room.
Heating technique is important for treatment outcome
In the first evaluation of treatment results in the group of patients treated with eight 
fractions of 4 Gy and hyperthermia, we found a CR rate of 58% [15]. When we evaluated 
later a larger group of patients, the CR rate was 71%.
A multivariate analysis showed that two factors were independent and significantly 
associated with local control probability: tumour size (maximum diameter < 3 cm or > 
3 cm) and used equipment (2450 MHz or 433 MHz equipment) [25]. The better overall 
results were the effect of a large improvement in CR rate in the larger tumours: 31% with 
2450 MHz heating and 65% with 433 MHz heating.
In tumours < 3 cm the results of 2450 and 433 MHz heating were not different; ap­
proximately 90% CR. The CR rate achieved with 2450 MHz in the larger tumours was 
similar to the results of reirradiation with 8×4 Gy without hyperthermia: 28% in the RTOG 
study [26] and 38% in the ICHG study [1]. Apparently, 2450 MHz heating was inadequate 
39
Reirradiation combined with hyperthermia in breast cancer recurrences ­ overview of experience in Erasmus MC
for the larger tumours. A disadvantage of using 2450 MHz compared to 433 MHz is the 
smaller penetration depth and thereby a smaller heated volume.
From this experience we learned that patients should not be accepted for hyperther­
mia treatment if we expect that we cannot adequately heat the whole target volume.
whole reirradiation volume is target for hyperthermia
Until July 1987, the aim of treatment was to heat the macroscopic tumour. With that 
approach, we observed in a few patients tumour regrowth within the radiation field, 
outside the margin of the hyperthermia field. At the same time, there was no regrowth 
within the combined treated field. Since then we choose the applicator set­up such that 
the radiation field is widely covered.
Further experiences suggest that hyperthermia is an effective additional treatment 
for microscopic tumour. The patient population in which we found better outcomes 
after 433 MHz heating compared to 2450 MHz heating included total 15 patients with 
microscopic disease. Three patients treated with 2450 MHz equipment all developed 
in­field tumour regrowth 10­12 months after start treatment.
In 12 patients treated with 433 MHz equipment only two in­field re­recurrences 
occurred, 10 and 13 months after start treatment. Three patients died with a locally 
controlled tumour after median 10 months and seven patients were still alive with a 
locally controlled tumour 16­70 months after treatment. This is a significant difference, 
suggesting that good­quality hyperthermia is effective here as well [25].
a tumour near the eye can be treated successfully
A patient was referred with a metastatic lesion of breast cancer in the lower eyelid, recur­
ring after two radiation treatments with partially overlapping fields. The tumour was 
progressive under second­line hormonal therapy and she was unfit for chemotherapy. 
The first local treatment of this tumour had been irradical resection (positive surgical 
margins) and radiotherapy, 10×3 Gy plus boost of 10×2 Gy. The tumour recurred 9 
months later at the margin of the radiotherapy field, was treated again with irradical 
surgery and 15×2 Gy. Four months later the tumour recurred again. With the patient 
two treatment options were discussed: surgery, including enucleation of the eye, or 
reirradiation with hyperthermia, with unknown risk of toxicity like eyelid fibrosis, retina 
damage, cataract and glaucoma. The patient preferred radiotherapy and hyperthermia. 
During radiotherapy the eyeball was shielded with a leaden contact lens.
We applied eight fractions of 4 Gy and four hyperthermia treatments of 60 minutes. 
The tumour regressed fast with a complete regression established one week after the 
last treatment. During follow­up, local tumour control was maintained.
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The only side effect was a dry eye for which the patient used eyedrops. Vision was 
unchanged. The patient died 22 months after the last treatment owing to a cerebrovas­
cular accident, unrelated to breast cancer [27].
no excessive toxicity in patients with tissue transfers
Between 1992 and 2009, 36 patients were treated on total 37 tissue transfers, including 
split skin grafts (15), transverse rectus abdominis myocutaneous (1), latissimus dorsi (14) 
or rhomboid (1) flaps or a combination of grafts and flaps.
The guidelines for treating these patients were not different from those for other 
patients. Hyperthermia toxicity (according to CTCAE version 3) grade 2 (minimal medi­
cal intervention required, no interference with ADL (activities of daily life) occurred in 
four patients and grade 3 (surgical intervention required and/or interference with ADL) 
in three. The incidence of toxicity appears not much different from that observed in 
patients without tissue transfer and is acceptable [28].
current treatment Procedure
Patient selection
In the Netherlands, national guidelines prescribe reirradiation and hyperthermia for 
recurrent breast cancer after previous irradiation in the same area, when the expected 
survival is 6 months or more. This concerns inoperable tumours, irradically resected 
tumours (tumour positive surgical margins), or radically resected tumours with a high 
risk of re­recurrence (multifocal recurrences or second recurrences).
The aim of the treatment is a CR, which means that it must be possible to heat the 
whole target volume. The target volume should be within 40 mm from the skin surface, 
but on occasion subcutaneous fat can be subtracted from this distance. It must be fea­
sible to place the applicators parallel to the surface of the treatment area.
When the area is larger than 20 × 30 cm2, two (or more) hyperthermia applications are 
scheduled for one treatment. We consider a pacemaker a contraindication for hyper­
thermic treatment. Metallic implants larger than surgical clips may give problems, e.g. a 
portacath has to be removed. In case of doubt we will model a treatment with SEMCAD 
X.
The patients receive a detailed explanation of the treatment procedure and informa­
tion on their own role in monitoring the temperature distribution, specifically instruc­
tions concerning the mentioning of complaints induced by hot spots.
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Preparation before first treatment
The treatment team of physician or nurse practitioner, physicist and technician examine 
the treatment area and decide which applicator set­up will be used. The aim is to cover 
the whole radiotherapy field with the footprint of the applicator array with an overlap 
of 1 cm all around.
Thereafter the closed tip catheters are placed under local anaesthesia, with the aim 
to have interstitial thermometry under each of the applicators. The catheters are fixed 
to the skin with Histoacryl® tissue adhesive (B. Braun, Melsungen AG, Germany) and 
Tegaderm® transparent dressing (3M, USA). The interstitial length and depth of each 
catheter are measured.
A life­size drawing of the treatment area is made on a transparent sheet including 
some anatomical landmarks (prominent bones, scars, and birth marks), the radiotherapy 
field margins, the location of macroscopic tumour, the location of the applicators, and 
the location of interstitial and superficial thermometry probes [29]. All necessary infor­
mation is loaded into the computer program for treatment monitoring, steering and 
registration.
The patient is positioned on the treatment bed in a position as comfortable as pos­
sible, and up to 23 thermometry probes are placed within the catheters and on the skin. 
Multi­sensor probes with four measuring points at 20 mm spacing are placed in the 
catheters, some of the superficial probes are placed on scars.
The applicator position is indicated on a gauze which is placed on the surface of 
the treatment area and then wetted. The waterbolus is placed such that it extends the 
planned position of the applicators with at least 25 mm. The waterbolus temperature is 
selected depending on the size of the waterbolus and the depth of the target volume.
Usually the applicators are placed “clockwise”: adjacent applicators have their E­field 
direction perpendicular to each other [4].
treatment
The treatment is administered by the technician. All necessary information is visible on 
PC screens during treatment: the position of all applicators and thermometry probes in 
relation to the patient’s anatomy, the power output and reflected power per applicator, 
the course of temperature under each applicator and the current temperature at each 
measuring site (Figures 2 and 3). The first treatment starts with a power of 30 W per ap­
plicator. The increase of power per applicator depends on the steepness of temperature 
increase under the specific applicator.
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Figure 2. The superficial hyperthermia treatment set­up. The technician observes both the patient and 
the temperature and power information. The PC screens show, from left to right (left) the course of tem­
peratures over time, per applicator; (middle) the drawing of the treated area with location of applicators 
and actual temperature per measuring site (details are shown in Figure 3), and (right) the power output 
per applicator.
Figure 3. An example of the middle PC screen during treatment with the drawing of the ventral treatment 
area. The drawing shows the tumour tissue, the mastectomy scar, four interstitially placed catheters, the 
footprints of the applicators, and actual interstitial (in bold) and superficial temperatures.
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The aim is to have all interstitial temperatures above 40°C. An interstitial temperature of 
maximum 43°C is allowed during the first 30 minutes, thereafter maximum 44°C.
In tumour tissue at a distance of more than 10 mm from normal tissue higher tem­
peratures are allowed. The treatment duration is 60 minutes with power on.
Evaluation between treatments, the course of the previous treatment is discussed with 
the whole team and adjustments for the application of the next treatment determined.
Special attention is paid to cold spots (average temperature below 40°C), treatment 
limiting hot spots, and the temperature distribution in depth. If a cold or a hot spot can 
be explained by the expected SAR distribution, the position of the applicators or their 
E­field direction is changed.
If superficial temperatures were power­limiting during treatment, the waterbolus 
temperature is decreased. If the treatment quality is limited by tumour related pain, 
general stress or anxiety, appropriate medication will be given during subsequent treat­
ments. A detailed description of this evaluation can be found in [30].
results
effect on tumour
Since we use 433 MHz for the application of hyperthermia, the results are rather stable. 
In 1999 we published a CR rate of 74% for the total group of patients treated with eight 
fractions of 4 Gy and eight hyperthermia treatments, 87% for patients with tumours 
smaller than 30 mm and 65% for patients with larger tumours [25]. With the same reir­
radiation schedule combined with four hyperthermia treatments, the overall CR rate is 
73%; 82% for small tumours and 65% for larger tumours [22].
The median duration of local tumour control is 32 months. In patients treated for 
a microscopic tumour residual, the local tumour control rate till death or date of last 
follow­up was 83% for the patients who received eight hyperthermia treatments and 
84% for those receiving four hyperthermia treatments.
toxicity
Acute radiation toxicity usually is no problem with this schedule with an incidence of 
epidermolysis in 11% of the patients [25]. In the randomised trial, no increase in radiation 
toxicity was found [1]. One case report even suggests a decrease in late toxicity (telangi­
ectasis) with the addition of hyperthermia [31]. Hyperthermia toxicity is rather frequent 
in these patients. In 1999 we reported second­degree burns in 19% of the patients and 
third­degree burns in 7% and subcutaneous burns in 3% after eight 433 MHz treatments. In 
71 patients who received four treatments we observed second­degree burns in 31%, third­
degree burns in 10% and subcutaneous burns in 7%. These side­effects usually are grade 2 
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or less according to the Common Terminology Criteria for Adverse Events version 3.0 scor­
ing system. The hyperthermia­induced burns generally cause no pain because they occur 
at sites of decreased sensitivity. Late radiation toxicity was evaluated in 121 patients treated 
with reirradiation (8 × 4 Gy) and hyperthermia (eight treatments) between 1992 and 2000. 
The overall incidence of late radiation toxicity was 12%: a skin ulcer in six patients, bone 
necrosis or fracture in seven patients, and both an ulcer and bone fracture in one patient.
The incidence of late radiation toxicity however increased with longer follow­up 
durations. In 38 patients with a follow­up duration >3 years it was 18%, and in eight 
patients followed longer than 5 years it was 38%. The median follow­up of all patients 
was between 1 and 2 years [van der Zee, unpublished results].
discussion
In approximately three­quarter of our patients, reirradiation with eight fractions of 4 Gy 
combined with hyperthermia results in a CR, which lasts for a median duration of 32 months.
In over 80% of the patients treated for microscopic disease, local tumour control lasts 
till death or date of last follow­up. We do not expect that a locally controlled chest wall 
recurrence will influence overall survival. Nevertheless, the absence of symptomatic 
local tumour can result in an improvement in quality of life [32]. In our view, the achieve­
ment of a partial response is less worthwhile, since regrowth is observed after median 4 
months and we find it unlikely that hyperthermia influences time to progression. That is 
the reason that we do not accept patients for hyperthermia treatment when we can heat 
only part of the target volume.
We have not included a test heating session in the patient selection procedure. Pa­
tients are selected on the basis of tumour location and extension in depth. We assume 
that a target volume can be adequately heated when the depth is limited to 4 cm from 
the skin surface and the applicators can be placed parallel to the surface over the whole 
target area. The results of the randomised trial of Jones et al., for which patients were eli­
gible after a test treatment had shown “heatability” (the achievement of a hyperthermia 
dose of 0.5 CEM43°CT90) [33], has triggered us to evaluate retrospectively this thermal 
dose parameter in our patients.
CR rates were the same for patients who were heatable and unheatable, and for patients 
who received less or more than 10 CEM43°CT90 during the whole treatment series [34].
Many clinical studies on hyperthermia in addition to radiotherapy included patients 
with recurrent breast cancer after previous irradiation. The results in this specific sub­
group, however, are not always reported separately. Table 1 summarizes CR rates in this 
subgroup which are available from published experience [1,21,26,35­52]. This table 
includes three studies in which not all but the majority of patients were reirradiated, 
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and one study reporting CR combined with partial response with >80% regression. Four 
studies included a control group treated with the same radiation alone: 3 randomised 
studies and one study in which patients with multiple lesions received radiation alone 
to 1 lesion and combined treatment to another. CR rates following reirradiation and 
hyperthermia vary widely, from 20% to 95%.
table 1. Results of reirradiation and hyperthermia in recurrent breast cancer.
Legend to Table 1:
Reference: *M: matched lesions; *R: randomized study; *reRT: % of patients that was reirradiated; RT = ra­
diotherapy.
RT dose and scheme: F = fraction size; T = total dose in Gy; n/wk = number of fractions per week; *C: treat­
ment schedule included chemotherapy as well; ETD = equivalent total radiation dose based on linear qua­
dratic model; HT = hyperthermia.
HT technique and scheme: A = application technique: microwave frequency, US = ultrasound, MW = mi­
crowave equipment and RF = radiofrequency equipment, not otherwise specified; R­H = HT after RT; D = 
duration per treatment in minutes (+: extra heating­up time); N = number of treatments.
CR after RT+HT: ª = no difference between 3 schemes
Chapter 2
46
This is not surprising, since the used radiotherapy schedule varies between studies and 
also within studies, and the prognostic variables of included patients will differ between 
studies as well. A summation of the data results in 61% CR after combined treatment and 
32% after radiotherapy alone. In the majority of studies, hyperthermia is combined with 
radiotherapy only and applied after radiation. Unusual approaches are simultaneous 
combination of radiation and hyperthermia and the addition of chemotherapy.
Myerson et al. [46] tested the simultaneous combination of radiotherapy and hyper­
thermia in 15 patients and achieved a CR in 79%. Feyerabend et al. [47] applied once 
weekly epirubicin and ifosfamide, simultaneously with hyperthermia, in the period 
of radiotherapy. Kouloulias et al. [48] applied once monthly liposomal doxorubicin 3 
to 40 hours before hyperthermia, once during the perod of radiotherapy and 5 times 
thereafter. The CR rates in the last two studies were lower than in all other studies: 22% 
and 20% respectively.
We find the schedule of 2 fractions of 4 Gy per week attractive in view of the pallia­
tive aim of the treatment. The overall duration of a treatment series is 3.5 weeks, during 
which period patients have to come to the hospital only twice weekly for around 2 
hours, so the inconvenience is limited. On the other hand, the incidence of late toxicity 
can be expected to be lower with a radiation schedule with smaller fraction sizes [53,54].
Oldenborg et al. recently reported a 40% incidence of ≥ grade 3 toxicity at three years 
in 78 patients treated with 8 x 4 Gy and hyperthermia for microscopic disease [55]. In our 
patients it was 38% at five years follow­up. For the majority of patients late toxicity will 
not be a problem in view of the limited overall survival, but for the patients with a longer 
expected overall survival smaller fraction sizes may be considered.
We are now investigating the potential use of predicted 3D SAR (Specific Absorption 
Rate) coverage as a prognostic indicator for treatment outcome. Patient­specific treat­
ment planning is done with SEMCAD X [8].
Predicted SAR­volume histograms, total absorbed energy per tissue type and calcu­
lated temperatures will be compared with measured temperatures, and we will analyse 
whether the predicted treatment quality correlates with treatment outcome.
A correlation of predicted treatment quality with measured temperatures, and/or with 
clinical outcome, would allow to abandon interstitial thermometry, to prescribe treat­
ments of a certain quality, and to apply reproducible treatments.
conclusions
It is feasible to achieve CR rates of 65 to 90% in breast cancer recurrences when reir­
radiation is combined with hyperthermia. The burden to the patient can be limited to 
four 2­hour visits to the clinic. To achieve high CR rates, it is important to heat the whole 
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radiotherapy field, and to choose an adequate heating technique. In special cases, hy­
perthermia treatment planning can be applied to support clinical decisions.
Chapter 2
48
reFerences
 [1]  Vernon CC, Hand JW, Field SB, Machin D, Whaley JB, van der Zee J, van Putten WLJ, van Rhoon GC, 
van Dijk JDP, Gonzalez Gonzalez D, Liu F­F, Goodman P and Sherar M. International Collaborative 
Hyperthermia Group. Radiotherapy with or without hyperthermia in the treatment of superficial 
localized breast cancer ­ results from five randomised controlled trials. Int J Radiat Oncol Biol Phys 
1996;35:731­744.
 [2]  Reinhold HS, van der Zee J, Faithfull NS, van Rhoon GC, Wike­Hooley J, Utilization of the Pomp­
Siemens hyperthermia cabin. Natl Cancer Inst Monogr 1982;61:371­375.
 [3]  van Rhoon GC, Rietveld PJM, van der Zee J. A 433 MHz Lucite Cone waveguide applicator for 
superficial hyperthermia. Int J Hyperthermia 1998;14:13­27.
 [4]  Rietveld PJM, van Putten WLJ, van der Zee J, van Rhoon GC. Comparison of the clinical effective­
ness of the 433 MHz Lucite Cone Applicator with that of a conventional wave guide applicator in 
applications of superficial hyperthermia. Int J Radiat Oncol Biol Phys 1999;43:681­687.
 [5]  de Bruijne M, Samaras T, Bakker JF, van Rhoon GC. Effects of waterbolus size, shape and con­
figuration on the SAR distribution pattern of the Lucite cone applicator. Int J Hyperthermia 
2006;22:15­28.
 [6]  van der Gaag ML, de Bruijne M, Samaras T, van der Zee J, van Rhoon GC. Development of a 
guideline for the water bolus temperature in superficial hyperthermia. Int J Hyperthermia 
2006;22:637­656.
 [7]  van der Zee J, van Rhoon GC, Broekmeyer­Reurink MP, Reinhold HS. The use of implanted closed­
tip catheters for the introduction of thermometry probes during local hyperthermia treatment 
series. Int J Hyperthermia 1987;3:337­345.
 [8]  SEMCAD Reference Manual. Zürich, Switzerland: Schmid & Partner Engineering AG; 2004. Ac­
cessed 24 November 2005. Available online at: http//www.semcad.com.
 [9]  de Bruijne M, Wielheesen DHM, van der Zee J, Chavannes N, van Rhoon GC. Benefits of superficial 
hyperthermia treatment planning: five case studies. Int J Hyperthermia 2007;23:417­429.
 [10]  Gillette EL, Ensley BA. Effect of heating order on radiation response of mouse tumor and skin. Int 
J Radiat Oncol Biol Phys 1979;5:209­213.
 [11]  Hill SA, Denekamp J. The response of six mouse tumours to combined heat and X rays: implica­
tions for therapy. Br J Radiol 1979;52:209­218.
 [12]  Hiraoka M, Miyakoshi J, Jo S, Takahashi M, Abe M. Effects of step­up and step­down heating 
combined with radiation on murine tumor and normal tissues. Jpn J Cancer Res 1987;78:63­67.
 [13]  Overgaard J, Overgaard M. Hyperthermia as an adjuvant to radiotherapy in the treatment of 
malignant melanoma. Int J Hyperthermia 1987;3:483­501.
 [14]  van der Zee J, De Bruijne M, van Rhoon GC. Letter to the Editor. Hyperthermia dose and schedule: 
no evidence yet for changing treatment design. Int J Hyperthermia 2006;22:433­447.
 [15]  van der Zee J, Treurniet­Donker AD, The SK, Helle PA, Seldenrath JJ, Meerwaldt JH, Wijnmaalen AJ, 
van den Berg AP, van Rhoon GC, Broekmeyer­Reurink MP and Reinhold HS. Low dose reirradiation 
in combination with hyperthermia: a palliative treatment for patients with breast cancer recur­
ring in previously irradiated areas. Int J Radiat Biol Phys Oncol 1988;15:1407­1413.
 [16]  Arcangeli G, Nervi C, Cividalli A, Lovisolo GA. Problem of sequence and fractionation in the clini­
cal application of combined heat and radiation. Cancer Res 1984;44:4857s­4863s.
 [17]  Valdagni R. Two versus six hyperthermia tratments in combination with radical irradiation for 
fixed metastatic neck nodes: progress report. Recent Results Cancer Res 1988;107:123­128.
49
Reirradiation combined with hyperthermia in breast cancer recurrences ­ overview of experience in Erasmus MC
 [18]  Kapp DS, Petersen IA, Cox RS, Hahn GM, Fessenden P, Prionas SD, Lee ER, Meyer JL, Samulski TD, 
Bagshaw MA. Two or six hyperthermia treatments as an adjunct to radiation therapy yield similar 
tumor responses: results of a randomized trial. Int J Radiat Oncol Biol Phys 1990;19:1481­1495.
 [19]  Emami B, Myerson RJ, Cardenes H, Paris KG, Perez CA, Straube W, Leybovich L, Mildenberger 
M, Kuske RR, Devineni R, Kucik N. Combined hyperthermia and irradiation in the treatment of 
superficial tumors: results of a prospective randomized trial of hyperthermia fractionation (1/wk 
vs 2/wk). Int J Radiat Oncol Biol Phys 1992;24:145­152.
 [20]  Engin K, Tupchong L, Moylan DJ, Alexander GA, Waterman FM, Komarnicky L, Nerlinger RE, 
Leeper DB. Randomized trial of one versus two adjuvant hyperthermia treatments per week in 
patients with superficial tumours. Int J Hyperthermia 1993;9:327­340.
 [21]  Lindholm C­E, Kjellen E, Nilsson P, Weber L, Hill S. Prognostic factors for tumour response and skin 
damage to combined radiotherapy and hyperthermia in superficial recurrent breast carcinomas. 
Int J Hyperthermia 1995;11:337­355.
 [22]  van der Zee J, Mens JW, Graveland WJ, Verloop­van ’t Hof EM, van Rhoon GC. Comparison be­
tween 4 and 8 hyperthemia treatments combined with reirradiation for breast cancer. Presented 
at 9th International Congress on Hyperthermic Oncology, Saint Louis 2004.
 [23]  van der Zee J, van Rhoon GC, Wike­Hooley JL, Faithfull NS, Reinhold HS. Whole­body hyperther­
mia in cancer therapy: a report of a phase I­II study. Eur J Cancer Clin Oncol 1983;19:1189­1200.
 [24]  van Rhoon GC, van de Poel JA, Van der Heiden JA, Reinhold HS. Interference of 433 MHz micro­
waves with a megavoltage linear accelerator. Phys Med Biol 1984;29:719­723.
 [25]  van der Zee J, van der Holt B, RietveldPJM, Helle PA, Wijnmaalen AJ, van Putten WLJ and van 
Rhoon GC. Reirradiation combined with hyperthermia in recurrent breast cancer results in a 
worthwhile local palliation. British J. Cancer, 1999; 79:483­490
 [26]  Perez CA, Pajak T, Emami B, Hornback NB, Tupchong L, Rubin P. Randomized phase III study 
comparing irradiation and hyperthermia with irradiation alone in superficial measurable tumors. 
Am J Clin Oncol 1991;14:133­141.
 [27]  van der Zee J, Koper PCM, Jansen RFM, de Winter KAJ, van Rhoon GC. Re­irradiation and hy­
perthermia for recurrent breast cancer in the orbital region: a case report. Int J Hyperthermia 
2004;20:1­6.
 [28]  Linthorst M, van Rhoon GC, Broekmeyer­Reurink MP, Drizdal T, van der Zee J. The tolerance of skin 
transfers for reirradiation and hyperthermia. Presented at 26th Annual Meeting of the European 
Society for Hyperthermic Oncology, Rotterdam 2010.
 [29]  Broekmeyer­Reurink MP, Rietveld PJM, van Rhoon GC, van der Zee J. Some practical notes on 
documentation of superficial hyperthermia treatment. Int J Hyperthermia 1992;8:401­406.
 [30]  de Bruijne M, van der Zee J, Ameziane A, van Rhoon GC. Quality control of superficial hyperther­
mia by treatment evaluation. Int J Hyperthermia 2011;27:199­213.
 [31]  van der Zee J, Wijnmaalen AJ, Haveman J, Woudstra E and van der Ploeg SK. Hyperthermia may 
decrease the development of telangiectasia after radiotherapy. Int J Hyperthermia 1998;14:57­
64.
 [32]  Liu F­F, Bezjak A, Levin W, Cooper B, Pintilie M, Sherar MD. Letter to the Editor. Assessment of 
palliation in women with recurrent breast cancer. Int J Hyperthermia 1996;12:825­826.
 [33]  Jones EL, Oleson JR, Prosnitz LR, Samulski TV, Vujaskovic Z, Yu D, Sanders LL, Dewhirst MW. 
Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol 2005;23:3079­
3085.
 [34]  de Bruijne M, van der Holt B, van Rhoon GC, van der Zee J. Evaluation of CEM43°CT90 thermal 
dose in superficial hyperthermia: a retrospective analysis. Strahlenther Onkol 2010;186:436­443.
Chapter 2
50
 [35]  Fazekas JT, Nerlinger RE. Localized hyperthermia adjuvant to irradiation in superficial recurrent 
carcinomas: a preliminary report on 46 patients. Int J Radiat Oncol Biol Phys 1981;7:1457­1463.
 [36]  Lindholm C­E, Kjellen E, Nilsson P, Hertzman S. Microwave­induced hyperthermia and radio­
therapy in human superficial tumours: clinical results with a comparative study of combined 
treatment versus radiotherapy alone. Int J Hyperthermia 1987;3:393­411.
 [37]  González González D, van Dijk JDP, Blank LECM. Chestwall recurrences of breast cancer: results of 
combined treatment with radiation and hyperthermia. Radiotherapy and Oncology 1988;12:95­
103.
 [38]  Egawa S, Tsukiyama I, Watanabe S, Ohno Y, Morita K, Tominaga S, Onoyama Y, Hashimoto S, 
Yanagawa S, Uehara S, Abe M, Mochizuki S, Sugiyama A, Inoue T. A randomized clinical trial of 
hyperthermia and radiation versus radiation alone for superficially located cancers. J Jpn Soc Ther 
Radio Oncol 1989;1:135­140.
 [39]  Dragovic J, Seydel HG, Sandhu T, Kolosvary A. Blough J. Local superficial hyperthermia in combi­
nation with low­dose radiation therapy for palliation of locally recurrent breast carcinoma. J Clin 
Oncol 1989;7:30­35.
 [40]  Li RY, Lin SY, Zhang TZ. Assessment of combined thermoradiotherapy in recurrent or advanced 
carcinoma of the breast. Adv Exp Med Biol 1990;267:521­523.
 [41]  Dubois JB, Hay M, Bordure G. Superficial microwave­induced hyperthermia in the treatment of 
chest wall recurrences in breast cancer. Cancer 1990;848­852.
 [42]  Masanuga S, Hiraoka M, Takahashi M, Jo S, Akuta K, Nishimura Y, Nagata Y, Abe M. Clinical results 
of thermoradiotherapy for locally advanced and/or recurrent breast cancer – comparison of 
results with radiotherapy alone. Int J Hyperthermia 1990;6:487­497.
 [43]  Phromratanapongse P, Steeves RA, Severson SB, Paliwal BR. Hyperthermia and irradiation for 
locally recurrent previously irradiated breast cancer. Strahlenther Onkol 1991;167:93­97.
 [44]  Engin K, Tupchong L, Waterman FM, Komarnicky L, Mansfield CM, Hussain N, Hoh LL, McFarlane 
JD, Leeper DB. Multiple field hyperthermia combined with radiotherapy in advanced carcinoma 
of the breast. Int J Hyperthermia 1994;10:587­603.
 [45]  Lee HK, Antell AG, Perez CA, Straube WL, Ramachandran G, Myerson RJ, Emami B, Molmenti EP, 
Buckner A, Lockett MA. Superficial hyperthermia and irradiation for recurrent breast carcinoma 
of the chest wall: prognostic factors in 196 tumors. Int J Radiat Oncol Biol Phys 1998;40:365­375.
 [46]  Myerson RJ, Straube WL, Moros EG, Emami BN, Lee HK, Perez CA, Taylor ME. Simultaneous su­
perficial hyperthermia and external radiotherapy: report of thermal dosimetry and tolerance to 
treatment. Int J Hyperthermia 1999;15:251­266.
 [47]  Feyerabend T, Wiedemann GJ, Jäger B, Vesely H, Mahlmann B, Richter E. Local hyperthermia, 
radiation, and chemotherapy in recurrent breast cancer is feasible and effective except for inflam­
matory disease. Int J Radiat Oncol Biol Phys 2001;49:1317­1325.
 [48]  Kouloulias VE, Dardoufas CE, Kouvaris JR, Gennatas CS, Polyzos AK, Gogas HJ, Sandilos PH, Uzu­
noglu NK, Malas EG, Vlahos LJ. Liposomal doxorubicin in conjunction with reirradiation and local 
hyperthermia treatment in recurrent breast cancer: a phase I/II trial. Clin Canc Res 2002;8:374­
382.
 [49]  Ben Yosef R, Vigler N, Inbar M, Vexler A. Hyperthermia combined with radiation therapy in the 
treatment of local recurrent cancer. IMAJ 2004;6:392­395.
 [50]  Li G, Mitsumori M, Ogura M, Horii N, Kawamura S, Masanuga S, Nagata Y, Hiraoka M. Local hy­
perthermia combined with external irradiation for regional recurrent breast carcinoma. Int J Clin 
Oncol 2004;9:179­183.
51
Reirradiation combined with hyperthermia in breast cancer recurrences ­ overview of experience in Erasmus MC
 [51]  Wahl AO, Rademaker A, Kiel KD, Jones EL, Marks LB, Croog V, McCormick BM, Hirsch A, Karkar MS, 
Motwani SB, Tereffe W, Yu T­K, Her D, Silverstein J, Kachnic LA, Kesslering C, Freedman GM, Small 
W. Multi­institutional review of repeat irradiation of chest wall and breast for recurrent breast 
cancer. Int J Radiat Oncol Biol Phys 2008;70:477­484.
 [52]  Gabriele P, Ferrara T, Baiotto B, Garibaldi E, Marini PG, Penduzzu G, Giovanni V, Bardati F, Guiot C. 
Radio hyperthermia for re­treatment of superficial tumours. Int J Hyperthermia 2009;25:189­198.
 [53]  Turesson I, Thames HD. Repair capacity and kinetics of human skin during fractionated therapy, 
erythema, desquamation, and telangiectasis after 3 and 5 year’s follow­up. Radiotherapy and 
Oncology 1989;15:169­188.
 [54]  Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M. Toler­
ance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109­122.
 [55]  Oldenborg S, van Os RM, van Rij CM, Crezee J, van de Kamer JB, Rutgers EJT, Geijsen ED, Zum 
Vörde sive Vörding PJ, Koning CCE, van Tienhoven G. Elective re­irradiation and hyperthermia 
following resection of persistent locoregional breast cancer: a retrospective study. Int J Hyper­
thermia 2010;26:136­144.

 Chapter 3
Eﬀ ect of a combined surgery, 
reirradiation and hyperthermia therapy 
on local control rate in radio-induced 
angiosarcoma of the chest wall
M Linthorst, AN van Geel, EA Baartman, SB Oei, W Ghidey, GC van Rhoon, 
J van der Zee
Strahlenther Onkol 2013;189:387-393.
Chapter 3
54
abstract
Purpose: Radiation­induced angiosarco ma (RAS) of the chest wall/breast has a poor 
prognosis due to the high percentage of lo cal failures. The efficacy and side effects of 
reirradiation plus hyperthermia (reRT + HT) treatment alone or in combination with sur­
gery were assessed in RAS patients.
Patients and methods: RAS was diagnosed in 23 breast cancer patients and 1 patient 
with melanoma. These patients had previ ously undergone breast conserving thera py 
(BCT, n=18), mastectomy with irradiation (n=5) or axillary lymph node dissection with 
irradiation (n=1). Treatment consisted of sur gery followed by reRT + HT (n=8), reRT + HT 
followed by surgery (n=3) or reRT + HT alone (n=13). Patients received a mean radiation 
dose of 35 Gy (32–54 Gy) and 3–6 hyperther mia treatments (mean 4). Hyperthermia was 
given once or twice a week following radio therapy (RT).
 
Results: The median latency interval be tween previous radiation and diagnosis of RAS 
was 106 months (range 45–212 months). Following reRT + HT, the complete response 
(CR) rate was 56%. In the subgroup of pa tients receiving surgery, the 3­month, 1­ and 
3­year actuarial local control (LC) rates were 91, 46 and 46%, respectively. In the subgroup 
of patients without surgery, the rates were 54, 32 and 22%, respectively. Late grade 4 RT 
toxicity was seen in 2 patients.
 
Conclusion: The present study shows that reRT + HT treatment­either alone or com bined 
with surgery­improves LC rates in pa tients with RAS.
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introduction
Radiation induced angiosarcoma (RAS) of the chest wall/breast is one of the most ag­
gressive types of tumor that can devel op in an irradiated area after breast con serving 
therapy (BCT) [19,25,31,39,40]. It constitutes less than 1% of all breast can cers [39]. RAS 
is thus a relatively rare com plication of BCT, but its incidence is likely to increase as more 
women undergo this treatment [12,24,32]. In three published series, the median times 
between BCT and RAS diagnosis were 59, 91 and 74 months [6,7,8]. Most cutaneous 
angiosarcomas are not amenable to surgical resection and a number of patients show 
metasta ses at diagnosis or develop them shortly after [1]. The prognosis of RAS patients 
is poor and the reported 5­year overall sur vival (OS) rate varies from 10 to 38% [9, 13, 39]. 
The most common cause of death is local progression along the chest wall [9]. Establish­
ment of local control (LC) is thus important for preventing distressing symptoms [27].
The occurrence of RAS in a previously irradiated field limits the therapeutic options. In 
many cases, sur gery is unfeasible and even after obtain ing negative margins by simple 
mastecto my, additional local tumors recur in ap proximately 70% of patients (29–100%) 
[3,7,13,16,20,23,28,29]. Full­dose reirra diation is usually not possible and reir radiation 
alone does not improve surviv al rate [21]. Reirradiation plus hyperther mia (reRT + HT) 
is an effective treatment for recurrent breast cancer with accept able toxicity. Results 
from five random ized trials have shown that the complete response (CR) rate for breast 
cancer re currences increases from 41 to 59% when hyperthermia is combined with 
radio therapy [36]. Multimodal therapies com prising surgery and reRT + HT may im prove 
local tumor control in the treatment of angiosarcoma [26].
In an attempt to improve LC rates, we have treated RAS patients with a combina tion 
of surgery wherever this was feasible, and reRT + HT. Results of a retrospective analysis 
are reported here.
materials and metHods
Patient characteristics
Between 2000 and 2011, 24 patients with pathologically confirmed RAS of the chest wall 
underwent surgery where feasible, and reRT + HT. Hyperthermia treatments were ap­
plied in the Erasmus MC­Daniel den Hoed Cancer Center (DHCC, n=21) and the Bernard 
Verbeeten Institute (BVI, n=3). Of the 24 patients, 23 had been treat ed for primary breast 
cancer by modified radical mastectomy followed by either ra diotherapy (n=4) or BCT 
(n=19). One pa tient had been treated for axillary melano ma.
RAS presentation varied and included purple cutaneous discoloration, eczema tous 
rash, swelling of the breast and re gional lymphadenopathy [22]. In all cas es, the RAS 
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diagnosis had been confirmed pathologically. Patient and tumor charac teristics are 
summarized in Table 1.
table 1. Characteristics of patients and tumors (n=24)
Legend to Table 1:
EQD2 equivalent dose in 2 Gy fractions, BCT breast conserving therapy, LND lymph node dissection. aAge in 
years at diagnosis of angiosarcoma bInterval in months between primary radiotherapy and angiosarcoma 
cSurgery after radiotherapy and hyperthermia.
treatment cHaracteristics
surgery
Surgery is the first choice of treatment for angiosarcoma and was performed wher ever 
feasible.
The surgery was scored an “R0 resection” if no microscopic tumor was found at the 
margin. An “R1 resec tion” indicates a microscopically positive margin after an otherwise 
complete resec tion and “R2 resection” indicates gross re sidual disease left behind after 
mastecto my.
radiotherapy
Following surgery or recurrence con firmed by biopsy, patients received elec tive external 
beam radiation weekly. Ra diotherapy was administered in 2–5 Gy fractions up to a total 
dose of 32–54 Gy (mean: 35 Gy), depending on previous therapy and tumor dimensions, 
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or at the discretion of the radiation oncologist. All patients had received prior irradiation 
and were treated using a radiation tech nique comprising photons (6–15 MV lin ear accel­
erators), electrons (6–10 MeV) or a mixture of photons and electrons. Type and energy 
of the radiation beam, as well as the particular application meth od varied depending on 
the clinical sit uation.
Patients received reirradiation to the chest wall, breast, reconstructed breast and/or 
regional nodes. The plan ning target volume (PTV) for radiation therapy included the 
clinical target vol ume (CTV) plus a margin of 1 cm. PTV could be defined for 8 patients 
and varied from 0.52 to 6.13 dm3 (median: 1.35 dm3). The field size for radiation therapy 
includ ed the recurrent tumor with a generous margin or the entire ipsilateral chest wall. 
Field size ranged from 175 to 1125 cm2 (median: 444 cm2) [17,30,38].
Hyperthermia
Hyperthermia treatments at DHCC were given once a week following the radio therapy, 
for a total of four treatments. Hyperthermia was delivered using Lu cite cone applicators 
and a 433 MHz tech nique, as previously described [2,4]. The applicator setup was chosen 
to heat the whole reirradiation volume [35]. At BVI, hyperthermia treatments were given 
twice a week for a total of six sessions. Hyper thermia was delivered using contact flex­
ible microstrip applicators (CFMA) oper ating at 434 MHz [10,15].
Treatment fields covered at least the area of surgery or re current tumor. For treatment 
areas too large to be covered by one applicator set up (those exceeding 20 by 30 cm2), 
the treatment was carried out in two appli cations.
Hyperthermia field size ranged from 200 to 1200 cm2 (median: 600 cm2). The hyper­
thermia treatment was given af ter the radiotherapy fraction on the same day.
The aim of the treatment is to main tain all interstitial temperatures between 40 and 
43°C [5]. At DHCC, surface tem perature control was performed using a perfused water 
bolus, with the tempera ture depending on various applicator ar rays and target depths 
[34]. At BVI, the water bolus temperature was usually set at 42°C. The standard prescribed 
dura tion of treatment was 60 min. This includ ed a heating­up period of 10 min, during 
which the temperatures were increased homogeneously to values as high as pa tients’ 
tolerance and normal tissue tem peratures permitted (max. 44°C). Tem peratures were 
either measured intersti tially and on the skin (n=18), or only on the skin (n=6).
endpoints
The primary endpoint of this study was defined by the duration of local control (DLC).
DLC was defined as the time be tween the start of treatment (surgery or radiotherapy) 
and the first observation of progression within the reirradiation field, made on either 
the day of death or at the last follow­up examination. Secondary endpoints were CR and 
acute or late tox icity due to either reirradiation or hyper thermia. Patients with persistent 
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locore gional disease at the end of treatment had local failure (F) at time zero. Toxicity ob­
served during or within 24 h after comple tion of a hyperthermia session was con sidered 
to be hyperthermia induced tox icity. All toxicity was scored according to the Common 
Terminology Criteria for Adverse Events (CTCAE), version 3.0 [33]. Only the maximum 
grade recorded was included in the analysis.
temperature parameters
Using the interstitial temperature data, various dose parameters were calculated. These 
included: the maximum (Tmax) and the average temperature (Tave) that was recorded 
over all temperature probes during the steady state period of each heating session (be­
ginning 10 min after the start of heating); the temperature ex ceeded by 90% of all tem­
perature probes during the steady state (T90) and the thermal isoeffect dose expressed 
in cu mulative equivalent minutes at a refer ence temperature of 43°C, based upon the 
temporal development of T90 in the tar get (CEM43ºCT90). For this analysis, the mean 
values of Tmax, Tave and T90 tem peratures were used. The formulation for CEM43ºCT90 
used in this study has been previously described and used extensive ly [6,11,14].
statistical analysis
Kaplan–Meier analysis was performed for DLC and OS duration. Univariate Cox regres­
sion was used to investigate which parameters were associated with LC and toxicity. 
For all calculations, p­values less than 0.05 were considered significant. For analysis, the 
Stata Statistical Software, re lease 11 was used (StataCorp, 2009).
results
Median age was 70 years, with a range of 46 to 88 years. The 3­month, 1­ and 3­year OS 
rates for the entire patient group were 91, 45 and 11%, respectively. After diagno sis of 
RAS, the duration of the follow­up period ranged from 1 to 78 months, with a median 
of 12 months.
Surgery was per formed on 11 patients (46%). Of these 11 patients, 3 underwent 
radiotherapy pre operatively and 8 postoperatively. The re maining 13 patients received 
reRT + HT alone.
tumor response and local control
All patients were eligible for response eval uation (Table 2).
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table 2. Characteristics of patients and outcome of treatment (n=24)
Legend to Table 2:
EQD2 equivalent dose in 2 Gy fractions, Tmax maximum steady state temperature, Tave average steady 
state temperature, T90 steady state temperature exceeded by 90% of all probes, CEM43°CT90 development 
of T90 at 43°C in cumulative equivalent minutes, DLC duration of local control, OS overall survival, CR com­
plete response, NR no response, PR partial response, mo months, min minutes aPatients with local control or 
still alive at the date of last follow­up bSurgery after radiotherapy and hyperthermia cStill alive.
At the completion of reRT + HT treatment in 16 patients with measurable tumors­
excluding the 8 pa tients with microscopic disease­9 patients (56%) exhibited CR, 4 
(25%) par tial response, 2 (13%) showed no change and 1 (6%) had progressive disease. 
In one patient who had received surgery af ter reRT + HT, a pathological CR was achieved. 
Including the patients with mi croscopic disease, 3­month, 1­ and 3­year LC rates were 
71, 38 and 29%, respectively. Median DLC was 8 months (range: 2–52 months). In the 
surgery group, 3­month, 1­ and 3­year LC rates were 91, 46 and 46%, respectively. Recur­
rence on the chest wall between 7 and 8 months was observed in 4 patients. In the 
no­surgery group, 3­months, 1­ and 3­year LC rates were 54, 32 and 22%, respectively 
and 4 patients had a recurrence on the chest wall between 6 and 51 months. These 
re sults are presented in Figure 1.
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Figure 1. Duration of local control for patients undergoing surgery versus no surgery. N number, F failure
Prognostic factors
We assessed several factors for prognostic significance to DLC using univariate analysis 
(Table 3). None of the parameters showed a significant correlation with the DLC, pre­
sumably due to the small number of patients in this study.
survival
The median latency interval between pre vious radiation and diagnosis of RAS was 
106 months (range: 45–212 months). The median survival time after reRT + HT for all 
24 patients was 12 months (range: 1–78 months). The median survival time following 
RAS diagnosis was 18 months (range: 2–79 months). Patients who had undergone sur­
gery (median survival: 13 months, range: 1–51 months) showed a trend toward better 
survival rates com pared to patients who received reRT + HT alone (median survival: 5 
months, 1–78 months), but this was not statistically sig nificant (p = 0.719, Figure 2). The 
4 pa tients treated by complete resection and the 7 undergoing incomplete resection 
had median survival times of 9 and 10 months, respectively.
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table 3. Association of patient, tumor and treatment characteristics with duration of local control (DLC, 
n=24)
Legend to Table 3:
HR hazard ratio, mo months, min minutes, Tmax maximum steady state temperature, Tave average steady 
state temperature, T90 steady state temperature exceeded by 90% of all probes, CEM43°CT90 development 
of T90 at 43°C in cumulative equivalent minutes. aAge in years at diagnosis of angiosarcoma.
At the last follow­up, 5 patients were still alive 1–8 months after the start of treatment 
(mean: 2 months); 1 had distant metastases and 1 had both local failure and distant 
metastases.
The 19 deaths oc curred 1–77 months (median: 8 months) after commencement of 
treatment. Causes of death were locoregional recur rence (n = 11), distant metastases (n 
= 3) and a combination of both (n = 5).
toxicity
The duration of hospitalization for the surgical procedure in 11 patients varied between 3 
and 12 days. Acute adverse eff ects from reirradiation included moder ate to pronounced 
erythema, dry desqua mation (21%), and moist desquamation (13%).
The effects were generally self­limiting and healed a few weeks after treat ment. In one 
patient, acute grade 3 radio therapy toxicity appeared after 2 months.
This patient developed an infection and required wound debridement of the chest 
wall. Thermal blisters occurred in 6 pa tients. No subcutaneous burns were observed. 
Grade 3 toxicity related to hyper thermia did not arise. Late grade 4 radio therapy toxic­
ity was seen in 2 patients, 7 and 11 months after the treatment. One of these patients 
developed osteoradionecro sis of the chest wall and required resection of this necrotic 
area. The other patient re quired debridement for a chronic wound.
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discussion
Secondary angiosarcomas have been asso ciated with previous surgery, irradiation or 
long­standing extremity edema in Stewart–Treves syndrome [19].
As BCT has become the standard treatment for patients with noninvasive and 
early breast cancer, the development of post­BCT angiosarcoma has become a well­
documented complica tion, with an incidence rate ranging from 0.05 to 1.11% [8,18,39]. 
This low incidence hinders conduction of large randomized studies on patients with 
angiosarcoma of the chest wall, and most available data has been determined from 
retrospective anal yses (Table 4).
table 4. Surgery, reirradiation and hyperthermia
Legend to Table 4:
reRT ± HT reirradiation plus/minus hyperthermia, reRT + HT reirradiation plus hyperthermia Tx treatment, 
M mastectomy, WLE wide local excision, LND lymph node dissection, CT chemotherapy, HART hyperfrac­
tionated and accelerated radiotherapy, RT radiotherapy, reRT reirradiation, HT hyperthermia, S surgery, 
com complete, income incomplete, OS overall survival, LC local control, mo months, yr(s) year(s).
A total of 151 patients who had received surgery alone could be identified in the litera­
ture [3,13,16]. The local tumor pro gression rate was 68% with a period of 12–81 months 
(median: 21 months) to relapse.
A total of 44 patients­including 11 from our series­received surgery plus radio therapy 
(± hyperthermia) [7,20,28]. Re sponse to treatment was observed for 46–92% of patients, 
with local recurrence in 20% after 8­19 months.
One patient un dergoing surgery after reRT + HT had a pathological CR following 
the combined therapy. In 26 patients, reRT + HT was the only treatment applied for an 
unresect able tumor. Local tumor progression oc curred in 27% of patients after a follow­
up of 1–77 months (median: 12 months). The 3­year LC rate was 22% in the current study 
and 31% in the study of de Jong et al. [7].
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Radical surgery is not always possible. Seinen et al. [29] report that in 23 out of 31 
patients who underwent surgery, the pri mary treatment resulted in R0 resections. 
Nevertheless, due to the multifocal growth of angiosarcoma and residual tumor tis sue, 
nearly two­thirds of these patients de veloped a local recurrence, even if the sur gical 
margins were considered free.
Radical excision of RAS is important not only for long­term LC, but also for OS; Jalalli et 
al. [13] found median survival times of 42 and 15 months for patients who had complete 
and incomplete resection, respectively, and Lindford et al. [16] reported a median OS 
of 81 months for 9 patients in whom the tu mor could be widely resected. Combina­
tion therapy comprising sur gery and reirradiation seems to improve both LC and OS in 
comparison to patients treated by surgery alone. Palta et al. [23] re ported an LC rate of 
71%, 2 years after post operative radiotherapy with a median dose of 60 Gy. Side effects 
included moist des quamation, which healed with antibacteri al and antifungal agents 
within a few weeks. One patient developed recurrent pleural effusion 5 years after treat­
ment.
Scott et al. [28] reported 5­year LC and OS rates of 92% and 75%, respectively, among 
pa tients receiving postoperative hyperfrac tionated accelerated radiotherapy (HART) 
with 1 Gy given three times daily to a total dose of 60 Gy. No patients developed CT CAE 
grade 3 or more severe complications, despite a high cumulative dose of radiation. In 
the current study, postoperative hypo fractionated reRT + HT resulted in a 1­ and 3­year 
LC rate of 46%, which is lower than that reported by Palta et al. [23] and Scott et al. [28]. 
These differences may be due to patient selection criteria.
The limitations of the current study are its retrospective nature and the relative ly small 
sample size, which preclude firm conclusions. Furthermore, it is difficult to compare 
the results with those of oth er studies and to establish the effect of hy perthermia. The 
outcome in the subgroup with a radiotherapy dose of 36–54 Gy (n=8) was a LC rate of 
75%, with a medi an of 7 months (range: 0–51 months). In the subgroup of patients with 
a radiother apy dose of 32 Gy (n=16), the LC rate was 69% for a duration of 0–52 months 
(medi an: 5 months, p=0.634). Late grade 4 toxicity developed in 2 patients; one in each 
subgroup.
conclusions
Although the chest wall already has been irradiated in patients with RAS, reirradi ation 
is still possible and improves post operative LC rates. The best published LC rates were 
achieved by combining sur gery and HART. With the increasing in cidence of angiosar­
coma, a prospective study comparing different radiotherapy schemes with or without 
hyperthermia may be possible in the future. Initial treatment for angiosarcoma should 
Chapter 3
64
be wide surgical resection (wherever fea sible) followed by radiotherapy, which may be 
more effective when combined with hyperthermia. For initially inopera ble tumors, the 
effect of reRT + HT alone can still be beneficial.
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abstract
Background: Breast cancer recurrences in previously irradiated areas are treated with 
reirradiation (reRT) and hyperthermia (HT). The aim of this retrospective study is to 
quantify the toxicity of HT in breast cancer patients with reconstruction.
Methods: Between 1992 and 2009, 36 patients were treated with reRT with a scheme 
of 8 fractions of 4 Gy in 4 weeks, and HT on a total of 37 tissue reconstructions. The types 
of reconstructions were: split­thickness skin graft (15), transverse rectus abdominis 
myocutaneous flap (1), latissimus dorsi flap (14), rhomboid flap (1) or a combination 
of grafts and flaps (6). Toxicities were graded according to the Common Terminology 
Criteria for Adverse Events (CTCAE), version 3.0. Patient, tumour, and treatment char­
acteristics predictive for the endpoints were identified in univariate and multivariate 
analyses. The primary endpoint was HT toxicity. Secondary endpoints were acute and 
late radiotherapy (RT) toxicity, complete response (CR), local control (LC) and overall 
survival (OS).
Results: The median follow­up time was 64 months. Grade 2 HT toxicity occurred in 
four patients and grade 3 in three. The three patients with grade 3 HT toxicity required 
reoperation. None of the evaluated parameters showed a significant relationship with 
HT toxicity. The CR rate in 15 patients with macroscopic disease was 80%. The 3 and 5 
year LC rates were 74% and 69%; the median OS was 55 months.
Conclusions: Combined reRT and HT in breast cancer patients with reconstruction is 
safe and effective.
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introduction
The treatment of breast cancer recurrences can involve a multimodal therapy that 
includes surgery and radiotherapy (RT), and, in the event of reirradiation (reRT), 
hyperthermia (HT). RT of breast or chest wall is indicated for patients on the basis of 
the following criteria: (1) recurrent tumour; (2) inoperable tumour; (3) microscopically 
incomplete excision. The standard therapy offered to patients with locoregional recur­
rent breast cancer in previous irradiated area in The Netherlands is reRT combined with 
HT [1,2]. The therapeutic benefit of HT when combined with RT has been documented in 
randomized comparative studies in various tumour types, including breast cancer [3­8].
After mastectomy or local excision, surgical defects may be covered using grafts or 
flaps. To cope with the psychological and aesthetic consequences of mastectomy, some 
patients choose a form of breast reconstruction. The options for reconstruction include 
myocutaneous flaps or tissue expander with subsequent placement of a prosthetic 
expander/implant, and, if necessary, reconstructions with grafts to cover wounds as a 
result of the surgical resection.
When postoperative RT is required, many surgeons avoid breast reconstruction for 
fear of wound complications [9­13]. Published experience on the tolerance of recon­
structions with grafts and flaps in previously or subsequently irradiated regions suggest 
that significant complications are limited, and that the cosmetic results are acceptable 
[14­23]. Reports in the literature on the tolerance of reconstructions with a graft or flap 
to HT in combination with reRT are scarce and are mostly single patient reports. We 
are aware of three studies that mention side effects from the combination therapy on 
reconstruction with a graft [24­27]. In this retrospective study we analyzed the occur­
rence of HT toxicity solely in patients with breast reconstruction suffering breast cancer 
recurrence after treatment with a combination of reRT and HT in attempt to inform the 
oncology committee on the benefit and toxicity risks in a larger patient group.
Patients and metHods
Patients
We retrospectively analyzed 36 patients with 37 breast reconstructions, 7% of all the 
patients, who had received postoperative reRT combined with HT at the Erasmus MC/ 
Daniel den Hoed Cancer Centre between 1992 and 2009. Thirty­five patients had recur­
rent adenocarcinoma of the breast and 1 patient had angiosarcoma. Fourteen patients 
(39%) had undergone surgery with breast reconstruction after their first diagnosis of 
breast cancer, 21 (58%) had undergone breast reconstruction after their recurrence and 
one (3%) patient had undergone two breast reconstructions, for the left­ and right­sided 
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chest wall after both recurrences. The median age at time of diagnosis was 59 years 
(range: 39–74 years).
Patient files were reviewed with regard to relevant medical history, details on breast 
reconstruction, use of chemotherapy and hormonal therapy, details of tumour and 
previously applied RT. Indication for reRT was recurrent tumour, inoperability or mi­
croscopically incomplete excision and systemic therapy was either inadequate or was 
deemed inappropriate, in the absence of systemic disease.
Distant metastasis was diagnosed before the start of the treatment in four patients. 
Table 1 summarizes patient and tumour characteristics.
table 1. Patient and tumor characteristics in relation to time period between reconstruction and HT and 
reRT
Legend to table 1: *Dose to chest wall without the boost.
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surgery
In all patients, a breast reconstruction was placed after mastectomy or local excision. Three 
patients had their reconstruction before the initial radiation. The surgical technique was 
not the same in all patients, because they had been operated on in different hospitals. The 
following breast reconstructions were included: split­thickness graft (15), latissimus dorsi 
flap (14), transverse rectus abdominis myocutaneous flap (1), rhomboid flap (1), a com­
bination: latissimus dorsi flap and split­thickness graft (1), or a combination: omentum 
and split­thickness graft (5). A brief explanation will follow to show the diversity in tissue 
vascularity and perfusion in the treated areas which may influence the risk of toxicity.
explanation of different surgical techniques
Split­thickness graft (described by the German surgeon Karl Thiersch in 1874) is a sheet 
of tissue containing epidermis and some dermis taken from a donor site. It is obtained 
by shaving the skin with an appropriate knife or blade. A skin graft depends for its 
survival on receiving adequate nutrition from the recipient bed. As it will contract to 
a certain extent, it will provide a far less aesthetic and durable form of coverage than a 
vascularised flap. Skin grafts may also be used as an adjunct for coverage of large defects 
(Figure 1a and Figure 2a and Figure 2b). The mesh graft is a partial or split­thickness skin 
graft that has had multiple slits cut into it.
Figure 1. a. Split­thickness graft, b. Latissimus dorsi flap, c. Transverse rectus abdominis muscle, d. Rhom­
boid flap.
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Figure 2. a. Combination split­thickness skin graft and latissimus dorsi flap, b. Combination split­thickness 
skin graft and omentum flap.
These allow the graft to be stretched to several times its original size, and thus to cover 
a larger area on the recipient. They also facilitate acceptance of the graft by permitting 
fluids to escape from beneath the graft.
A latissimus dorsi flap takes advantage of the thoracodorsal vessels, which enter the mus­
cle just below its insertion into the humerus as a consequence their vascularity is generally 
robust. Even if these vessels have been ligated, the latissimus dorsi flap may survive on col­
lateral blood flow between the thoracodorsal and serratus branches. The great advantages 
of the latissimus dorsi flap chest wall reconstruction are that it can be used as a muscle flap 
alone to cover a large defect, or the muscle can be used to transplant a small island of skin. 
It can be used as a pedicled flap for breast or chest wall reconstruction. It can also be used 
as a free flap. In our study only pedicled flaps were used (Figure 1b and Figure 2a).
The transverse rectus abdominis myocutaneous provides an alternative flap to the 
latissimus dorsi muscle. It has the advantage that it can normally transplant sufficient 
autologous tissue to avoid the need for an implant. The flap can also be used to recon­
struct the chest­wall defects (Figure 1c).
A Rhomboid (or Limberg) flap, is as its name suggests, a flap with the shape of an 
equilateral parallelogram ­ a lozenge shape. It is designed to contain the maximal blood 
supply, and takes advantage of well­known principles of flap surgery. The base of the 
flap should be centred over a regional blood supply source, and the length of the flap 
should be aligned along the principal direction of the subcutaneous vessel work. Ro­
tation and transposition flaps should also be designed to be large enough to enable 
adequate movement and closure without tension (Figure 1d).
The highly vascularised omentum flap is a large flap and can be used as a pedicle or a 
free flap to cover chest­wall and sternal wounds. It is usually folded as an apron utilizing 
the left gastroepiploic vessels, but occasionally, if additional length is needed, either of 
the gastroepiploic vessels can be used. It has been used as a pedicled flap covered with 
a skin graft to treat RT injury to the chest wall (Figure 2b).
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treatment
radiation
The post­operative external beam irradiation therapy of eight fractions of 4 Gy, twice 
weekly, was given to 35 patients on 36 breast reconstructions. In one patient a higher 
total dose of 60 Gy, 30 fractions of 2 Gy five times weekly, was given because of an inop­
erable third recurrence of breast cancer. There was one patient with subclinical disease 
on the left and a macroscopic tumour on the right side of the chest wall for which she 
received combined treatment in different time periods. This patient was evaluated as 
two different breast reconstructions.
Radiation techniques included electrons (n = 12), photons (n = 11) or a combination 
(n = 14) depending on the tumour location and depth. The RT field included the full­
thickness chest wall. A summary of treatment characteristics is given in Table 2.
table 2. Treatment characteristics.
Legend to table 2: *CEM, cumulative equivalent minutes.
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Hyperthermia
HT for breast cancer recurrences is given four times once weekly after a RT fraction.
During the early part of this study HT was administered twice a week with a total of 
eight treatments, but since 1996 it was administered once a week with a total of four 
treatments. This is now the standard scheme [28].
HT was delivered using Lucite Cone applicators (LCA) with a 433 MHz technique as 
previously described [29,30]. The applicator set­up was chosen to heat the whole reRT 
volume [2]. The maximum area that can be treated in one session, using six LCAs, is 20 
x 30 cm2 (n = 27). Three fields were treated one after the other by standard waveguide 
applicators and LCAs to test the performance of both waveguide types in the clinical 
setting.
In 1996 LCAs replaced the standard waveguides primarily because of better tempera­
tures in the periphery of the treatment field [31]. To cover larger than 600 cm2 fields, 
the treatment was carried out with two (n = 7) or four (n = 1) applicator set­ups. The HT 
treatment was started as soon after the RT treatment as possible (usually within 30­60 
minutes). Surface temperature control was performed by using a perfused water bolus. 
The temperature of the circulating water in the bolus is selected in accordance to the 
desired heating depth over the whole treatment volume as published in a previous 
paper [32]. The standard prescribed duration of a treatment was 60 minutes, including 
a heating­up period of 10 minutes, during which temperatures were increased to as 
high and homogeneous as patient tolerance and normal tissue temperatures permitted 
using the independent power control for each LCA.
In addition to measured temperatures, patients were carefully instructed and repeat­
edly questioned during the treatments to mention any pain or unpleasant sensation 
suggestive of a hot­spot. In cases of too high temperature, the power output of the 
concerning applicator and/or the applicator position was adjusted [33].
thermometry
For thermometry, a 24­channel scanning fibre­optic system (FT1210 and FT1310, 
Takaoka Japan) was used. Five multisensory probes (up to four sensors) and four 
single­sensor probes were available to measure skin and interstitial temperatures con­
tinuously during treatment. Under local anaesthesia, up to four thermometry catheters 
were inserted subcutaneously in the treatment volume, with at least one interstitial 
temperature measuring point aimed below each antenna. The catheters were fixed in 
place with Histoacryl (B. Braun, Melsungen AG, Germany) and Tegaderm adhesive (3M, 
USA). They were left in place for the duration of the full reRT and HT treatment course, 
provided there were no signs of infection or pain. The multisensory probes were placed 
in the closed­end interstitial thermometry catheters and the single­sensor probes were 
placed superficially, prior to each HT treatment [34].
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endpoints
The primary endpoint of this study was acute HT toxicity. Acute side effects of HT occur 
during or within 24 hours after completion of a treatment. Acute toxicity was registered 
according to the National Cancer Institute (NCI) Common Terminology Criteria for Ad­
verse Events, version 3.0 (CTCAE v3 2006) [35,36] (Table 3) and the WHO scoring system 
(Table 4). For acute HT­related toxicity analysis, the highest CTCAE grade toxicity a 
patient developed was included.
table 3. CTCAE v3 scoring of hyperthermia toxicity.
table 4. World Health Organization scoring of thermal burns.
Secondary study endpoints were acute and late RT toxicity (CTCAE v3), complete re­
sponse (CR), duration of local control (LC) and overall survival (OS). Acute RT­induced 
toxicity was defined as toxicity developing during treatment or in the three months 
thereafter (Table 5). Late RT­induced toxicity was defined as toxicity occurring at least 
three months after the last fraction of RT.
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table 5. CTCAE v3 scoring of acute radiotherapy toxicity.
CR was defined according to WHO criteria: clinical disappearance of all tumours in the 
irradiated volume for at least two measurements separated by visits of at least four 
weeks. LC duration in patients treated for subclinical disease and in patients in whom 
CR was achieved, was defined from the start of treatment until the first in­field tumour 
progression. Patients who did not show a CR were considered local failures. OS was 
defined as the time from the start of treatment to death from any cause or was censored 
at the time of the last follow­up visit in patients who survived. Assessment was based 
on the registered information in the files, telephone interviews and letters from medical 
professionals.
temperature parameters
From the measured temperatures, Tmax, Tave, and T90 were derived. Tmax and Tave are 
the maximum and the average temperature of all invasive temperature probes and T90 
represents the temperature exceeded by 90% of all invasive temperature points during 
steady state (from 10 minutes after start of heating). For this analysis, the means of the 
maximum, average and T90 temperatures for each HT session were selected.
The thermal dose parameter used in this study, CEM43°CT90, has been used exten­
sively and has been previously described [6,33,37­41]. In a mathematical description all 
time­temperature data are converted to an equivalent number of minutes at 43°C, where 
CEM43°C is cumulative equivalent minutes at 43°C. The sum of CEM43°C (CEM43°CT90tot) 
acquired per treatment (CEM43°CT90i) was calculated from the number of treatments 
actually given, and normalised using the number for which time­temperature data was 
available [33].
The analysis of thermal dose was limited to interstitially measured temperatures 
because the temperatures measured from the thermometry probes placed on the skin 
were influenced by the water bolus and therefore uncertain (Table 6a).
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table 6a. Thermal parameters in relation to hyperthermia toxicity.
Legend to table 6a: *SD, standard deviation.
other treatment and patient related parameters
In addition to temperature parameters, a number of other treatment and patient related 
parameters were evaluated for prognostic value regarding toxicity (Table 6b).
table 6b. Patient and treatment characteristics included in the evaluation of prognostic factors for toxicity.
Legend to table 6b: RT, radiotherapy, HT, hyperthermia.
statistical methods
Toxicity and response rates were evaluated for each treatment field. The association 
between toxicity and thermal parameters was evaluated for each HT session.
Pearson’s chi­squared test was used to determine which parameters associated with 
acute toxicity were caused by the combined treatment. The association between toxicity 
and thermal dose parameters Tmax, Tave, T90 and CEM43°CT90, was tested using the 
nonparametric Kruskal­Wallis test. All data were tabulated in Excel spreadsheets and 
were further processed using Statistica® for Windows. Actuarial probability of LC and 
OS was plotted from the time of initiation of treatment using the Kaplan­Meier product­
limit method. A relationship was defined to be statistically significant when the p­value 
was < 0.05. The statistical analysis was performed using Stata statistical software release 
11 (StataCorp 2009) [042].
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results
toxicity
All patients were eligible for toxicity evaluation. For patients still alive at last follow­up (n 
= 13) the median follow­up time was 64 months (range 4­188 months).
HT toxicity occurred in 17 patients (46%; split­skin (Thiersch) graft 19%, latissimus 
dorsi flap 16%, combination of split­thickness graft and omentum 8% or transverse 
rectus abdominis myocutaneous flap 3%). The burns were located inside the breast 
reconstruction (n = 6), outside the breast reconstruction (n = 8), or on the margin (n = 2), 
and one patient had two burns, one inside and one outside the breast reconstruction. 
The maximum skin toxicities are shown in Table 7.
table 7. Maximum acute HT toxicity per patient and reconstruction.
Legend to table 7: *Three ulcerations which required necrotomy.
HT CTCAE grade 3 toxicity was observed in three patients (8%). Two grade 3 HT toxicities 
developed in a latissimus dorsi flap and one in a transverse rectus abdominis myocuta­
neous flap. Removal of the latissimus dorsi flap was required in both patients.
In one patient the skin defect was repaired by primary closure and the wound healed 
without event. The other patient required composite reconstruction of the chest wall.
Four months afterwards she required removal of the composite reconstruction be­
cause of an infection and the wound was closed primarily. The last patient developed 
fever and appeared to have fat necrosis which was removed.
She required transposition of transverse rectus abdominis myocutaneous tissue with 
a latissimus dorsi flap.
Acute grade 3 RT toxicity appeared after 2.7 months in one patient (3%). She required 
wound debridement of the chest wall without removal of her split skin graft and healed 
with conservative treatment. Late RT toxicity was observed in two patients (5%) other 
than those with maximum HT toxicity. One patient had a large (14.5 cm) ulcerating 
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tumour mass before the start of the combined treatment. As a result of capsular contrac­
ture, her prosthesis and latissimus dorsi flap had to be removed after 12 months and the 
wound was closed primarily. The second patient developed skin necrosis and required 
hyperbaric oxygen therapy after 5.5 years. The breast reconstruction, a combination of a 
flap and a graft remained in situ. All patients subsequently recovered well and required 
no further intervention.
Patient and treatment cHaracteristics in relation to 
HyPertHermia toxicity
Table 6a shows patient­ and treatment­related parameters according to maximum toxic­
ity. All parameters are summarized in order of their p­value. We did not find a relation­
ship with toxicity for any of the parameters.
The relation between acute HT toxicity and thermal dose parameters was evaluated 
for 46 HT applicator set­ups; for one treatment field temperature data were not avail­
able. HT­induced toxicity was not correlated with any of the thermal dose parameters, 
(p­values varying between 0.108 and 0.408) (Table 6b).
The mean thermal dose parameters for patients who had less than grade 2 toxicity 
were T90 = 39.8°C, Tmax = 43.5°C, Tave = 41.1°C, and CEM43°CT90tot = 5.19 min; for grade 
2 toxicity T90 = 40.3°C, Tmax = 43.5°C, Tave = 41.6°C, and CEM43°CT90tot = 8.25 min; for 
grade 3 toxicity T90 = 39.7°C, Tmax = 43.5°C, Tave = 41.3°C, and CEM43°CT90tot = 3.65 min.
tumour resPonse, duration oF local control and overall 
survival
The patient with angiosarcoma of the breast was excluded from the response analysis. 
A CR was observed in 12 out of 15 (80%) patients with a macroscopic tumour (6 patients 
with a graft, 5 with a flap and 1 with a combination of a flap and a graft).
All 3 patients with less than complete response had a reconstruction with a split­
thickness skin graft. Including the 21 patients with subclinical disease, the LC rate was 
92%.
Local tumour control rate was 83% after 1 year, 74% after 3 years and 69% after 5 
years with seven local recurrences were included to date (Figure 3). One local recur­
rence occurred in a field with a latissimus dorsi flap after 3 months, one in a field with a 
transverse rectus abdominis myocutaneous flap after 17 months, and five in a field with 
a split­thickness skin graft after 3, 5, 24, 25 and 46 months. Depth of target volume had 
no effect on duration of local control (p = 0.367).
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Figure 3. Duration of local tumor control for 36 tissue transfers in 35 patients from the time of initiation of 
treatment treatment (N = number of tissue transfer, F = number of failures).
Fourteen patients died with local tumour control, after a median survival of 50 months, 
whereas twelve patients were free of local disease after a follow­up period of 22­188 
months (median 65 months). The OS rate was 83% after 1 year, 63% after 3 years and 
46% after 5 years with a median survival of 55 months (Figure 4).
Figure 4. Overall survival for 36 tissue transfers in 35 patients from the time of initiation of treatment (N = 
number of tissue transfer, F = number of failures).
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discussion
In our study we retrospectively evaluated the results of reRT and HT in a group of 36 
patients with 37 breast reconstructions, treated between October 1992 and March 2009. 
We found no HT toxicity in 20 patients (54%). CTCAE Grade 1 toxicity was seen in 10 
patients (27%), grade 2 in four (11%) and grade 3 in three (8%). In 12 of the 15 patients 
(80%) with macroscopic disease a CR was achieved and the 5­year LC rate in all patients 
was 69%.
Breast reconstructions are sometimes considered to be a contraindication for treat­
ment with RT and/or HT. A problem in patients with reconstruction can be that sensitiv­
ity is disturbed, and that therefore they can not report too high temperatures. From 
published results and clinical experiences with reRT and HT, however, it is unclear how 
high the incidence of severe toxicity in breast reconstructions really is.
Kim et al. [25,26] reports on 54 patients treated postoperatively with combined RT and 
HT, among whom only one patient had received a skin graft. This patient was treated with 
two series of RT and HT to a grafted area for a locally recurrent malignant melanoma. The 
patient developed an acute moist reaction in the grafted area which healed within four 
weeks. Nishimura et al. [27] reports as late toxicity two patients who developed ulcers 
in grafted skin. Hehr et al. [043] treated six patients with flap reconstructions among 
total 39 patients, but does not report specifically on severe toxicity in this subgroup. 
Zagar et al. [44] reports on one patient with a third­degree burn in a transverse rectus 
abdominis myocutaneous flap reconstruction that healed with conservative measures. 
In our institute, patients with breast reconstruction are not excluded from HT treatment.
Compared to results of a previous study in patients with recurrent breast cancer [01], 
acute hyperthermia toxicity was similar: WHO second­degree 31% compared to 27% 
and WHO third­degree 14% compared to 10%.
We further found that the sensitivity impairment in patients with breast reconstruc­
tion did not stop our patients from complaining during hyperthermia treatments. The 
number of complaints for which power was adjusted was 0­13 (mean 5) in patients with 
reconstruction (0­13, mean 5, in patients with CTCAE grade 0 or 1 toxicity and 3­8, mean 
5, in patients with CTCAE grade 2 or 3 toxicity) while it was 0­10 (mean 4.2) in patients 
without reconstruction. The side effects were usually grade 2 or less according to the 
CTCAE scoring system. The HT­induced burns generally caused no pain because these 
preferentially developed at sites of decreased sensitivity. We considered only CTCAE 
grade 3 as severe toxicity. HT caused in three (8%) patients a CTCAE grade 3 burn of the 
thoracic wall. Removal of the latissimus dorsi flap was required in two patients and the 
transverse rectus abdominis myocutaneous flap stayed in situ. CTCAE grade 3 late radia­
tion toxicity developed in two patients which is not significantly different from what we 
found in our previous study in which the majority of patients had no graft [01]. One of 
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these grade 3 toxicities resulted from tumour ulceration before treatment and the other 
was due to skin necrosis. Data on the tolerance of breast reconstructions to adjuvant RT 
are limited.
The side effects in the tissue grafts and flaps after RT have resulted in acceptable rates 
of complications and reconstruction failures; the need for major corrective surgery was 
0 ­ 11% [14­23]. The grafts and flaps in these published studies were placed on a skin 
that had not been previously irradiated. In an experimental study on the effects of reRT 
on vascularised breast reconstruction in 100 rats, none of the transferred flap or reirradi­
ated receiver musculature developed radiation necrosis after 72 Gy in 8 fractions in 10 
days [045].
Combined treatment with 32 Gy and HT resulted in our patients in an 80% CR in the 
15 patients with macroscopic tumours and a 92% LC rate in the whole group of patients. 
After five years the LC rate was 69%. In patients with breast cancer recurrences, reRT 
combined with HT is an effective treatment.
The ESHO 5­88 study [4] which compared reRT alone (with reRT schedule of 8 x 4 Gy) 
with reRT plus HT has shown a large improvement by additional HT. The CR rate after 
combined treatment was 78% and 38% after reRT without HT. The tripling of the CR rate 
in various superficial tumours for reRT and high­dose HT vs. RT and low­dose HT as dem­
onstrated in a randomized study by Jones et al. [6] made the National Comprehensive 
Cancer Network (NCCN) to include RT plus HT in its 2007 Breast Cancer Guidelines for 
recurrent breast cancer and other localized cancer recurrences. Although patients with 
recurrent breast cancer often are beyond cure, the achievement of local tumour control 
is important for the quality of life.
Bedwinek et al. [46] reported that in 62% of the patients, who experienced local 
recurrence, uncontrolled symptomatic local tumour can result in serious deterioration 
in quality of life. Liu et al. [47] also reported that achievement of LC results in an improve­
ment of quality of life. There has been no randomized trial investigating whether HT is 
beneficial in the subgroup of breast cancer patients with subclinical disease. Neverthe­
less, we have reasons to believe that HT is effective in this situation as well.
In the first place, a larger RT dose is required to achieve high LC rates. Bedwinek et al. 
[46] advised to applying at least 50 Gy in 2 Gy fractions in the elective situation, and 60 
Gy after microscopic irradical tumour excision.
The scheme of 8 fractions of 4 Gy in 4 weeks is biologically less effective than 50 Gy 
in 2 Gy daily fractions (biologically effective dose (BED) = 44.8 Gy with α/β = 10 for an 
acutely responding tumour).
In our experience, two types of observations suggest that 8 fractions of 4 Gy indeed 
are insufficient to control subclinical disease [01].
Secondly, at the time that we were still developing our HT system and had only a few 
applicators, the aim was to apply HT to the macroscopic tumour only, or, after resection, 
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to the site of surgery. Five patients that had HT applied to part of the reRT field showed 
tumour progression within the RT field but outside the HT field, while the combined 
treated region remained controlled.
Another finding was the difference in tumour control between patients treated for 
subclinical disease with 2450 MHz or 433 MHz equipment. An important difference 
between the 2450 and 433 MHz technique is that the homogeneity of heating is much 
better with the latter technique; with 2450 MHz a large part of the treatment volume 
receives an insufficient heat dose. The three patients treated with 2450 MHz all had in­
field tumour regrowth after 10­12 months. Only two of 12 patients treated with 433 MHz 
had a recurrence at 10 and 13 months after treatment, while 10 of 12 patients remained 
locally controlled after average 32 months. Although these numbers are small, this dif­
ference was significant.
All patient, tumour and treatment characteristics, including thermal dose parameters, 
have been analysed concerning their impact on the toxicity of breast reconstructions 
and no statistically differences were found. Of course, the retrospective nature and 
relatively small sample size of this study do not allow firm conclusions, but this lack of 
correlation makes it difficult to prevent HT toxicity by thermometry. In the near future, 
HT treatment planning may become a tool to prevent the occurrence of burns. Predic­
tion of the energy distribution in the tissues will allow better power control procedures 
and minimize the risk of toxicity. A thorough analysis of predicted 3D SAR (specific ab­
sorption rate) coverage as a prognostic indicator for treatment outcome and hot­spots 
during treatment is the subject of an ongoing study in our department.
conclusions
Based upon our results, breast reconstructions in previous irradiated areas are not a 
contraindication for treatment with reRT and HT, in view of the incidence of severe acute 
(8%) and late (5%) normal tissue reactions and the high LC rate (92%).
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abstract
Background and Purpose: Randomized studies have shown that adding hyperthermia 
(HT) to reirradiation (re­RT) improves treatment outcome for patients with breast cancer 
recurrences. We evaluated the efficacy and side effects in patients treated with re­RT and 
HT for irresectable locoregional breast cancer recurrences.
Material and methods: From September 1996 to December 2011, 248 patients with 
a macroscopic breast cancer recurrence were treated with re­RT and HT. Radiotherapy 
(RT) was applied to a dose of 32 Gy in 4 Gy fractions, twice weekly. HT was prescribed 
once weekly after RT. Primary endpoints for this analysis were complete response (CR) 
and local control (LC). Secondary endpoints were overall survival (OS), and toxicity. 
Patient­, tumor­, and treatment­related characteristics predictive for the endpoints were 
identified in univariate and multivariate analyses.
Results: The median follow­up period was 32 months. The CR rate was 70%. At 1, 3, and 
5 years LC was 53%, 40% and 39%, and OS was 66%, 32%, and 18%, respectively. OS after 
10 years was 10%. Thermal burns developed in 23% patients, healing with conservative 
measures. The incidence of 5 years late grade 3 toxicity was 1%. A few patients survived 
more than 10 years without evidence of disease.
Conclusions: The combination of re­RT and HT results in a high rate of long­term LC 
with acceptable late toxicity, and many patients remained locally controlled for the rest 
of their survival period.
93
Local control rate after the combination of reirradiation and hyperthermia for irresectable recurrent breast cancer
introduction
Addition of hyperthermia (HT) to reirradiation (re­RT) is an effective treatment for lo­
coregional recurrences of breast cancer [1,2]. After completion of the randomized ESHO 
5­88 trial, with pooled results of five trials showing a statistically significant improve­
ment of local control (LC) with the addition of HT to RT [1], re­RT with 8 fractions of 4 
Gy in 4 weeks and HT became the standard treatment for patients with recurrent breast 
cancer in the Netherlands. In the present study, we retrospectively evaluated complete 
response (CR) rate, local tumor control, overall survival (OS), and acute and late toxicity 
of 248 patients with macroscopic breast cancer recurrences treated with re­RT and HT 
at our department.
materials and metHods
Patients
From September 1996 to December 2011, we treated 248 patients with macroscopic 
breast cancer recurrences with re­RT and HT at our department. The inclusion criteria 
for this evaluation were as follows: previous RT to the breast or thoracic wall, biopsy 
confirmed locoregional recurrent adenocarcinoma of the breast, inoperable or irresect­
able tumor, and planned treatment with re­RT of 32 Gy and HT. Eleven patients with 
reconstructions included in the current study, were included in a previously published 
study [3]. HT was considered feasible when the tumor was located not deeper than 4 
cm from the skin surface, and the antenna apertures could be placed parallel to the skin 
surface over the whole volume at risk.
Five patients had a tumor extending to a depth of 5 cm and were accepted since 
there was a fat layer of ≥1 cm between skin and tumor, and energy loss in fatty tissue is 
neglectable [4]. In patients with multiple tumors, maximum tumor diameter and tumor 
volume represent that of the largest lesion. Tumor volume was calculated according to 
the formula 1/6πa×b×c, in which a and b are the largest diameters measured by calipers 
and c is the maximum extension in depth.
radiotherapy
Radiotherapy (RT) was delivered using two tangential photon fields (6­15 MV linear accel­
erators), electrons (6­12 MeV) or a combination of photons and electrons. Type, technique 
and energy of the radiation beam varied depending on the location and depth.
Radiation was given at 4 Gy per fraction, twice a week, to a total dose of 32 Gy to the 
clinical target volume. The RT field size for chest wall recurrences usually included most 
of the ipsilateral chest wall.
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Hyperthermia
HT was applied once weekly to a total of 4 treatments of 60 minutes each, after RT. 
For HT treatments, water filled Lucite Cone Applicators (LCA) were used operating at 
a frequency of 433 MHz [5]. This applicator has a square aperture of 10×10 cm2; the 
effective field size is up to 80% of the aperture. With six applicators combined an area 
of 20×30 cm2 can be effectively heated to a depth of up to 4 cm [6]. The applicator array 
was chosen such that the radiation field was widely covered [2].
Temperatures were measured interstitially, within catheters, and on the surface. For 
thermometry, a 24­channel fiber­optic system (FT1210 and FT1310, Takaoka Japan) 
was used used with five multisensor probes (up to four sensors) and four single­sensor 
probes for continuous measurements during treatment [2,6].
For each treatment the maximum (Tmax), average (Tave) and the value above which 
90% of all interstitially measured temperatures had been (T90) was calculated from mea­
surements taken after the 10 minutes heating­up phase. For this analysis the means of 
these temperatures over all treatments were selected. The calculated thermal parameters 
of superficial measurements were used in the evaluation of acute toxicity. Additionally, 
the CEM43°CT90 represents the thermal isoeffect dose expressed in cumulative equiva­
lent minutes at a reference temperature of 43°C. The formulation for CEM43ºCT90 used 
in this study has been used extensively and has been previously described [7,8,9­11].
endpoints and statistical analysis
Primary endpoints were CR and duration of LC. A CR was defined according to WHO 
criteria as the complete clinical disappearance of all measurable disease in the treatment 
field, observed twice with a time interval of at least 4 weeks. Patients who never obtained 
CR were considered as local failures at time zero. Duration of LC was defined from the 
date of initiation of treatment till the first observation of progression within the treatment 
volume, or censored at the day of death or last follow­up. Secondary endpoints were OS 
and toxicity.
Acute toxicity was observed as a result from either RT or HT. Radiation­induced acute 
toxicity included erythema (none, mild, moderate or severe) and moist desquamation. 
Thermal burns included second and third degree skin burns, and subcutaneous burns. 
The time to occurrence of late toxicity was defined from the start of re­RT to the date of 
worst late toxicity observation.
Late toxicity was scored according to the Common Terminology Criteria for Adverse 
Events (CTCAE v3.0) [12]. The Kaplan­Meier method was used to estimate the probability 
of LC, OS, and late toxicity. Cox regression was used to investigate which parameters 
were associated with duration of LC. A Chi­squares test was applied to determine pa­
rameters that were associated with CR rate or the development of acute toxicity. The 
non­parametric Kruskal­Wallis test was applied when the parameter is continuous or 
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ordinal variable. A value of p<0.05 (two­tailed) was considered statistically significant. 
For analysis, the Stata statistical software release 13 was used (StataCorp 2013).
results
Patient- and tumor-related characteristics
The median follow­up duration was 32 months. Data were collected till March 2014, or to 
a minimum follow­up of 2 months. Table 1 summarizes patient­ and tumor­related charac­
teristics at the time of first diagnosis. Patient­ and tumor­related characteristics at the time 
of combined treatment are summarize in Table 2. The hormone receptor status (ER and/or 
PR) was unknown in 52 (21%) of the patients and HER2neu protein status was unknown 
in 67 (27%) of the patients, since before 2000 the receptors were not routinely checked. 
In 70 (28%) patients hormonal treatment was continued during re­RT and HT. Thirty­five 
of these patients had started hormonal therapy 2 months or longer before re­RT and HT.
table 1. Initial patient­ and tumor­related characteristics.
Chapter 5
96
table 2. Patient­ and Tumor­related characteristics at the time of combined treatment.
Legend to table 2:
SD = standard deviation, *dose to chest wall
treatment-related characteristics
Radiotherapy
One hundred eight patients (44%) received RT in the Erasmus MC; 140 patients were 
treated in one of the 16 other radiation therapy institutes and received their HT at Eras­
mus MC. The
RT plan was adjusted to a lower dose in five patients. Three patients received a lower 
total dose because of general deterioration, and two refused further treatment. The 
lateral chest wall and/or regional lymph node area were treated with two tangential 
photon fields (6­15 MV; n=77) and the anterior chest wall with electrons (6­12 MeV; 
n=107); in 58 patients a combination of photons and electrons was used. In six patients 
the radiation technique was unknown. The average RT field size was 425 cm2 (range 
25­1485).
Hyperthermia
The HT treatments of 60 minutes each were administered after RT and generally well 
tolerated. Two hundred forty­one patients received 4 HT treatments as planned. Seven 
patients (3%) received fewer HT treatments; five patients who received a lower total RT 
dose treatment and fewer HT treatments, and two patients refused the fourth treatment. 
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The average HT field size was 604 cm2 (range 84­1700). Most of the patients could be 
treated with one applicator set­up (n=194), for the remaining patients a second (n=51) 
or third (n=3) applicator set­up was required to treat the whole RT field (total treatment 
time per session 120 or 180 minutes). The median number of interstitial thermometry 
sensors was 13 (range 2­27).
The median Tmax, Tave and T90 and median CEM43°CT90tot values were 43.6°C (range 
40.8­46.1), 41.2°C (range 38.9­42.4), 39.7°C (range 37.0­41.5) and 2.7 min (range 0.3­37.6).
comPlete resPonse rate, local control and overall survival
The median follow­up duration was 32 months (range, 1­164). A CR was achieved in 70% 
of all patients. After CR, local recurrence occurred in 56 patients. The median duration of 
LC was 15 months and at 1, 3, and 5 years LC rate was 53%, 40% and 39%, respectively 
(Figure 1). The median OS was 19 months with an OS rate of 66%, 32%, and 18% at 1, 3, 
and 5 years, respectively. OS after 10 years was 10%.
Figure 1. Duration of local control for 248 patients with irresectable breast cancer recurrences from the 
time of initiation reirradiation and hyperthermia. N, number of patients; F, failures.
Fourteen patients were alive with no evidence of disease 5 years after treatment, and 
six 10 years after treatment. The CR rate in 70 patients receiving concurrent hormonal 
therapy was 83%, which was significantly higher than 65% in the patients without hor­
monal therapy (p = 0.006) however the LC was not different.
The CR rate in 88 patients with distant metastasis was 63%, which was not significantly 
different from the CR rate in patients without distant metastasis (74%).
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There was no difference in CR rate of patients irradiated in the Erasmus MC compared 
to patients irradiated elsewhere.
Prognostic Factors
A number of patient­, tumor­, and treatment­related characteristics were evaluated for 
an association with duration of LC (Table 3). In multivariate analysis none of the param­
eters remained significant.
table 3. Results of univariate and multivariate Cox regression analyses for duration of local control.
Legend to table 3:
CEM, cumulative equivalent minutes; HR, hazard ratio; CI, confidence interval.
a Statistically significant.
b The variables were re­scaled in the analysis by dividing by 100.
treatment toxicity
Acute radiation toxicity included moderate to marked erythema in 49 patients (20%), 
and moist desquamation in 23 (9%). The effects were generally self­limiting and healed 
a few weeks after the treatment. Late toxicity was seen in three patients after a follow­up 
of 8, 10 and 124 months: radiation­induced skin necrosis, which was treated with either 
surgery or hyperbaric oxygen. Thermal burns occurred in 57 patients. Three patients had 
subcutaneously burns. All healed without further intervention (CTCAE grade 1 or 2).
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All factors (Table 3) were also investigated for prognostic significance on acute HT 
toxicity.
Univariate analysis showed that various parameters associated with the size of the 
treatment field (HT and RT field size, number of thermal probes, number of HT applica­
tor set­ups, RT technique) influenced thermal toxicity (p­values 0.001­0.006), with more 
toxicity in larger fields. None of the interstitial thermal dose parameters influenced HT­
induced toxicity (p­values 0.319­0.970). The maximum temperature measured on the 
skin (n=244) did influence HT toxicity. The incidence of WHO grade 2 and 3 skin burns 
clearly increases with a higher superficial Tmax: 28% (37/130) when > 43°C, 29% (20/70) 
when > 43.5°C, and 40% (8/20) when > 44°C, while it was 13% (15/114) when Tmax < 
43°C (Fisher exact Tmax > 43°C versus Tmax < 43°C, p = 0.003).
discussion
In this report we present a large­scale observational study of the results of planned 
treatment with 32 Gy re­RT combined with 4 HT treatments in patients with irresectable 
breast cancer recurrences. Overall, a CR was achieved in 70% of all patients, and LC rates 
at 1, 3, and 5 years were 53%, 40%, and 39%, respectively.
OS after 1, 3 and 5 years was 66%, 32%, and 18% respectively, and after 10 years still 
10%. A few patients may have been cured.
Our results are comparable with those of combined treatment in the ESHO 88­5 phase 
III trial [1], in which the same re­RT scheme was used. In this study CR was 38% after 
re­RT alone and 78% after re­RT and HT. The achievement of a local tumor control is 
important for quality of life [13], and can prolong OS [14].
Of the 110 patients with less than 2 year interval between primary treatment for breast 
cancer and first recurrence, five survived more than 5 years after re­RT and HT, two of 
them without evidence of disease.
Of the whole group, 14 patients were alive without evidence of disease more than 5 
years after treatment, and six more than 10 years. Patients irradiated elsewhere showed 
no worse results in spite of the longer time interval between re­RT and HT. Skin burns, 
WHO grade 2 or 3, occurred in 54 patients, and a subcutaneous burn in three patients. A 
higher risk of HT toxicity was seen in larger treatment fields.
No correlation was found between interstitial thermal parameters and acute toxicity, 
but with superficially measured temperatures above 43°C, the risk of burns was higher. 
Limitation of skin temperatures to a maximum of 43°C may result in a decrease of acute 
side effects of HT and this can be used for treatment guidelines.
Chapter 5
100
The cumulative incidence of late grade 3 toxicity was 1% after 5 years follow­up. The 
three patients with grade 3 toxicity could be treated well with either surgery or hyper­
baric oxygen.
Locoregional recurrences of breast cancer may be the cause of severe suffering when 
uncontrolled, with symptoms such as pain, ulceration, and bleeding.
Systemic treatment usually is less effective in a region previously irradiated [15,16]. 
In patients with local recurrences of breast cancer after previous RT, the treatment of 
choice is surgery. In extensive disease, chest wall resection may be required.
Fanyete et al. [17] report on chest wall resection in 44 patients. A re­recurrence was 
observed in 14% of the patients. OS after 5 years was 45%. In the thirty patients who 
underwent chest wall resection with curative intent, 5 years OS was 58%. Postoperative 
complications occurred in 41% of the patients and median duration of hospitalization 
was 21 days, which makes it a relatively cumbersome treatment.
Van der Pol et al.[ 18] treated 77 patients with curative intent. A R0 resection was pos­
sible in 64% of the patients. Complications occurred in 29 patients (38%) which were 
severe in 16 (21%). LC rate after 5 years was 51% and DFS 12%. Five years OS was 25%. 
Publications on 5 years OS after curative chest wall resection, reviewed in their article, 
show that this varies from 18% to 71%.
Despite that our patients were less favourable with irresectable tumors, our results 
are comparable. In view of the LC rates achieved, local surgery, when feasible, remains 
the treatment of choice, and can be followed by re­RT and HT in case of an incomplete 
resection. However, in view of the favourable outcome with less toxicity, re­RT and HT 
is preferred to extensive chest wall resection. In previous studies we have shown that 
re­RT plus HT for subclinical disease results in 78% 5 years LC and 60% 5 years OS [15,19], 
and further that it is safe and effective in patients with tissue transplants [3].
We are using the re­RT scheme of 8 fractions of 4 Gy, given twice weekly. The ques­
tion is whether this is the optimal schedule, or that better results would be achieved 
with e.g. a higher total dose, lower fraction sizes and/or concurrent systemic therapy. 
A higher total radiation dose may result in better LC rates, but also in more toxicity. 
Published results of higher total RT doses do not show better CR rate than we found 
in the present study. Hehr et al. [20] treated 39 patients with an average total RT dose 
of 56 Gy in fractions of 1.2­2 Gy and HT. A CR was achieved in 40% of the 30 patients 
with an irresectable tumor; 2 years LC in all patients was 46%. Ulceration of the skin was 
observed in 1 patient.
Wahl et al. [15] reviewed results in 81 patients treated with re­RT, which was combined 
with HT in 44. Re­RT total dose was median 48 Gy and fraction size approximately 2 Gy.
In patients with macroscopic tumors combined re­RT and HT resulted in 67% CR and 
58% LC after 1 year. After a median follow up of 1 year, 4 patients of the whole group 
had developed grade 3­4 toxicity. Li et al. [16] report 56% CR in 41 patients treated with 
101
Local control rate after the combination of reirradiation and hyperthermia for irresectable recurrent breast cancer
a mean re­RT dose of 43 Gy combined with HT, a dose biologically equivalent to our 
convenient schedule of 32 Gy in 4 Gy fractions. In the present study the incidence of 
toxicity is only 1% after a median follow up of 30 months, which is acceptable. In view 
of the achieved LC and limited toxicity, we prefer to continue with the hypofractionated 
schedule.
Another question is whether clinical outcome can be improved with concurrent 
systemic therapy. Published results on radiation combined with both HT and chemo­
therapy sofar have not shown better results. Bornstein et al. [21] report a CR rate of 53% 
for 34 fields in 29 patients treated with various drugs in addition to radiation and HT. 
Feyerabend et al. [22] report a CR rate of 44% in patients treated with epirubicin and 
ifosfamide in addition to radiotherapy, mean total dose 49 Gy, and HT. Kouloulias et al. 
[23] achieved 20% CR in 15 patients treated with 31 Gy, liposomal doxorubicin and HT. 
Patients did not receive chemotherapy during local treatment, but concurrent hormonal 
treatment was given to 71 patients. In these patients there was a trend to a higher LC.
However, the risk of selection bias in this comparison is obvious: 50% of the patients 
continuing hormonal therapy had started this >2 months previously, indicating that the 
therapy had beneficial effects. Therefore, these patients may represent a subgroup with 
a better prognosis.
conclusions
The treatment of irresectable recurrent breast cancer with re­RT and HT results in 70% 
CR and 39% 5 years LC with acceptable toxicity, and may be curative in a small subgroup 
of patients. In operable cases, surgical resection is the treatment of choice and can be 
followed by re­RT and HT. In irresectable disease, re­RT and HT is the treatment of choice. 
In the Netherlands this therapy is the recommended treatment for patients with breast 
cancer recurrence and reimbursed by the Health Insurance.
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abstract
Purpose: Evaluation of efficacy and side effects of combined reirradiation and hyperther­
mia electively or for subclinical disease in the management of locoregional recurrent 
breast cancer.
Methods and Materials: Records of 198 patients with recurrent breast cancer treated 
with reirradiation and hyperthermia from 1993­2010 were reviewed. Prior treatments 
included surgery (100%), radiotherapy (100%), chemotherapy (42%), and hormonal 
therapy (57%). Ninety­one patients were treated for microscopic residual disease fol­
lowing resection or systemic therapy and 107 patients were treated electively for areas 
at high risk for local recurrences. All patients were re­irradiated to 28­36 Gy (median 32) 
and treated with 3­8 hyperthermia treatments (mean 4.36). Forty percent of the patients 
received concurrent hormonal therapy. Patient and tumor characteristics predictive 
for actuarial local control (LC) and toxicity were studied in univariate and multivariate 
analysis.
Results: The median follow­up was 42 months. Three and 5 years LC­rates were 83% 
and 78%. Mean of T90 (tenth percentile of temperature distribution), maximum and aver­
age temperatures were 39.8°C, 43.6°C, and 41.2°C, respectively. Mean of the cumulative 
equivalent minutes (CEM43°C) at T90 was 4.58 minutes. Number of previous chemo­
therapy and surgical procedures were most predictive for LC. Cumulative incidence of 
grade 3 and 4 late toxicity at 5 years was 11.9%. The number of thermometry sensors 
and depth of treatment volume were associated with acute hyperthermia toxicity.
Conclusions: The combination of reirradiation and hyperthermia results in a high LC­
rate with acceptable toxicity.
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introduction
The treatment of locoregional failures in previously irradiated regions presents a difficult 
problem. When resectable, irradiation may be indicated thereafter. However, elective 
reirradiation is either not done at all or leads to unsatisfactory results [1].
Over the past three decades, hyperthermia as an adjunct to radiotherapy has demon­
strated to be effective in the treatment of locoregional recurrences in previous irradiated 
breast cancer [2]. Therefore, we elected to combine radiation with hyperthermia. There 
are only four published studies in this regard, all including less than 90 patients [1,3,4,5].
We retrospectively analyzed the clinical outcome of all 198 patients treated by us from 
1993 to 2010, which makes this the largest study sofar. The endpoints of the study were 
local control (LC), and treatment complications. Further we analyzed which patient and 
tumor characteristics as well as treatment characteristics correlated with LC and toxicity.
metHods and materials
Patients
The inclusion criteria for this evaluation were as follows: recurrent adenocarcinoma of 
the breast in previously irradiated area after resection with high risk of re­recurrence 
(subclinical disease: after R1 resection; elective treatment for close margins, multiple 
previous recurrences, and/or multicentricity), and treatment with radiotherapy plus 
hyperthermia. In­breast recurrences were treated by mastectomy (R0:23, R1:19), two of 
these patients had a reconstruction of the breast. Chest wall recurrences were removed 
by local excision (R0:79, R1:58). In three patients the wound was closed with a recon­
struction. Recurrences caudal in the axilla or supraclavicular region were treated with a 
resection (R0:7, R1:7). The whole reirradiation field had to be coverable with hyperther­
mia applicators and the maximum accepted depth was 4 cm.
radiotherapy
Patients received elective external beam radiation to a prescribed dose of 32 Gy at 4 
Gy per fraction, twice a week, following surgery (n = 193) or when in clinical complete 
remission after systemic therapy (n = 5). In the majority of patients, the radiotherapy 
field included the whole mastectomy scar.
Hyperthermia
The hyperthermia treatments of 60 minutes each were given at intervals of at least 72h, 
once or twice (11 patients) a week, after radiotherapy [6,7]. Hyperthermia was delivered 
using Lucite Cone applicators (LCA) operating at 433 MHz as previously described [3,6,8]. 
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This applicator has a square aperture of 10x10 cm2; the effective field size is up to 80% 
of the aperture. With six applicators combined an area of 20x30 cm2 can be effectively 
heated to a depth of up to 4 cm. The applicator set­up was chosen to heat the whole 
reirradiation volume [7]. When the radiotherapy field could not be covered with one 
applicator set­up, the remaining part was treated subsequently with a second applicator 
set­up (total treatment time 120 minutes).
Temperatures were measured interstitially, within catheters, and on the surface.
For thermometry, a fiber­optic system (FTP­5 Medical Array Sensor, Takaoka Electric 
Mfg, Tokyo, Japan) was used with five multisensory probes (up to four sensors) and 
four single­sensor probes [6,7]. From the interstitially measured temperature data vari­
ous parameters were calculated: Tmax, Tave, T90 (tenth percentile of temperature) and 
CEM43ºCT90 (5).
CEM43ºCT90 represents the thermal isoeffect dose expressed in cumulative equiva­
lent minutes (CEM) at a reference temperature of 43°C, based on the low end of the 
temperature distribution (T90) [9,10]. For this analysis the mean of these thermal dose 
parameters was used. The superficially measured thermal parameters were used for 
evaluation of acute toxicity.
endPoints and statistical metHods
Only the first treated field in each patient was included in this analysis. Kaplan­Meier 
estimates were performed for actuarial probability of LC and late toxicity. Duration of 
LC was defined as the time between initiation of treatment until the first observation of 
progression within the treated volume, or censored at the day of death or last follow­up.
The actuarial incidence of late toxicity was calculated using the Kaplan Meyer method 
from the start of reirradiation to the date of last follow­up. Toxicity was scored according 
to the Common Terminology Criteria for Adverse Events (CTCAE v3.0) [11].
Cox regression, univariate as well as multivariate, was used to investigate which pre­
treatment and treatment parameters were associated with LC and the incidence of late 
toxicity. Logistic regression was used to investigate which parameters were associated 
with the development of acute toxicity. For analysis, the Stata statistical software release 
11 was used (StataCorp 2009).
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results
Patient and tumor characteristics
Table 1 summarizes the tumor characteristics at the time of first diagnosis. Table 2 sum­
marizes the patient’s characteristics at the time of reirradiation and hyperthermia.
table 1. Initial patient and breast cancer characteristics at the time of first diagnosis.
Legend to table 1: SD = standard deviation
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table 2. Patient and tumor characteristics at the time of hyperthermia.
Legend to table 2:
SD = standard deviation
treatment cHaracteristics
radiotherapy
Ninety­five patients (48%) received current radiotherapy in our institute. For the others, 
the radiation was applied by their referring radiation oncologist in one of the other 13 
radiotherapy centers.
The radiotherapy plan was adjusted in three patients. One patient received 28 Gy, as 
her treatment was discontinued because of general deterioration due to rapid progres­
sion of systemic disease. Two patients received 36 Gy. In one patient, the treatment was 
interrupted because of abscess formation due to an infection around a thermometry 
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catheter, and a ninth fraction was given to compensate for the delay. In another patient, 
a ninth fraction was given for an unknown reason.
Hyperthermia
All patients received hyperthermia in our institute. Eighty­nine percent of patients 
received 4 hyperthermia sessions and 9% 8, as planned. Four patients (2%) received 
less than the planned number of treatments. Two patients received 7 instead of 8 treat­
ments for logistic reasons, and two patients 3 instead of 4 treatments, because of cardiac 
asthma and general deterioration, respectively. The mean number of hyperthermia 
treatments was 4.36. The average hyperthermia field size was 562 cm2 (range 84­1700 
cm2). The mean number of interstitial thermometry sensors was 11 (range 1­25). The 
averages of Tmax, Tave, and T90 were 43.6°C, 41.2°C and 39.8°C, respectively. The average 
of CEM43°CT90tot was 4.58 minutes.
local control and overall survival
One hundred and nine patients (55%) are still alive with a median follow­up of 42 months 
(range, 1­194). Thirty­five patients had a locoregional recurrence (18%) after 1­74 months 
(median 16). Actuarial LC­rates after 1, 3, 5 and 10 years are 93%, 83%, 78%, and 75% 
respectively (Fig. 1). The 3, 5 and 10 years overall survival (OS) rates are 75%, 60% and 36%, 
respectively, with a median survival of 82 months. Five years LC for patients from Erasmus 
MC is 72%, and for patients from other institutes, this is 82% (p = 0.065).
Figure 1. Actuarial local control for all 198 patients from the time of initiation of treatment. N, number of 
patients; F, failures.
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Prognostic Factors
Only a high number of previous chemotherapies and surgical procedures remained 
significantly associated with probability of LC in multivariate analysis (Table 3).
table 3. Results of univariate and multivariate Cox regression analysis for local control.
Legend to table 3:
HR, hazard ratio; CI, confidence interval; CEM, cumulative equivalent minutes; pos, positive; neg, negative
a Statistically significant
b Sample size too small
c Univariate
d Multivariate
complications of treatment
In one patient acute grade 4 radiotherapy toxicity appeared after 1 month. Radionecro­
sis of the chest wall occurred due to radiotherapy requiring wound debridement and 
reconstruction.   
Grade 3 hyperthermia toxicity occurred in five patients, of which three in a flap, which 
all required surgical repair (12). In two patients, an abscess developed during the treat­
ment course at the site of an interstitial thermometry catheter. One patient required 
surgical intervention during the treatment and completed the treatment with an extra 
radiation fraction. The second patient required abscess drainage after the treatment. In 
both patients the wound healed uneventful.
Late grade 3 and 4 toxicity was seen in 20 patients after a median follow­up of 14 
months (range, 4­97 months). The cumulative incidence of late toxicity was 4.8%, 9.5% 
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and 11.9% at 1, 3 and 5 years, respectively. Fifteen patients developed ulceration and 
five osteoradionecrosis, for which they were treated with necrotomy, reconstruction 
and/or hyperbaric oxygen. In multivariate analysis, only the institute where patients 
received radiotherapy was significantly associated with late toxicity (p = 0.031) (Table 4). 
Late grade 3 and 4 toxicity occurred in 15% of patients from Erasmus MC and in 7% of 
patients from other institutes.
influencing hyperthermia damage
Univariate analysis showed that a high number of thermometry sensors and a less 
deep target volume (<2.5 cm) were associated with more hyperthermia toxicity (p = 
0.021, p = 0.034); in multivariate analysis these factors remained significant (p = 0.014, 
p = 0.032). Interstitial thermal parameters had no influence on hyperthermia induced 
toxicity (p­values varying between 0.148 and 0.968). Thermal parameters derived from 
measurements on the skin were higher in patients with WHO grade 2 and 3 burns than 
in patients with no and grade 1 burns (Table 5), although there was a large overlap 
between the ranges of temperatures. The incidence of grade 2 and 3 burns clearly 
increases with higher superficial Tmax: 32% (31/98) when > 43°C, 34% (18/53) when > 
43.5°C, 41% (9/22) when > 44°C, while it was 15% (14/92) with Tmax < 43°C (Fisher exact 
Tmax > 43°C versus Tmax < 43°C, p = 0.006).
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table 5. Superficial measured thermal parameters and acute toxicity.
Legend to table 5:
CEM, cumulative equivalent minutes
discussion
This paper presents results of reirradiation and hyperthermia in patients with recurrent 
breast cancer treated electively or for subclinical disease following excision or systemic 
therapy. The 3 and 5 years actuarial LC­rates are 83% and 78%. Late grade 3 and 4 toxicity 
occurred in: 9.5% and 11.9% of the patients after 3 and 5 years, respectively.
The results are comparable with the results reported by others. Kapp et al. [3] have 
shown that reirradiation and hyperthermia for presumed or known microscopic residual 
tumors resulted in a 3­year LC of 68%. Welz et al. [4] treated 50 patients for microscopi­
cally involved or close margins after surgery for locoregional recurrence achieved a 
3­year LC­rate of 81%.
Oldenborg et al. [5] showed a 3­year LC­rate of 78% in 78 patients all treated for mi­
croscopic residual disease.
Müller et al. [1] achieved a prolonged LC in 86% of patients with microscopically posi­
tive margins treated with reirradiation and hyperthermia. For macroscopic breast cancer 
recurrences, the beneficial effect of hyperthermia added to radiotherapy has been 
demonstrated [2]. The tripling of complete response by adding high­dose hyperthermia 
(compared to low­dose hyperthermia) to reirradiation in breast cancer recurrences [9], 
made the National Comprehensive Cancer Network (NCCN) to include radiation plus 
hyperthermia in its 2007 Breast Cancer Guidelines for recurrent breast cancer when 
failures occur after surgery and radiation.
For microscopic breast cancer recurrences, the effect of adding hyperthermia to reir­
radiation is less clear. We found a few small studies on the effect of reirradiation alone, 
in patients with a recurrence after breast conserving therapy (BCT). Racadot et al. [13] 
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reported on 20 patients treated with surgery and reirradiation with a median dose of 
45 Gy (range, 33­65) and achieved a LC­rate of 75% after mean follow­up of 48 months.
Late complications were rib fractures in four patients (20%). Deutsch et al. [14] treated 
39 women with an in­breast tumor recurrence with excision and whole breast irradiation 
with 50 Gy. The LC­rate after median 52 months was 76.9% without severe toxicity (< 
CTCAE grade 2). Harkenrider et al. [15] reviewed eight patients with nine locoregional 
breast cancer recurrences, treated with reirradiation (46.7 Gy). The median follow­up 
time was 30 months.
LC was achieved in nine fields (100%). CTCAE grade 3 late toxicity developed in two 
patients. In the above listed three studies, overall 87% of the patients were treated 
after R0 resection. Overall, reirradiation alone to a dose of 45­50 Gy results in a LC of 75 
to 100% after 2­4 years of follow­up, which is similar to our 3 to 5 years LC in patients 
of whom 54% had a R0 resection. Müller et al. [1] report how, in R1 resected patients, 
hyperthermia added to reirradiation (median 60 Gy) improved LC from 50 to 86%.
We have more reasons to believe that elective or adjuvant radiotherapy in combina­
tion with hyperthermia is effective in locoregional recurrent breast cancer. In a previous 
study in our institute [3], hyperthermia was applied to only part of the reirradiation field, 
the site of the visible tumor, in five patients. During follow­up tumor progression was 
observed outside the hyperthermia field, where earlier no tumor was apparent, while 
the combined treated region remained controlled. Reirradiation can only be given one 
more time and therefore should be given to maximal effect.
Concurrent chemotherapy does not seem to improve the results of radiotherapy in 
recurrent breast cancer [16,17]. Surgery is another possible treatment. Chest wall resec­
tion with curative intent may result in 80% LC [18] but in this study complications requir­
ing surgery occurred in 30% of the patients and 5­year disease­free survival was 35%.
Only two parameters were associated with duration of LC i.e. number of previous 
chemotherapy courses and surgical procedures. Although these parameters probably 
reflect a more aggressive tumor type, it could also mean that patients would have a 
better prognosis when referred in an earlier stage.
The cumulative incidence of late toxicity was relatively high, but such toxicity was only 
observed in patients with continuing LC and could be treated well with either surgery or 
hyperbaric oxygen, and therefore acceptable in view of the high LC rate.
The incidence of late grade 3 and 4 toxicity was significantly lower in patients from 
other institutes compared to patients irradiated at Erasmus MC. This may be explained 
by a longer time interval between radiotherapy and hyperthermia in patients irradiated 
elsewhere.
The general idea is that hyperthermia should be given within a short time before or 
after radiotherapy to get maximum enhancement. The longer time interval for patients 
irradiated elsewhere did not lead to a lower LC rate.
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Two parameters were significant in multivariate analysis for the development of 
hyperthermia toxicity. An explanation for the finding between a high number of ther­
mometry sensors and toxicity would be that more probes are inserted in a larger target 
area. Larger radiation fields entail an increased risk of late toxicity. Indeed, we found in 
this patient material a highly significant correlation between number of sensors and 
size of radiotherapy and hyperthermia field (p = 0.000, p = 0.000). The second parameter 
was depth which can be explained by the use of higher water bolus temperature for 
less deep target volume. No correlation was observed between interstitial thermal 
parameters and acute toxicity, but the superficial temperature was of prognostic signifi­
cance for grade 2 and 3 toxicity (Table 5). The increase of incidence of burns at higher 
temperatures can be used for treatment guidelines.
Some clinically relevant questions still exist. In the first place, what is the optimal ra­
diotherapy scheme? Lower fraction sizes might result in a lower incidence of late grade 
3 and 4 toxicity. On the other hand, it also may result in lower LC­rates.
In the ESHO trial [2], using eight fractions of 4 Gy, CR­rates were 38% for radiotherapy 
alone and 78% for combined treatment. In the MRC BrR study with eight fractions of 3.6 
Gy, these were 29% and 56%, and in the PMH trial with 18 fractions of 1.8 Gy, these were 
31% and 29%, respectively [2]. Oldenborg et al. [5] report a 3­year LC­rate of 78% with 
the same schedule.
A few studies have reported CR and LC after smaller radiotherapy fractions to a higher 
total dose. Two to 4 years LC­rates varied between 75% and 100% [1,14,15], which is 
comparable to what we found, while there were more patients with R1 resection in our 
study. Reported late toxicity CTCAE grade 3 or higher varies from 0% to 25% after reir­
radiation with total doses of 45­60 Gy with fraction sizes of 1.8 to 2.0 Gy, after median 
follow­up times of 2 to 4 years. The late toxicity found by us (11.9% after 5 years) falls 
within this range. We have no explanation why Oldenborg et al. [5], treating 78 patients 
with microscopic disease with eight fractions of 4 Gy and hyperthermia, found a much 
higher (43%) incidence of > CTCAE grade 3 toxicity after 3 years.
Another question is how important the continuation of or change in systemic therapy 
is. In our study, continuation of chemotherapy during combined treatment was not 
allowed, but the LC­rate in 78 patients who continued hormonal therapy during treat­
ment was not significantly higher than in the remaining patients: 86% compared to 80% 
(p = 0.245).
Waeber et al. [19] randomized patients with chest wall recurrences that were ER 
positive and had other good prognostic factors, to tamoxifen or placebo after complete 
local excision and radiation. The 5­year disease­free survival was improved in postmeno­
pausal women with the use of tamoxifen, 33% to 61%. The 5­year OS was not different 
for both groups. In premenopausal women, there was no improvement in disease­free 
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survival by tamoxifen medication, while a decrease in OS was observed in patients tak­
ing tamoxifen (90% vs. 67%).
Results of Willner et al. [16] suggest no benefit of hormonal or chemotherapy added 
to postoperative radiotherapy on overall survival.
Thirdly, what the optimal number of hyperthermia sessions is. In multivariate analysis, 
we found no influence of number of treatments on LC. A comparison of results after 
four or eight hyperthermia treatments combined with reirradiation in patients with 
macroscopic breast cancer is the subject of an ongoing evaluation.
conclusions
Reirradiation and hyperthermia applied to patients with breast cancer recurrence elec­
tively or for subclinical disease results in a high rate of durable LC and is well tolerated 
with acceptable toxicity. This combined treatment should therefore be offered to all 
patients with a high risk of local recurrence after surgical resection of a recurrence.
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abstract
In the current clinical practice, prior to superficial hyperthermia treatments (HT), tem­
perature probes are placed in tissue to document a thermal dose. To investigate whether 
the painful procedure of catheter placement can be replaced by superficial HT planning, 
we study if the specific absorption rate (SAR) coverage is predictive for treatment out­
come. An absolute requirement for such a study is the accurate reconstruction of the ap­
plicator setup. The purpose of this study was to investigate the feasibility of the applica­
tor setup reconstruction from multiple­view images. The accuracy of the multiple­view 
reconstruction method has been assessed for two experimental setups using six Lucite 
Cone applicators (LCAs) representing the largest array applied at our clinic and also the 
most difficult scenario for the reconstruction. For the two experimental setups and 112 
distances, the mean difference between photogrametry reconstructed and manually 
measured distances was 0.25 ± 0.79 mm (mean±1 standard deviation). By a parameter 
study of translation T (mm) and rotation R (°) of LCAs, we showed that these inaccura­
cies are clinically acceptable, i.e. they are either from ±1.02 mm error in translation or 
±0.48° in rotation, or combinations expressed by 4.35R(2) + 0.97T(2) = 1. We anticipate 
that such small errors will not have a relevant influence on the SAR distribution in the 
treated region. The clinical applicability of the procedure is shown on a patient with a 
breast cancer recurrence treated with reirradiation plus superficial hyperthermia using 
the six­LCA array. The total reconstruction procedure of six LCAs from a set of ten photos 
currently takes around 1.5 h. We conclude that the reconstruction of superficial HT setup 
from multiple­view images is feasible and only minor errors are found that will have a 
negligible influence on treatment planning quality.
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introduction
At least 19 randomized studies have shown that adding hyperthermia (HT) to radio­
therapy (RT) and/or chemotherapy leads to improved survival and tumor control in 
oncological patients without a significant increase in observed side effects [40]. In all 
these studies, the differences were remarkably large. In a multicenter randomized trial 
on malignant melanoma by Overgaard et al. [20], the addition of HT to RT improved 
the complete response (CR) from 35% to 62%, and 2­year local control (LC) from 28% 
to 46%. Addition of HT to RT in recurrent or advanced breast cancer improved the CR 
from 41% to 59% [42]. The difference in LC was maintained over the 3­year follow­up. 
The tripling of the CR rate in various superficial tumors for reirradiation and high­dose 
HT vs RT and low­dose HT as demonstrated in a randomized study by Jones et al. [13] 
resulted in the inclusion of radiation plus HT in the 2007 Breast Cancer Guidelines for 
recurrent breast cancer and other localized cancer recurrences by the National Com­
prehensive Cancer Network (NCCN). HT is both the ideal complementary treatment 
to, and a strong sensitizer of, RT and in general well tolerated by patients [14]. The HT 
treatment effect depends on the temperature rise and the treatment duration at the 
elevated temperature. In several clinical trials, a correlation between treatment outcome 
and thermal dose parameters was demonstrated [3,9,26,31,39,43]. However, translation 
of these experimental dose–effect relationships to the clinical situation is complicated. 
Simple approaches to describe a clinically delivered thermal dose include the use of 
maximum, average, or minimum temperature for the duration of the treatment or the 
use of measurements for temperature distribution, such as T10 or T90 (the temperature 
level above which 10% or 90%, respectively, of the measurements was). The temperature 
distribution during clinical treatment is spatially inhomogeneous due to variable tissue 
properties and blood flow, and changes over time due to changes in blood flow [7]. A 
disadvantage of thermal dose parameters is that these have been shown to depend on 
the number of measurement sites and on tumor characteristics such as blood flow and 
tumor size [4].
Major limitations for further improvement of treatment quality lay in the difficulty to 
improve dosimetry and in the inability to prescribe a specified thermal dose [6]. We do 
not consider it clinically feasible to increase the density of interstitially placed tempera­
ture probes. Furthermore, noninvasive thermometry (NIT) by magnetic resonance imag­
ing is not realistic for superficial hyperthermia treatment (SHT), and NIT by microwave 
radiometry or ultrasound has not been shown to provide the required spatial resolution 
and temperature sensitivity.
Clinical data support that the Specific Absorption Rate (SAR) distribution is a valuable 
parameter to predict the CR [40]. Lee et al. [16] studied the relationship between SAR 
and clinical outcome in 151 patients with 196 lesions of recurrent breast carcinoma of 
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the chest wall. They found that both CR rate and local tumor control were statistically 
higher when the tumor was covered by the 25% iso­SAR contour. The clinical outcome 
was better predicted by SAR coverage than by thermal dose parameters. In a different 
way, van der Zee et al. [38] also found that the HT technique, i.e. the SAR distribution, is 
important for clinical outcome. In patients with recurrent breast cancer, they observed 
a much higher LC rate after the introduction of a better heating technique, especially in 
the patients with larger tumors.
In a follow­up to these findings, we started a clinical study to investigate whether the 
predicted three­dimensional (3D) SAR distribution from SHT modeling is prognostic for 
treatment outcome in patients with breast cancer recurrences in a previously irradiated 
area [23,24,25]. In order to adequately conductance of this study, the modeling should 
accurately reflect the applied HT quality.
The first step in this approach is the correct input of the tissue and applicator configu­
ration, i.e., the 3D model.
This technical note describes our experience with making a multislice CT scan and 
segmenting CT images for creating a 3D patient model. The study of the relationship 
between the calculated 3D SAR distribution and the clinical outcome is still ongoing 
and will be reported later. We believe that this paper contains important information 
for other researchers with an interest in similar studies or designing procedures for 
implementation of HTP as a routine.
metHods
Patients and treatment
Patients with recurrent breast adenocarcinoma referred for reirradiation (8 × 4 Gy, twice 
weekly) and HT (four times, once weekly, 60 min, after RT), and with the possibility to 
place interstitial thermometry catheters in the treatment area were eligible for the study 
on predicted SAR distribution as a prognostic parameter for temperature distribution 
and clinical outcome. This study was approved by the Medical Ethics Committee (METC). 
Written informed consent was obtained from all patients.
Closed­tip catheters were placed immediately before the first HT treatment. HT was 
induced with 433 MHz, utilizing up to six Lucite Cone Applicators (LCA), with a perfused 
water bolus between the skin and applicators [33,36,37,41]. Each applicator has an 
independent power control. Multipoint fiber­optic thermometry probes (FTP­5 Medical 
Array Sensor, Takaoka Electric Mfg, Tokyo, Japan) are placed in the catheters and on the 
skin.
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specification of a ct scan
The CT scans were performed with a Siemens Somatom Sensation Open with a large 
bore of 85 cm. The resolution of the CT scans was 512 × 512 pixels, 3.0 mm slice thick­
ness, a slice distance of 2.5 mm, and together this corresponds to a 1 × 1 × 5 mm3 voxel 
cube. Between 120 and 140 slices with margins of 5 cm superiorly (including the su­
praclavicular region) and margins of 5 cm inferiorly (including the thoracic diaphragm) 
of the treatment volume were required. The CT scan was made without intravenous 
contrast agents.
Procedure
making the ct scan
Thus far, a treatment­specific CT scan has been made for 26 patients (Table 1). In the first 
few patients, the CT scan was performed before the start of the first HT treatment, using 
moulds representing the LCA footprints, without stubs.
table 1. Patient characteristics and details of CT scanning. Ma: macroscopic, Mi: microscopic, RT: radio­
therapy, HT: hyperthermia, chemo: chemotherapy, horm: hormonal therapy, B/A: before/after first HT treat­
ment.
This appeared insufficient to create a patient­ and treatment­specific model for SHTP: 
information about the margins of the RT field, the HT treatment position of the patient, 
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the distance of the applicators from the skin, and the location of the tumor was lacking. 
Therefore, the following adjustments to the procedure were made.
marking the rt Field
In combination with reirradiation, the whole RT volume is the target for HT treatment 
[35].
The HT applicators are placed such that the RT field is widely covered; the RT target 
volume can, therefore, not be deduced from the position of the HT applicators. Thus, 
starting with the fifth patient, the margins of the RT field were made visible with a metal 
thread (Figure 1).
Figures 1a and 1b. a Axial CT image of breast tissue demonstrating a marked RT field (green), fat (orange), 
muscle (brown), bone (yellow), air (blue) and moulds (pink). b Location of the RT field is enlarged in this im­
age (green).
ct scan timing and Patient Positioning
In the first 8 patients, the CT scan was made after the catheters were inserted, prior to 
the first HT treatment. The patients were not always lying in the same position in the CT 
scanner as during the HT treatment. In the next 18 patients, the CT scan was planned 
after the first treatment, or the treatment position was simulated before the CT scan was 
made.
water bolus
The position of the LCAs had been marked on the skin. Moulds representing the LCA 
footprints were used to show the position of the LCA on the thoracic wall. At first (in 7 
patients), the moulds were placed 2 cm from the skin by stubs, simulating the thickness 
of the water bolus (Figures 2 and 3). In later patients, a water bolus was placed between 
the skin and the moulds. A water­filled bolus appeared inaccurate because there were 
no applicators to maintain its correct position (Figure 4). In Figure 5, a dummy air­filled 
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bolus is used which is not visible on the CT scan, but adequately shows the distance 
between applicators and skin.
Figure 2. Axial CT image of breast tissue demonstrating tumor (red), catheter in tumor (green), fat (orange), 
muscle (brown), bone (yellow), air (blue), moulds (light blue) and stubs (pink).
Figure 3. Axial CT image of breast tissue demonstrating moulds representing LCA footprints with stubs 
simulating the thickness of the water bolus.
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Figure 4. Moulds representing LCA footprints with stubs turned up­side down on top of the water­filled 
bolus.
Figure 5. Moulds representing LCA footprints (not segmented) with stubs turned up­side down on top of 
a dummy water bolus (not visible on CT scan).
radiolucent catheters
During the course of the study, a change was made from radioopaque to radiolucent 
catheters, because the radioopaque catheters were not available anymore. Therefore, 
from patient 8, the radiolucent catheters were made visible with radioopaque markers 
(Figure 6).
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Figure 6. Enlarge image of a radiolucent catheter made visible with a radioopaque marker.
marking the visible and Palpable tumor
It is not possible to predict whether a tumor will be visible on the CT scan. Therefore, 
the clinically apparent tumors were marked with a metal thread on the skin. This is not 
always possible, e.g., when there are many lesions or when the tumor is subclinical. 
Figure 7 shows the markers around the tumor, which by itself can be discriminated from 
the surrounding fat tissue.
Figure 7. Axial CT image demonstrating a tumor marked with a radioopaque marker and a dummy water 
bolus (not visible on CT scan).
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segmentation of ct images
The process was started by displaying a CT image in the workstation screen. The mul­
tislice CT images were transferred in DICOM (Digital Imaging and Communications in 
Medicine) format to the workstation for 3D visualization and model generation. For 
the planning system, a patient­specific model by assigning each tissue type was car­
ried out by a HT physician (ML) using the dedicated segmentation program (i.e. iSeg). 
Next the model was imported into SEMCAD X, a 3D electromagnetic field simulator 
[28]. Previously, de Bruijne et al. [5] demonstrated that the SEMCAD model provides 
reliable quantitative agreement between predicted and measured SAR distributions 
in a homogenous model. With an obtained dose difference (DD) < 2% and distance to 
agreement (DTA) < 2 mm, these results are comparable to that achieved in radiotherapy 
treatment planning (RTP).
marking the visible and Palpable tumor
The HT physician first defined the anatomical structures in the CT images.
Automatic and manual segmentation of the structures were performed by the same 
HT physician in order to promote uniformity. The dielectric properties assigned to the tis­
sues are described in Table 2 [10]. Even though they may consist of significantly different 
tissues concerning dielectric and thermoregulatory properties (e.g., previous surgery 
and/or RT) [2], the tissue of any structure was considered to be homogeneous. Muscle, 
fat, bone, and air were segmented automatically, even though manual review and cor­
rections of these structures were still mandatory. This manual review was performed on 
each image using an electronic pen on a tablet.
The automatic segmentation took 1 h. The RT field, catheters, and LCA moulds were 
segmented manually. The segmented structures were all visible on the CT slice. Defining 
the target volume could be difficult. Color photographs and a life size drawing of the HT 
treatment area made on a transparent sheet were available.
The tumor was segmented to evaluate the position of a hot spot during treatment, to 
predict the total absorbed energy in the tumor, and to compare this with the measured 
temperatures. Without segmentation of the tumor, the manual segmentation took 2 h; 
with segmentation of the tumor, it could take up to 3 h.
discussion
In this article, we present the procedure of making a CT scan and segmenting the CT 
images to create a patient­ and treatment­specific model for SHTP that represents the 
real patient treatment set­up. For this aim, it is important that the CT scan is made with 
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the patient in the treatment position and that all relevant information is visible. Several 
adaptations to the original procedure were introduced during the study period.
Dummies representing the LCAs were used from the beginning. Since the irradiated 
volume is the target for HT and the area covered by the applicators is larger than the 
RT field, markers were introduced for the RT field margins. The dummy water bolus was 
introduced to make the distance from the applicator to the skin more realistic than with 
the stubs on the corners of the dummies placed on the skin. A change from radioopaque 
to radiolucent catheters made it necessary to place markers in the catheters.
Tumors were not always visible on the CT scan. Therefore, it was necessary to intro­
duce marking of the visible/palpable tumor.
In order to have the same patient positioning during the actual treatments as on the 
CT, the same HT physician and technicians should prepare all treatments, and photo­
graphs should be taken of the patient during treatment. It is unclear how others ensured 
having a representative CT scan for HTP. In the study of Kumaradas and Sherar [15], the 
CT imaging was performed before the HT treatment to determine the position of the 
catheters, to predict the temperature profile, and to identify possible hot spots, but they 
do not provide details about the procedure they used to place the patient in the CT 
scanner. In studies of Sreenivasa et al. [29] and Gellermann et al. [11], a patient­specific 
HT planning was made but the procedure of making the CT scan is not explained in 
further detail. We previously made CT scans for deep HTP. A CT scan of the patient lying 
in a BSD sling system, i.e., in the HT treatment position, was obtained [8,34].
Since HT is almost always used in combination with RT, it would be beneficial to 
integrate the RT CT scan in both planning techniques [1,12,17,18,19,27,32]. However, 
this is not possible for SHT and deep HT treatments, since the positioning for RT differs 
from that for HT. For head and neck treatment, this is possible, since the positioning of 
the patient during the HT treatment is the same as during RT treatment. In the study 
of Paulides et al. [21], the patient model with a head and neck tumor, treated with the 
HYPERcollar, was segmented from a CT scan that was made for RTP.
A much mentioned drawback of the segmentation of the CT images is the time­
consuming and subjective process, especially of the manual segmentation. Automatic 
segmentation takes 10–20 min and manual segmentation 2­4 h.
The time for manual segmentation can be reduced by further improvements to the 
program, e.g., by importing information on RT field margins from the RTP, like was done 
for head and neck patients [22].
We are convinced that HTP will be an important tool for quality assessment and be­
lieve that the SAR distribution has the potential to be a HT dose parameter.
The first step in HTP is to procure a high quality CT scan with the patient in the treat­
ment position. This CT scan must provide all information which is relevant to calculate 
the energy distribution. The manual segmentation of tissues requires the largest amount 
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of time in the model creation. It is important that this time to be decreased with auto­
matic segmentation.
conclusions
Our results show that the construction of a representative 3D model for SHTP is feasible. 
We expect that the use of SHTP will translate into better HT treatment control.
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abstract
In the current clinical practice, prior to superficial hyperthermia treatments (HT), 
temperature probes are placed in tissue to document a thermal dose. To investigate 
whether the painful procedure of catheter placement can be replaced by superficial HT 
planning, we study if the specific absorption rate (SAR) coverage is predictive for treat­
ment outcome. An absolute requirement for such a study is the accurate reconstruction 
of the applicator setup. The purpose of this study was to investigate the feasibility of 
the applicator setup reconstruction from multiple­view images. The accuracy of the 
multiple­view reconstruction method has been assessed for two experimental setups 
using six lucite cone applicators (LCAs) representing the largest array applied at our 
clinic and also the most difficult scenario for the reconstruction.
For the two experimental setups and 112 distances, the mean difference between 
photogrametry reconstructed and manually measured distances was 0.25 ± 0.79 mm 
(mean±1 standard deviation). By a parameter study of translation T (mm) and rotation R 
(°) of LCAs, we showed that these inaccuracies are clinically acceptable, i.e. they are ei­
ther from ±1.02 mm error in translation or ±0.48° in rotation, or combinations expressed 
by 4.35R(2) + 0.97T(2) = 1. We anticipate that such small errors will not have a relevant 
influence on the SAR distribution in the treated region. The clinical applicability of the 
procedure is shown on a patient with a breast cancer recurrence treated with reirra­
diation plus superficial hyperthermia using the six­LCA array. The total reconstruction 
procedure of six LCAs from a set of ten photos currently takes around 1.5 h. We conclude 
that the reconstruction of superficial HT setup from multiple­view images is feasible and 
only minor errors are found that will have a negligible influence on treatment planning 
quality.
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introduction
Several randomized studies have shown a benefit when adding hyperthermia to the 
radiotherapy treatment for superficial diseases such as melanoma and breast cancer 
recurrences at the chest wall [14,18,27]. Hyperthermia treatment (HT) quality is gener­
ally assessed by superficially and interstitially placed temperature measurement probes. 
Temperature measurements at the skin are in general affected by the water bolus tem­
perature so temperature measurements in tissue are required for an accurate thermal 
dose evaluation, especially if the tumour extends to depths over 5 mm [24].
The procedure to place invasive catheters is labour intensive, causes patient discom­
fort and increases the risk of infection, as they stay in place up to 4 weeks. Aiming to 
replace invasive thermometry by predictive HT planning, we investigate the predic­
tive value of the specific absorption rate (SAR) coverage for the treatment outcome. 
Superficial HT planning is not standardly applied in the clinical practice. The value of 
pretreatment superficial HT planning in situations where (1) the treatment area is close 
to critical organs or metal and (2) when the tumour extends more than 4 cm from skin, 
i.e. the maximal allowed depth at 434 MHz, was demonstrated by de Bruijne et al. [8].
Superficial HT planning can also be used as a tool for detailed 3D retrospective analy­
ses of treatment quality and to evaluate the appropriateness of applicator selection, 
applicator positions and applied power during HT. In clinical practice, the HT setup 
strongly depends on patient acceptance and comfort. Hence, the applicator position 
applied to the patient is determined at the start of the first treatment. Consequently, 
superficial HT planning in clinical practice demands an accurate, automatic and fast 
procedure to reconstruct the treatment setup.
A number of techniques (optical, laser scanning, etc) [4] are available to reconstruct 
the superficial HT setup; however, they differ substantially in cost and ‘user friendliness’. 
Reconstruction from multiple­view images is one of the methods used in radiotherapy 
practice for creation and documentation of the patient position during treatment 
[2,22]. Bert et al. [3] showed that an accuracy of 1 ± 1.2 mm for the simulated patient 
positioning is feasible using a commercially available 3D surface imaging system for 
accelerated partial­breast irradiation. In comparison to radiotherapy treatment, where 
cameras have clear visibility to the reconstructed patient anatomy, the superficial HT 
setup at our clinic is more complex. Fixation arms holding the antennas in treatment 
positions, power cables and inflow–outflow tubes for circulating deionized water make 
the reconstruction scene more irregular. This prevents using the photogrametry systems 
used in radiotherapy.
The objective of this study was to investigate the feasibility to accurately reconstruct 
the lucite cone applicator (LCA) array from multiple­view images. Threshold for accept­
able reconstruction accuracy was set at 2 mm following the accuracy for predicting the 
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SAR profile of a single LCA, as demonstrated by de Bruijne et al. [7]. The accuracy of the 
reconstruction procedure was studied on setups with one and six LCAs. As a first step, 
we compared reconstructed and real dimensions of the LCAs. In the next step, we com­
pared reconstructed and manually measured distances among subsequent applicators 
in six­LCA array configuration.
Finally, the clinical feasibility of photogrametry reconstruction was demonstrated us­
ing photos taken during superficial HT in which an array of six LCAs was applied.
metHods
lucite cone applicator
The LCA is the standard applicator for superficial HT at the Erasmus MC­Daniel den Hoed 
Cancer Center, Rotterdam, the Netherlands [25]. It is a waveguide­based applicator 
working at 434 MHz with a horn aperture of 100 × 100 mm (inner dimensions) [21,26]. 
Clinically, up to six applicators can be combined in a non­coherent antenna array, allow­
ing to cover an area of 200 × 300 mm2 with the effective field size, defined in Hand et al. 
[11], Bakker et al. [1] and de Bruijne et al. [5].
treatment planning procedure
To document interstitial catheters, radiotherapy margin and the LCAs, a hyperthermia 
specific computer tomography (CT) scan is made. During the CT scan, up to six plastic 
squares were placed at the patient to indicate the positions of the LCAs during the treat­
ment. The CT scan typically consists of 120 slices with 2.5 mm distance between slices. 
From this CT, a 3D patient specific model is created in iSeg (version 3.1, Zurich Med Tech 
AG, Zurich, Switzerland) [17]. Subsequently, the patient model is imported into the finite 
difference time domain (FDTD) based software SEMCAD X (v.14.6, Schmid & Partner 
Engineering AG, Zurich, Switzerland) for electromagnetic and temperature simula­
tions. SEMCAD X has been evaluated for clinical use in our institute for both superficial 
and deep HT [8,19,20]. The LCA array, reconstructed from multiple­view images, was 
imported into SEMCAD X and placed in treatment position on top of the patient model. 
The LCA array was positioned such that it matched the plastic squares from the CT. The 
dielectric properties of normal tissues are taken from Gabriel et al. [9] (see table 1) and 
the properties for tumour tissue were chosen with respect to the measurements made 
by Jones et al. [13].
145
Reconstruction of applicator positions for accurate superficial hyperthermia treatment planning
table 1. Dielectric tissue properties at 434 MHz.
reconstruction procedure
For the setup reconstruction, we apply the photogrametry method in which geometric 
properties of real objects are determined using multiple­view images [12]. We used the 
commercial photogrametry package PhotoModeler Scanner (v.6.3, Eos Systems Inc., 
Vancouver, Canada) for the applicator setup reconstruction. The reconstruction proce­
dure is done through assignment of selected points on each applicator at the individual 
photos.
Points visible in at least two photos can be reconstructed but the highest accuracy is 
achieved for pairs of photos taken under a 90°spatial angle. To ensure good visibility of 
the points at every photo, we fixed all power cables and deionized water tubes to the 
arms holding the applicator in treatment position, as in figure 1.
Figure 1. Example of photo from superficial HT used for photogrametry reconstruction.
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The photos are taken using a standard SONY (Minato, Tokyo, Japan) DSC F707 CyberShot 
camera which was in manual mode to ensure that all photos have identical settings.
exPerimental validation
Experimental validation of the reconstruction procedure was first performed using 
single LCA setups, where we compared reconstructed and real dimensions of the six 
LCAs. Afterwards, reconstructed and manually measured distances among subsequent 
applicators were compared for six­LCA array configuration. For clarity, we define
•	 dimension	 differences-differences	 between	 the	 dimensions	 of	 the	 reconstructed	
wireframe LCA (figure 2(c)) and the real LCA (figure 2(a)),
•	 distance	 differences-differences	 between	 the	 distances	 among	 the	 LCAs	 in	 array	
configuration of the wire­frame LCA array model and the experimental HT setup 
(figure 3).
Figure 2. (a) Photo of LCA, (b) 3D LCA model created from manual measurements of real applicators, (c) 
reconstructed wire­frame LCA model from PhotoModeler with 16 indicated reconstructed points.
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Figure 3. (a) Photo of the experimental setup for a six­LCA array with highlighted several measured dis­
tances, (b) top view of the middle part of LCAs (points 9–12 from the 3D LCA model in figure 2) with 28 
measured distances.
exPeriment 1: single lca reconstruction
Single LCA reconstruction was applied to each of the six clinically available LCAs and 
eight photos were taken per applicator. Sixteen dimensions of individually reconstructed 
LCA models were compared with the real physical dimensions of the tested applicators. 
Because there are no other objects present in the photos but the applicator itself, the 
single LCA case represents the ‘easiest’ reconstruction scenario.
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Figure 2(b) shows a 3D LCA model created from manual measurements of clinically 
available LCA (see figure 2(a)). To improve accuracy of the reconstruction procedure, a 
specific LCA model was developed for each of six real applicators.
Sixteen points characterizing the LCA were selected to describe the physical model, 
i.e. eight points at the top (1–8), four in the middle part (9­12) and four at the bottom 
(13­16) of the LCA.
Using the PhotoModeler package, 16 corresponding points were connected creating 
the wire­frame LCA model (see figure 2(c)). We compared sixteen dimensions for each 
LCA, i.e. eight in the top part (between points 1–8, 2–7, 3–6, 4–5, 6–7, 5–8, 1–4 and 2–3), 
four in the middle part (points 9–12, 10–11, 9–12 and 11–12) and four in the bottom 
part (points 13–16, 14–15, 13–14 and 15– 16). By comparing the dimensions of the 
reconstructed wire­frame LCA model with the real dimensions of the LCA, an indication 
of the accuracy of the photogrametry reconstruction was obtained.
exPeriment 2: lca array reconstruction
To verify the correctness also of an LCA array reconstruction from multiple­view images, 
we reconstructed two setups consisting of six LCAs (figure 3). A setup with six LCAs 
represents the most challenging scenario for the photogrametry reconstruction due to 
the presence of power cables and inflow–outflow tubes for each LCA. Two setups were 
build to mimic two sequential superficial HT sessions, where the LCAs are rotated with 
a 90°angle [5,25]. The LCAs were placed on top of a 420 × 310 × 20 mm3 water bolus 
lying on a cylindrical water tank (diameter 290 mm) simulating a curvature similar to the 
clinical practice [6]. Fourteen photos from different view angles were taken for the first 
setup and nine for the second one.
As in experiment 1, we calculated the dimension differences of the reconstructed 
wireframe LCAmodels with their dimensions in reality. Subsequently, the reconstructed 
wire­frame LCA array model was imported into a MATLAB (v.2011a, Natick, MA, USA) 
interface. In this interface, we minimized position differences between the 3D LCA 
models and the wire­frame model by optimizing translation and rotation of the 3D LCA 
models using a particle swarm optimization algorithm. After optimization, 112 distance 
differences among the applicators were calculated by comparing the reconstructed 
six­LCA array with experimental setup shown in figure 3. Some of the 112 measured 
distances among LCAs are also shown in figure 3(a). Figure 3(b) shows a top view of the 
middle parts of LCAs (points 9–12 from the 3D LCA model in figure 2) with 28 measured 
distances.
In the same way, we derived distances for the top part of LCAs and also second experi­
mental setup, i.e. in total 2(28 + 28) = 112 distance differences were measured.
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clinical relevance oF tHe remaining distance diFFerences
In order to assess the clinical relevance of our method, we studied the dependence of 
the distance differences obtained in experiment 2 on translation T (mm) and rotation R 
(°) of the LCAs. Using two virtual ‘reference setups’ corresponding to the two­LCA array 
setups from experiment 2, we created 1000 virtual setups (500 for each reference model) 
by varying T and R of each of the six LCAs. For each of the 1000 virtual setups, we calcu­
lated the mean ± standard deviation of the 112 distance differences found between the 
new (virtual) and the reference setups, i.e. we obtained 1000 means and 1000 standard 
deviations.
The mean value of the 1000 standard deviations SD distance differences obtained in 
experiment 2 on translation T (mm) and rotation R (mm) was compared to the standard 
deviation found in experiment 2, i.e. SDexp2 (mm). For the situation where SDexp2 =SDm1000, 
we assume that such translation and/or rotation of the LCAs would lead to the same 
distance differences measured in experiment 2.
exPeriment 3: clinical setuP reconstruction
To demonstrate the feasibility to reconstruct a clinical applicator setup, we selected 
a representative patient with a recurrent breast cancer treated with a six­LCA array 
configuration. The LCAs were positioned and the quantitative 3D SAR distribution was 
calculated.
results
experiment 1: single lca reconstruction
Figure 4(a) shows the histogram of the 96 dimension differences (six LCAs, 16 dimensions 
per LCA) between the reconstructed wire­frame LCA models and the real applicators. 
The small difference of ­0.73 ± 0.53 mm (mean ± 1 standard deviation) shows the high 
accuracy of the photogrametry reconstruction. The negative mean value is due to the 
fact that measured dimensions of the LCAs were generally larger than the reconstructed 
ones.
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Figure 4. Histogram of the dimension differences between the dimension of the wire­frame models and 
their corresponding physical dimensions of the real applicators. (a) Single LCA reconstruction (n = 96, six 
LCAs, 16 dimensions per LCA), mean dimension difference −0.73 ± 0.53 mm; (b) LCA array reconstruction (n 
= 192, six LCAs, 16 dimensions per LCA, two setups), mean dimension difference −0.66 ± 0.61 mm.
experiment 2: lca array reconstruction
Figure 4(b) shows the dimension differences between the reconstructed wire­frame LCAs 
and the real applicators for the two studied array configurations. For the 192 (six LCAs, 16 
dimensions per LCA, two setups) dimension comparisons, we found a mean difference of 
­0.66 ± 0.61 mm. These results, and those from the single LCA experiment, show that the 
accuracy of the photogrametry reconstruction method is comparable for the reconstruc­
tion of the single LCA and the reconstruction of a six­LCA array. Figure 5 shows a histogram 
of the 112 distance differences between distances obtained from the reconstructed wire­
frame model and the distances measured manually on the two experimental LCA setups. 
The mean distance difference was found to be 0.25 ± 0.79 mm (setup is shown in figure 3).
Figure 5. Histogram of the 112 distance differences between distances measured on the reconstructed 
wire­frame model and distances manually measured on two experimental LCA setups, mean distance dif­
ference 0.25 ± 0.79 mm.
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clinical relevance oF remaining distance diFFerences
Figure 6 shows the mean value of the 1000 standard deviations (SD) calculated for all 
combinations of virtual and reference models. T and R of each LCA were changed from 
­2 to 2 mm and from ­1° to 1°, respectively, allowing the comparison of SDm1000 with the 
standard deviation measured in experiment 2 (SDexp2 = ±0.79 mm). The iso­contour in 
figure 6, defined by SDm1000 = ±0.79 mm, represents maximum errors in translation T = 
±1.02 mm (for R = 0°) and in rotation R = ±0.48° (for T = 0 mm). The maximum combined 
uncertainties can mathematically be described by the following approximate elliptic 
function: 4.35R2 + 0.97T2 = 1.
Figure 6. Mean value of the 1000 standard deviations (SDm1000) calculated between the virtual and the 
reference models. The area defined by the SD = ±0.79 mm iso­contour represents the combinations of un­
certainty in T and R that leads to the same errors in distance differences measured for the two experimental 
setups.
exPeriment 3: clinical setuP reconstruction
To demonstrate the clinical feasibility of the photogrametry method, we reconstructed 
the superficial HT setup for a recurrent breast cancer patient treated with six LCAs using 
ten photos. The reconstructed wire­frame LCA array model together with the camera 
positions in PhotoModeler is shown in figure 7(a). In total, the reconstruction of 79 points 
was possible and a mean dimension difference of ­0.88 ± 0.85 mm was found for the 68 
dimensions. Figure 7(c) shows the final superficial HT planning setup in SEMCAD X after 
placement of the LCA array in the treatment position. Combining the individual 3D SAR 
(IEEE­1529,1 g) distributions for all six LCAs, taking into account the actual HT power fed 
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in each LCA, the final 3D SAR (IEEE­1529,1 g) iso­surface of 30 Wkg­1 was calculated (see 
figure 7(d)). In this particular setup, the 30 Wkg­1 contour represents the 25% isoSAR 
surface coverage (i.e. 25% of the maximum SAR inside the patient model) 1 min before 
the end of the HT.
Figure 7. (a) Reconstructed wire­frame LCA array model together with ten camera positions in PhotoMod­
eler, (b) best fit of the six applicator specific 3D LCA models with the reconstructed wire­frame LCA array 
model, (c) superficial HT planning setup in SEMCADX, (d) 3D SEMCAD X­1529,1 g) iso­surface of 30 Wkg­1 1 
min before the end of the superficial HT.
discussion
In this study, we investigated the feasibility to accurately reconstruct superficial HT ap­
plicator setups using multiple­view images.
As a first step, the accuracy and the reproducibility were studied by analysing the 
reconstruction accuracy of the LCAs dimensions, and a mean difference of ­0.73 ± 0.53 
mm for six individual LCA (experiment 1) was found.
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For the situations where LCAs were reconstructed from the setups of six LCAs, we found 
a mean dimension difference of ­0.66 ± 0.61 mm (phantom; experiment 2) and ­0.88 
±0.85 mm (clinic; experiment 3). The smaller dimension of the reconstructed applicators 
leading to the negative mean value is caused by the difficulty in the manual procedure 
to correctly assign all the selected points at the photos for LCAs with blended edges re­
quired for secure clinical handling. Clear visibility experienced to be an important aspect 
for the reproducibility of the reconstruction process, i.e. the highest reproducibility (SD 
=±0.53 mm) was found for a single LCA reconstruction. However, the inaccuracies in the 
reconstructed dimensions for six LCA setups were acceptable, i.e. the most difficult case 
(clinic; experiment 3) was within 1.73 mm (mean+1SD).
The clinical feasibility of the reconstruction procedure was studied on two realistic 
setups consisting of six LCAs. For these two setups, the distance differences varied from 
­1.6 to 2.7 mm with a mean value of 0.25 ± 0.79 mm. This is affected by the inaccuracy 
from the manual measurements during six­LCA array phantom experiments where we 
had limited access to the LCAs, especially in the middle part of the array. Finally, we 
demonstrated that a SD of ±0.79 mm corresponds with translation errors of maximum 
1.02 mm or rotation errors of maximum of 0.48° for the most challenging case, i.e. six 
LCAs. We anticipate that such small changes will not have a relevant influence on the 
SAR distributions. However, this is the topic of future studies.
At this moment, practical implementation of the reconstruction procedure from mul­
tipleview images requires a number of manual steps. It takes around 1.5 h to complete a 
reconstruction of six LCAs from a set of ten photos. This time is acceptable for retrospec­
tive superficial HT planning, but clinically unacceptable.
Prospective clinical application requires a fully automatic reconstruction of the super­
ficial HT setup, so planning can be done prior to treatment. The first step in automation 
of the reconstruction procedure is possible by placing coded targets to specific points at 
each LCA, i.e. marks that PhotoModeler can automatically recognize. Every coded target 
has a specific number and it is every time reconstructed under this number. Using this 
method, the LCA positions in the array configuration can be automatically assigned. The 
second step of clinical application of superficial HT planning requires monitoring of the 
LCAs positions with respect to the patient anatomy.
During the current retrospective planning procedure, we manually placed the recon­
structed LCA array on the top of the patient model in order to overlap plastic LCA foot­
prints. Automation of this procedure is possible by placing coded targets at predefined, 
always visible, locations on the patient body and reconstructs them automatically 
together with LCA array. However, this requires assigning these points also at the CT and 
segmenting them along with the patient anatomy.
A potential limitation of the photogrametry reconstruction technique could be the 
requirement of full coded target visibility on every photo, which is affected by the pres­
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ence of power cables and water tubes. Hence, the treatment system would need to be 
redesigned to facilitate this.
The feasibility of the superficial HT setup reconstruction procedure for six­LCA array 
can also be extended to other applicators. Contact flexible microstrip applicators (CFMA) 
are one of the most common used applicators in clinical practice [10,16,23]. They are 
usually placed directly on the patient body and stretched to cover the treatment area.
In combination with coded targets placed on the outer surface of the CFMA, it is 
feasible to use automatic reconstruction inside PhotoModeler Scanner to document e.g. 
the realistic curvature during the superficial HT, which has been shown to influence SAR 
pattern [15]. Hence, this method also holds promise for other applicator systems.
conclusions
This study demonstrates the feasibility of accurately reconstructing the superficial 
hyperthermia applicator setup using multiple­view images. The accuracy of our pho­
togrametry reconstruction technique was assessed by comparing 112 photogrametry 
reconstructed and manually measured distances in two configurations of the six­LCA 
array. For the patient treated with six LCAs in the chest wall region, we demonstrated the 
feasibility of superficial HT setup reconstruction for clinical conditions.
This study shows that applying photogrametry allows the reconstruction of the 
clinically applied LCA array setup with an accuracy of ±1 mm, which fulfils our accuracy 
requirement of 2 mm. This method will be developed further to enable the automatic 
fast reconstruction of the treatment setup to meet time requirements for prospective 
treatment planning for superficial HT.
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general discussion, Future considerations and conclusions
superficial hyperthermia in combination with reirradiation
At the time that the combination of reirradiation plus hyperthermia was introduced for 
treatment of recurrent breast cancer in previously irradiated areas no effective treatment 
was available for this patient group. Reirradiation alone was considered ineffective, while 
hyperthermia appeared to be an interesting sensitizer of radiotherapy as described in 
chapter 1. Chapter 2 describes the process of finding the optimal treatment schedule, 
technological developments and other lessons learned. When I started my work on the 
studies described in this thesis, reirradiation with 8 fractions of 4 Gy combined with 4 
fractions of hyperthermia had become standard care. Long term results of the treatment 
and the effect in specific subgroups were missing.
The best published local control rates in patients with radiation­induced angiosar­
coma were achieved with surgery combined with hyperfractionated and accelerated 
radiotherapy (HART) [1,2]. The data reported in chapter 3 demonstrate that for initially 
inoperable tumors the effect of reirradiation and hyperthermia can be worthwhile. It 
would be interesting to investigate whether addition of hyperthermia to HART will 
improve the probability for local control.
Tissue transfers are sometimes considered to be a contraindication for treatment with 
radiotherapy and/or hyperthermia. In our retrospective study (chapter 4) in 33 patients 
we found an incidence of 8% acute and 5% late grade 3 toxicity. In view of the high 
control rate this is acceptable, therefore there is no reason to withhold the treatment 
from patients with tissue transfers.
In chapters 5 and 6 results in patients with gross and subclinical disease, respectively, 
are reported in detail. A complete response was achieved in 70% of the patients with 
irresectable breast cancer, which is comparable to the complete response rate in the 
ESHO 88­5 phase III trial [3]. Local tumor control rate at 1, 3, and 5 years was 53%, 41% 
and 39%, respectively. The overall survival rate at 1, 3, 5 years, and 10 years was 67%, 
32%, 18% and 10%, respectively. For subclinical disease the local tumor control rates 
at 1, 3, 5 and 10 years are 93%, 83%, 78%, and 75% respectively. The 3, 5 and 10 years 
overall survival (OS) rates are 75%, 60% and 36%, respectively, with a median survival of 
82 months. Remarkable in both studies is the overall survival after 10 years, contradict­
ing the initial assumption that the treatment is only palliative. Moreover, these effects 
are achieved with acceptable toxicity.
An alternative treatment for chest wall recurrences is chest wall resection. Publica­
tions on 5 years overall survival after curative chest wall resection, reviewed in van der 
Pol et al. [4], show that this varies from 18% to 71%.
The 5 years overall survival of 18% for irresectable recurrences as achieved in our study 
falls within this range, despite that our patients had worse prognostic characteristics 
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(i.e. irresectable tumors, appearance of metastasis). Further, morbidity after chest wall 
resection can be severe, even resulting in death [5].
For post­operative radiotherapy of primary recurrences 5 years survival ranging from 
49 to 59% have been reported [6,7,8,9], where we found 60%.
An interesting finding in both studies is that the incidence of hyperthermia toxicity 
(skin burns) considerably increased when the maximum temperature measured on the 
skin is 43°C or higher. Another interesting finding is that both complete response and 
local tumor control are not worse in patients receiving radiotherapy outside the Erasmus 
MC in whom the time interval between radiation and hyperthermia is longer. At the 
same time the incidence of late grade 3 toxicity was lower in patients with subclinical 
disease radiated in another institute.
Today, the Dutch Association of Comprehensive Cancer Centers guidelines consider 
reirradiation plus hyperthermia for recurrent breast cancer in previously irradiated areas 
regular care in the Netherlands (www.oncoline.com).
HyPertHermia dose eFFect relationsHiP indicates tHe need For 
imProved Heat delivery
From experimental studies, we know that the biological effectiveness of hyperthermia 
depends on the height of the temperature and the duration of treatment at elevated 
temperature [10], and this has been confirmed in clinical studies. Therefore, there is a 
clear need to monitor and optimize the quality of the hyperthermia treatment.
Due to the variation in tumor size, shape, dielectric and thermal (i.e. blood flow) 
properties and localization relative to other dielectric interfaces of the body, the treat­
ment quality varies from patient to patient. Hyperthermia treatment planning tools can 
provide a method to calculate the 3D SAR (Specific Absorption Rate) or temperature 
distributions and derive predicted hyperthermia­dose parameters from these distribu­
tions. In some patients with non­standard clinical problems, the benefits of SEMCAD X (= 
Simulation platform for ElectroMagnetism Compatible, Antenna Design and Dosimetry) 
[11] treatment planning have been shown to be a useful tool for decision making in 
superficial hyperthermia treatment.
The main benefit is the insight in the 3D SAR coverage of the target in specific anato­
mies. At present, most superficial hyperthermia treatments are applied empirically, i.e. 
experience and dedication of the treatment team plays a major role in the achieved 
treatment quality. In general, the occurrence of too high temperatures, either measured 
or reported by the patient, limits the overall temperature increase during hyperthermia.
Commonly, the strategy is to monitor temperatures with interstitial thermometry. In 
general, the quality of any dose parameter derived from measured temperatures will be 
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subject to great variations from patient to patient (large versus small target areas) and 
varies from center to center based on their ability and readiness to insert a high number 
of interstitial thermometry catheters. Neither the patient nor the clinician appreciates 
increasing the density of interstitial temperature measuring points. Nevertheless, we 
often are able to insert four interstitially thermometry catheters per hyperthermia 
treatment field, whereby the aim is to have at least one temperature sensor under each 
applicator. It must be noted that the current number provides only a sample of the 
3D temperature distribution which might provide a good representation of the mean 
and standard deviation, however, the number is insufficient to perform a good spatial, 
3D optimization of thermal dose. At present there are no realistic options available to 
improve the temporal and spatial resolution of temperature monitoring. The use of non­
invasive thermometry (NIT) by MRI is not realistic for superficial hyperthermia, due to 
respiratory motion and artifacts, and NIT by microwave radiometry or ultrasound has 
not been demonstrated to provide the required spatial resolution and temperature 
sensitivity.
Predicted 3d sar coverage: a Prognostic indicator For treatment 
outcome in suPerFicial HyPertHermia For breast cancer 
recurrences at tHe cHest wall
The development of the patient and applicator models as described in chapters 7 and 8 
was an important step to enable a clinical study to evaluate the potential of calculated 
3D SAR distribution as a predictive parameter. Patients with breast cancer recurrences 
referred for reirradiation and hyperthermia treatment at the chest wall were eligible for 
the study, summarized in figure 1. After written informed consent a CT scan was made 
before the start of the first treatment, after placement of thermometry catheters and 
in hyperthermia treatment position. Figure 2 shows an example of a study patient with 
tumor localized in and around the ribs, who was treated with an applicator set­up of four 
Lucite Cone Applicators (LCAs).
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Figure 1: Study schematic diagram.
Figure 2: A ­ Example of patient model in SEMCAD X, B ­ simulation setup including four LCAs, C­iso sur­
face of 25 % spatial peak SAR (IEEE­1529,1g), D­iso­surface for a temperature of 40 °C.
Clearly, the accuracy of hyperthermia treatment planning is strongly dependent on the 
accurate translation of the modelled applicator configuration to the clinically applied 
applicator configuration. Hence, continuous evaluation of the positioning of the patient 
from the start to the end of the treatment is very important for reliable assessment of 
the SAR distribution with the SEMCAD X platform.
Preliminary analyses in 41 patients showed a local control rate of 90% after a median 
follow up duration of 9 months. We found a significant positive correlation between 
SAR25, i.e. the absolute SAR value that is applied to upper 25% of tumor volume, with 
the probability of local control. Longer follow­up of this data is needed to assess the full 
value of this finding as a great number of the patients included had microscopic tumor 
at the start of the treatment. Nevertheless, this finding is encouraging as it is a first time 
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ever indication that hyperthermia treatment planning can play a substantial role in clini­
cal hyperthermia for patient selection and optimization of the SAR distribution.
Future work and PersPectives in tHe HyPertHermia treatment oF 
breast cancer recurrence
Application of hyperthermia in a more controllable manner, and less labor intensive 
while maintaining its clinical effectiveness would promote its wider acceptance. One 
way to achieve this is to have reliable hyperthermia treatment planning. Realization of 
this still requires substantial efforts in the development of hyperthermia equipment, 
thermal dosimetry and fast hyperthermia treatment planning.
A first step will be to confirm that in superficial hyperthermia the predicted SAR dis­
tribution is related to the measured interstitial temperature distribution. Further, it is 
relevant to verify that SAR coverage is related to treatment outcome in a larger patient 
group.
Concerning the treatment scheme of radiotherapy plus hyperthermia there are a 
number of remaining questions, regarding radiotherapy scheme, number of hyperther­
mia treatments, time interval between the two modalities, and concomitant systemic 
therapy.
For patients with an expected longer overall survival optimization of the radiation 
dose with smaller fraction sizes may be considered [12], i.e. to adjust the radiation 
schedule of 8 times 4 Gy twice weekly to 23 times 2 Gy daily. With smaller fraction size 
the incidence of late toxicity might be lower [13,14], though it should be verified that 
this does not affect tumor control. In our patients with irresectable tumors late grade 3 
toxicity occurred in only 1%, so for this group the 8 x 4 Gy schedule is acceptable and 
convenient.
In the past we changed the hyperthermia schedule from 8 hyperthermia treatments 
to 4. Preliminary analysis showed no significant differences between 8 versus 4 hyper­
thermia treatments, but a definitive analysis should demonstrate that there is indeed no 
clinical benefit of 8 hyperthermia treatments.
Further improvement of the local control rate in breast cancer recurrences is still 
possible. Adding chemotherapy to radiation plus hyperthermia is one of the strategies 
under investigation. Sofar, the experience with concomitant chemotherapy has not 
clearly shown improvements of clinical outcome. Bornstein et al. [15] report a complete 
response rate of 53% for 34 fields in 29 patients treated with various drugs in addition 
to radiation and hyperthermia. Feyerabend et al. [16] report a complete response rate 
of 44% in patients treated with epirubicin and ifosfamide in addition to radiotherapy, 
mean total dose 49 Gy, and hyperthermia. Kouloulias et al. [17] achieved 20% complete 
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response in 15 patients treated with 31 Gy, liposomal doxorubicin and hyperthermia. At 
the same time there is no evidence to suggest that the addition of chemotherapy adds 
to the toxicity of radiotherapy.
We found that a longer time interval between radiotherapy and hyperthermia had no 
negative influence on local control rates, while it did decrease late toxicity in patients 
with subclinical disease. It would be interesting to investigate this prospectively.
general conclusions
– Reirradiation plus hyperthermia is the treatment of choice for patients with recur­
rent breast cancer and should be available for each of these patients.
– The clinical results achieved in patients with a high risk of local recurrence after 
surgical resection of a recurrence strongly suggest that hyperthermia is beneficial 
for these patients as well.
– For patients with irresectable radiation­induced angiosarcoma the effect of reirradia­
tion and hyperthermia is worthwhile.
– Breast reconstructions in previous irradiated areas are not a contraindication for 
treatment with reirradiation and hyperthermia as the incidence of acute and late 
toxicities is acceptable in view of the high local tumor control rates.
– For reliable superficial hyperthermia treatment planning, it is important that the CT­
scan is made with the patient in treatment position and that all relevant information 
is visible.
– For superficial hyperthermia treatment planning the hyperthermia device should be 
validated in detail.
– Dose­effect relationship studies in hyperthermia are required for improvement of 
treatment strategy.
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Summary
Hyperthermia is the use of elevated temperature for the treatment of cancer, increasing 
the tissue temperatures to between 40°C to 44°C for 1 hour or longer.
Several randomized trials have shown that hyperthermia in addition to radiotherapy 
and/or chemotherapy can substantially improve the clinical outcome in a variety of 
tumor types. The ESHO 5­88 study in recurrent breast cancer, for example, has shown 
that addition of hyperthermia to reirradiation increases the local control rate from 38% 
after reirradiation only to 78% after combined treatment. In the Netherlands, Germany, 
Switzerland, Czech, Italy and Greece, the combination of radiotherapy and hyperthermia 
is offered to patients with breast cancer recurrence at the chest wall. In the Netherlands, 
treatment of these patients consists of radiotherapy, 8 x 4 Gy (2fr/wk) combined with 
4 hyperthermia treatments, given once weekly (www.oncoline.nl/mammacarcinoom).
For many years, we have continuously invested in the improvement of the systems 
for superficial hyperthermia. Over the years this resulted in an increase of the average 
invasive tissue temperature by 1.3°C [unpublished results]. In 1999 we showed a dou­
bling of the complete response rate from 31% to 65% for larger tumors (diameter > 
3 cm) tumors when adequate heating technology was used. Within the hyperthermia 
community there is general consensus that .
In this thesis, the current status of hyperthermia in the treatment of breast cancer 
recurrence at the chest wall in the Netherlands is presented and factors related to treat­
ment outcome are identified. A potential way to improve the understanding of the qual­
ity of hyperthermia is to apply treatment modeling that is to calculate 3­dimensional 
(3D) SAR or temperature distribution and derive predicted hyperthermia dose param­
eters from these distributions. Next, these parameters can be used in future research for 
dose­effect relationships and optimization of treatment quality.
chapter 1 describes the rationale for using hyperthermia in cancer treatment, and the 
current practice of treatment of patients with breast cancer recurrences. An overview of 
randomized trials shows that hyperthermia in addition to radiotherapy for superficial 
tumors can significantly improve outcome.
Part 1 motivation and clinical studies
The history and details of superficial hyperthermia treatments in breast cancer recur­
rences at the Erasmus MC are reviewed in chapter 2. For hyperthermia treatments we 
used, the water filled Lucite Cone Applicators (LCAs), operating at a frequency of 433 
MHz. With six applicators combined an area of 20 x 30 cm2 can be heated effectively to 
a depth of up to 4 cm. Temperatures are measured interstitially with fiber­optic multi­
sensor probes. In some patients with special clinical problems hyperthermia treatment 
planning can be applied to support decision making with regard to the treatment 
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strategy. In 74% of the patients with macroscopic breast cancer recurrences a complete 
response is achieved with a reirradiation scheme of 8 fractions of 4 Gy in 4 weeks, com­
bined with 4 or 8 hyperthermia treatments, approximately twice as high as the complete 
response rate following the same reirradiation alone as demonstrated by in the random­
ized trial. To reach a high complete response and local control the whole volume at risk 
should be regarded as target and an adequate heating technique has to be used.
In chapter 3 the effect of a combined treatment of surgery, reirradiation and hyper­
thermia therapy on local control rate in radio­induced angiosarcoma of the chest wall 
is presented. In the subgroup of pa tients treated after surgery, the 3 months, 1 and 3 
years actuarial local control rates were 91%, 46% and 46%, respectively. In the subgroup 
of patients without surgery, the rates were 54%, 32% and 22%, respectively. Late grade 
4 radiotherapy toxicity was seen in two patients, 7 and 11 months after the treatment. 
Wide surgical resection is the current treatment of choice for the treatment of radiation­
induced angiosarco ma. The best published local control rates were achieved by com­
bining sur gery and hyperfrac tionated accelerated radiotherapy. For initially inopera ble 
tumors, the effect of reirradiation and hyperthermia alone can still be beneficial.
chapter 4 describes the toxicity of the combination of reirradiation and hyperthermia 
in breast cancer patients with reconstructions. When postoperative radiotherapy is 
required, many surgeons avoid thoracic wall resection for fear of wound complications. 
In our study, an incidence of severe acute (8%) and late (5%) normal tissue reactions 
was observed in 36 patients with 37 reconstructions. At the same time, the treatment 
resulted in a complete response in 12 of 15 (80%) patients with a macroscopic tumor. 
For all patients, local tumor control rate was 83% after 1 year, 74% after 3 years and 69% 
after 5 years. Based upon these results, we consider breast reconstructions in previous ir­
radiated areas not a contraindication for treatment with reirradiation and hyperthermia.
In chapter 5 results in 248 patients with macroscopic breast cancer recurrence 
treated with reirradiation and hyperthermia from 1996 to 2011 are described. Overall, 
the treatment resulted in a complete response rate of 70%, 3 and 5 years local tumor 
control rates of 40% and 39%, respectively. Ten years overall survival was 10%. The acute 
and long­term toxicity was acceptable. Grade 3 hyperthermia toxicity occurred in five 
patients and grade 4 in one patient. The 5 years incidence of late grade 3 toxicity was 1%.
chapter 6 describes the results for 198 patients after surgery for recurrent breast 
cancer, who were treated electively or for subclinical disease with reirradiation and 
hyperthermia between 1993 and 2010. The 3 and 5 years local control rates were 83% 
and 78%. Late grade 3 and 4 toxicity was seen in 20 patients with a cumulative incidence 
of 11.9% after 5 years. At 10 years after diagnosis the overall survival was 36%.
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Part 2 towards Finding a ProsPective quality indicator
In chapter 7 the development and implementation of the CT scanning procedure 
specific for superficial hyperthermia treatment planning, including an indication of the 
positions of the LCAs and the interstitial thermometry catheters, is described. Further, 
the procedure of segmenting the CT­images to create a patient and treatment spe­
cific 3D model, that mimics the real patient treatment set­up, is presented. Automatic 
segmentation takes 10–20 min and manual segmentation 2–4 h. The time for manual 
segmentation can be reduced by improving the program.
In chapter 8 accurate reconstruction of the applicator setup from multiple­view im­
ages and calculation of the specific absorption rate, SAR, distribution using the actual 
applicator set­up is described. The total reconstruction procedure of six LCAs from a set 
of ten photos takes around 1.5 h. Minors errors of ±1.02 mm in translation or ±0.48° in 
rotation were found with negligible influence on treatment planning quality.
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Hyperthermie is een kankerbehandeling waarbij de temperatuur wordt verhoogd tussen 
40°C en 44°C gedurende 1 uur of langer. Gerandomiseerde studies hebben aangetoond 
dat hyperthermie in combinatie met radio­ of chemotherapie de klinische resultaten 
voor verschillende tumortypes aanzienlijk kan verbeteren. De ESHO 5­88 studie in re­
cidief borstkanker, bijvoorbeeld, heeft aangetoond dat toevoeging van hyperthermie 
aan herbestraling de lokale controle van 38% na herbestraling alleen verhoogt tot 
78%. In Nederland, Duitsland, Zwitserland, Tsjechië, Italië en Griekenland, wordt de 
combinatie van radiotherapie en hyperthermie aangeboden aan patiënten met recidief 
borstkanker. In Nederland bestaat de behandeling voor deze patiënten uit 4 weken ra­
diotherapie met een schema van 8 fracties van 4 Gy, twee keer per week, gecombineerd 
met 4 hyperthermiebehandelingen, eenmaal per week (Richtlijn “Behandeling van het 
mammacarcinoom 2012”).
Jarenlang is sterk ingezet op continue verbetering van onze systemen voor oppervlak­
kige hyperthermie. Een van die verbeteringen resulteerde in een stijging van complete 
respons van 31% naar 65% bij grote tumoren (diameter > 3 cm). De gemiddelde weefsel­
temperatuur steeg met 1.3°C (ongepubliceerde data). Er bestaat algemene consensus 
dat de klinische uitkomst sterk beïnvloed wordt door de kwaliteit van de hyperthermie 
behandeling.
Deze thesis beschrijft toepassing van hyperthermie als deel van de behandeling van 
recidief borstkanker in Rotterdam en voorspellende factoren voor de uitkomst van de 
behandeling. Een mogelijkheid om de huidige oppervlakkige hyperthermie te verbete­
ren is, om een 3­dimensional (3D) model van de behandeling te ontwikkelen, waarmee 
in 3D de specifieke absorptie ratio (SAR) en/of de temperatuurverdeling berekend kan 
worden. Vervolg onderzoek moet aantonen of deze berekende waarden voorspellend 
zijn voor de uitkomst van de behandeling.
Hoofdstuk 1 beschrijft de rationale voor toepassing van hyperthermie als onderdeel 
van de kankerbehandeling, behandelingsmogelijkheden van patiënten met recidief 
borstkanker. Eede klinische resultaten significant verbetert bij oppervlakkige tumoren.
deel 1 motivatie en kliniscHe studies
Een overzicht van de ervaringen met oppervlakkige hyperthermie bij de behandeling 
van recidief borstkanker in het Erasmus MC wordt gegeven in hoofdstuk 2.
In Rotterdam wordt oppervlakkige behandeling uitgevoerd met Lucite Cone applica­
toren (LCAs) bij een frequentie van 433 MHz. Met zes applicatoren kan een veldgrootte 
van maximaal 20 x 30 cm2 met een diepte van maximaal 4 cm effectief worden verwarmd. 
Temperaturen worden interstitieel gemeten met glasvezel temperatuursensoren. Bij 
enkele patiënten met specifieke klinische problemen is een hyperthermie planningssys­
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teem gebruikt ter ondersteuning van het behandelplan. Met het behandelschema van 
8 fracties van 4 Gy in 4 weken gecombineerd met 4 of 8 hyperthermiebehandelingen 
wordt bij 74% van de patiënten een complete respons bereikt. Dit is ongeveer tweemaal 
zo hoog als het complete responspercentage met deze herbestraling zonder hyperther­
mie. Voor een hoge kans op complete respons en lokale controle is het belangrijk om het 
gehele risicogebied te verwarmen, en een goede verwarmingstechniek te gebruiken.
In hoofdstuk 3 wordt het resultaat van behandeling met herbestraling en hyperther­
mie, al dan niet voor of na chirurgie, bij patiënten met bestralingsgeïnduceerd angiosar­
coom van de borstwand gepresenteerd. In de subgroep van patiënten met chirurgie 
is de lokale controle na respectievelijk 3 maanden, 1 en 3 jaar, 91%, 46% en 46%. In de 
subgroep van patiënten zonder chirurgie is dit 54%, 32% en 22%. Late graad 4 radio­
therapie toxiciteit werd gezien bij twee patiënten, 7 en 11 maanden na de behandeling. 
Ruime chirurgische resectie is de huidige voorkeursbehandeling van bestralingsgeïn­
duceerd angiosarcomen. De beste lokale controle wordt bereikt door het combineren 
van chirurgie samen met gehyperfractioneerde en geaccelereerde radiotherapie. Voor 
inoperabele tumoren kan herbestraling en hyperthermie gunstige effecten hebben.
Hoofdstuk 4 beschrijft de toxiciteit van de combinatie van herbestraling en hyper­
thermie in 36 borstkankerpatiënten met 37 reconstructies van de borstwand. Wanneer 
postoperatieve radiotherapie geïndiceerd is, vermijden veel chirurgen borstwandresec­
ties vanwege het risico op wondcomplicaties. De incidentie van respectievelijk acute en 
late graad ≥3 toxiciteit na herbestraling met hyperthermie was 8% en 5%. Tegelijkertijd 
was de kans op complete respons in 15 patiënten met een macroscopische tumor 80%. 
De lokale tumor controle voor alle patiënten was 83% na 1 jaar, 74% na 3 jaar en 69% 
na 5 jaar. Reconstructies van de borstwand in eerder bestraalde gebieden zijn dus geen 
contra­indicatie voor herbestraling gecombineerd met hyperthermie.
In hoofdstuk 5 worden de resultaten bij 248 patiënten met een irresectabel recidief 
borstkanker na herbestraling met hyperthermie beschreven. Een complete respons 
werd gezien bij 70% van de patiënten. De kans op lokale tumorcontrole na respectie­
velijk 3 en 5 jaar was 40% en 39%, en de 10­jaars overleving was 10%. De cumulatieve 
incidentie van late graad 3 toxiciteit was 1% na 5 jaar.
Hoofdstuk 6 beschrijft de resultaten bij 198 patiënten die na chirurgie voor recidief 
borstkanker werden behandeld met herbestraling en hyperthermie. De kans op lokale 
tumorcontrole na respectievelijk 3, 5 en 10 jaar was 83%, 78% en 78%. Late graad 3 en 4 
toxiciteit werd gezien in 20 patiënten met een cumulatieve incidentie na respectievelijk 
1, 3 en 5 jaar van 4.8%, 9.5% en 11.9%. De 10­jaars overleving na de gecombineerde 
behandeling was 36%.
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deel 2 oP weg naar een ProsPectieve kwaliteitsindicator
In hoofdstuk 7 wordt de ontwikkeling van een procedure voor het maken van een CT 
scan specifiek voor het modelleren van patiënt en behandelopstelling ten behoeve van 
hyperthermie treatment planning beschreven. Op de CT scan moeten hiervoor ook 
de posities van de LCA’s en de thermometriecatheters zichtbaar zijn. Verder wordt de 
procedure van het segmenteren van de CT­beelden beschreven, waarmee de werkelijke 
behandelsituatie driedimensionaal in het berekeningsmodel kan worden opgenomen. 
Voor automatische segmentatie is 10 tot 20 minuten nodig, en voor manuele segmenta­
tie 2 tot 4 uur. De benodigde tijd voor segmentatie kan nog teruggebracht worden door 
verbetering van het programma.
In hoofdstuk 8 wordt beschreven hoe de applicator setup nauwkeurig kan worden 
gereconstrueerd met behulp van uit meerdere hoeken gemaakte foto’s, en hoe de 
verdeling van de specifieke energie absorptie (SAR) voor de actuele applicator setup 
berekend kan worden. De nodige tijd voor het reconstrueren van een combinatie van 
6 LCA’s vanuit een serie van 10 foto’s is ongeveer 1,5 uur. De gevonden afwijkingen 
waren ±1.02 mm in positie, en ±0.48° in rotatie, met een verwaarloosbare invloed op de 
kwaliteit van de treatment planning.
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